Official Title of Study: 
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipi[INVESTIGATOR_470217] (TMB -H) 
(CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848) 
 
Study ID: [REMOVED] 
Document Date (Date in which document was last revised): May 4, 2021 
Page: 1
Protocol Number: CA209848
IND Number: 140,[ADDRESS_602559] Number: 2016-002898-35
Date: 13-Oct-2016
Revised Date: 04-May-2021
Clinical Protocol CA209848
A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination with Ipi[INVESTIGATOR_470218] (TMB-H)
(CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848)
Protocol Amendment 04
Incorporates Administrative Letters 04, 05, 06, and 07
Clinical ScientistClinical Trial Physician-
Medical Monitor
Bristol-Myers Squibb Company Bristol-Myers Squibb Company
3401 Princeton Pi[INVESTIGATOR_2531] 3401 Princeton Pi[INVESTIGATOR_452681], NJ [ZIP_CODE]
Telephone (mobile): 
Email: Lawrenceville, NJ [ZIP_CODE]
Telephone (office): 
Email:
24-hr Emergency Telephone Number
[LOCATION_003]: 
International: 
Bristol-Myers Squibb Research and Development
[ADDRESS_602560] de Finlande 4
B-1420 Braine-l‚ÄôAlleud, Belgium
This document is the confidential and proprietary information of Bristol-Myers Squibb 
Company and its global affiliates (BMS). By [CONTACT_52212], you agree to keep it 
confidential and to use and disclose it so lely for the purpose of assessing whether your 
organization will participate in and/or th e performance of the proposed BMS sponsored 
study. Any permitted disclosures will be made only on a confidential "need to know" basis 
within your organization or to your independent  ethics committee(s). Any other use, copying, 
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Protocol Amendment No.: 04
Date: 04-May-2021 2disclosure or dissemination of this information  is strictly prohibited unless expressly 
authorized in writing by [CONTACT_20444]. Any supplemental information (eg, amendments) that may 
be added to this document is also confidential  and proprietary to BMS and must be kept in 
confidence in the same manner as the conten ts of this document. Any person who receives 
this document without due authorization fr om BMS is requested to return it to BMS or 
promptly destroy it. All other rights reserved. References to BMS in this protocol may apply to partners to which BMS has transferred obligations, eg, a Contract Research Organization 
(CRO).
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Protocol Amendment No.: 04
Date: 04-May-2021 3DOCUMENT HISTORY
Document Date of Issue Summary of Change
Protocol 
Amendment 0404-May-2021Clarified statistical analysis populations for blood tumor mutational burden
(bTMB) final analysis, tissue tumor mutational burden (tTMB) interim 
analysis, and tTMB final analysis.
Updates made to align with current nivolumab Investigator Brochure (IB)
and Bristol-Myers Squibb Company (BMS) guidelines for protocols with 
nivolumab using Common Terminology Criteria for Adverse Events(CTCAE) v5. Updates made to treatment management algorithms for 
immuno-oncology agents.
Added safety reporting and dose modification related to severe acute 
respi[INVESTIGATOR_6507] 2 (SARS-CoV-2).
Incorporated Administrative Letters 04, 05, 06, and 07. Note: After 
Administrative Letter 07, Medical Monitor/Clinical Trial Physician responsibility transitioned from , to  
. Since Protocol Amendment [ADDRESS_602561] the Study Design Schematic of 
Revised Protocol 03. In the section referencing the Study Design Schematic, Synopsis, Figure 2.1 and Section 5.1, Figure 5.1-1 (Overall Design) the sample size is referenced incorrectly as n = 159. As part of Revised Protocol 03, the number of randomized participants was updated to range from approximately 183 to 342 however was inadvertently not updated in the 
Study Design Schematic therefore this should be updated to n = 183.
Revised 
Protocol 0314-Aug-2019Provided clarification that pre-screen ing requirements on tTMB and bTMB 
results should be ‚â• 10 mut/Mb (tTMB ‚â• [ADDRESS_602562] interim analysis).
Clarified that Belgium and the Netherlands will not enroll adolescent 
participants and therefore all content related to pediatric/adolescents is not 
applicable for sites in those countries.
Added Section 3.2.[ADDRESS_602563] 
scanner.
Clarified biomarker tissue collection to occur during pre-screening.
Also included updates per Administrative Letter 02, update to study 
personnel Medical Monitor and Study Director, and Administrative Letter 
03, clarified and corrected a typo in Exclusion Criteria (Section 6.2).
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602564] a typo in the Exclusion Criteria of 
Revised Protocol 02.  In the section referencing Exclusion Criteria (Section 6.2), Physical and Laboratory Test Findings, (bullet number 3) regarding the calculated creatinine clearance reflecting the normal range. This exclusion criteria is intended to exclude patients with significant renal function impairment as indicated by [CONTACT_470357], 
respectively.
Administrative 
Letter 0207-Mar-2019The purpose of this administrative letter is to advise of a change in study 
personnel.
Revised 
Protocol 0211-Dec-2018Incorporates feedback received from FDA on the study design of CA209-848 and Administrative Letter 01.
Administrative 
Letter 0110-Jul-2018Notification that a new IND number (140,266, for tissue agnostic, pan tumor 
in TMB-H population) will be used for CA209-848 protocol.
Revised 
Protocol 0118-May-2018This protocol is listed a ‚ÄúRevised protocol 1‚Äù to remain Title 21 CFR Part 11 
compliant (FDA regulations on electronic records and electronic signatures). The initial protocol CA209848 was never activated as initially written. The study was fully revised and, therefore, there are no summary of changes to 
compare to the initial protocol.
Original 
Protocol13-Oct-2016 Not applicable
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 04:
This amendment incorporates clarifications concerning the analysis populations used for the blood 
tumor mutational burden (bTMB) and tissue tumor mu tational burden (tTMB) cohorts and the type 
of analysis (interim or fin al primary) bei ng performed. E nrollment into the bTMB high population 
was closed in Dec-2019, as the required number of participants needed for final analysis was met.
Enrollment into the tTMB high population rema ined ongoing to complete enrollment for this 
participant population. Because of the varying enrollment rates, the bTMB final analysis will 
coincide with the tTMB interim efficacy analysis, leading to the need for clarifi cation of the 
primary analysis populations for both analyses. Both of these analyses will take place after study-wide randomization has completed.
‚Ä¢The final analysis population for the primary endpoint (overall response rate [ORR] based on 
blinded independent central review [BICR] assessments) for the bTMB high population will be all participants in the salvage setting randomized before the study closed enrollment to this 
cohort in Dec-2019; the database cutoff (last patient last visit [LPLV]) for the analysis will be 
at least [ADDRESS_602565] treatment and after completion of study-widerandomization.
‚Ä¢The primary analysis population for the tTMB interim analysis (ORR based on BICR 
assessments) is limited to tTMB high participants in the salvage setting randomized at least 12 months prior to the LPLV for the analysis to allow sufficient time to demonstrate durability of response. Study-wide randomization will comple te prior to the LPLV for the analysis.
‚Ä¢The final analysis of the primary e ndpoint (ORR based on BICR assessments) for the tTMB 
high population in the salvage setting will be performed at least [ADDRESS_602566] been randomized.
Protocol Amendment 04 incorporates changes per previous Administrative Letters 04, 05, 06, and 
07, and updates to align with current [COMPANY_016] Company (BMS) guidelines for 
nivolumab studies (including current nivolu mab Investigator Brochure [IB] version 19, addendum 
version 1) and s
evere acute respi[INVESTIGATOR_6507] 2 (SARS-CoV-2) guidance.
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Synopsis : Data Monitoring 
Committee;  Section 
[IP_ADDRESS] : Data Monitoring 
CommitteeAdded data monitoring committee (DMC) 
review of the bTMB final analysis results.The bTMB final analysis will 
coincide with the tTMB interim 
analysis, so it was decided to have the DMC review both results.
Synopsis: Figure 2: Study 
Design Schematic;  Section 
5.1: Overall Design; Figure 
5.1-1 : Study Design 
SchematicCorrected the number of potential 
randomized study participants.As part of Revised Protocol 03, the 
number of randomized participants 
was updated to approximately [ADDRESS_602567] this change.
Protocol Amendment No.: 04
Date: 04-May-2021 5
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Synopsis : Key Inclusion 
CriteriaAdded ‚Äò(salvage setting)‚Äô to criterion 1a.Clarified that the eligible 
participant disease characteristics described in Inclusion Criterion 1a 
(updated in Revised Protocol 02 
dated 11-Dec-2018) represent salvage setting characteristics. No change to the actual criterion for eligibility.
Section 2: Schedule of 
Activities
Tables 2-1 , 2-2, 2-3 , 2-4, 
and 2-5Added collection of all serious adverse 
events (SAEs) and non-serious adverse 
events (AEs) associated with SARSCoV-2 infection.Aligned with current BMS 
guidelines for protocol updates 
concerning SARS-CoV-2.
Section 2: Schedule of 
Activities Table 2-1; 
Section 5.1: Overall Design; Section 6.1:
Inclusion Criteria 2cAdded ‚Äúvalidated CLIA‚Äù to instances of 
acceptable bTMB resultsClarification that the Foundation Medicine bTMB assay is validated 
by [CONTACT_470358] (CLIA).
Section 5.4.5 : Rationale for 
Two Year Duration of Treatment Deleted prior references to Keynote-010 and Keynote-006.Aligned with current BMS guidelines for protocols with nivolumab, in which outdated background information on analyses of pembrolizumab progression rates has been 
removed.
Section 5.5.4 : Clinical 
Pharmacology SummaryUpdated current nivolumab pharmacokinetic (PK) parameters to include 
more details of nivolumab clearance in nivolumab monotherapy and nivolumab plus ipi[INVESTIGATOR_470219], among which are those with renal/hepatic impairment.Nivolumab clinical PK assessed 
using a population PK approach; 
updated to align with the current nivolumab  IB.
Section 5.5.5 : Rationale for 
30-minute InfusionAdded current approval status for a 30-minute infusion for nivolumab, either as monotherapy or in combination, and for ipi[INVESTIGATOR_470220]. Aligned with current [LOCATION_002] prescribing information (USPI) for nivolumab and current USPI [INVESTIGATOR_470221] 6.1: Inclusion 
Criteria 
2) Type of Participant and 
Target Disease Characteristics
3) Age and Reproductive 
Status; Appendix 4 : 
Women of Childbearing Added ‚Äú(salvage setting)‚Äù to Criterion 2a.
Removed male contraception language. 
Inclusion Criterion 3e is no longer 
applicable.
In Appendix 4, the guidance for male 
participants is now designated as Not Applicable.Clarified that the eligible 
participant disease characteristics
described in Inclusion Criterion 2a(updated in Revised Protocol 02dated 11-Dec-2018) represent salvage setting characteristics. There was no change to the actual criterion for eligibility.
Aligned with the current nivolumab 
IB and BMS guidelines for 
Protocol Amendment No.: 04
Date: 04-May-2021 6
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Potential Definitions and 
Methods of Contraception;Appendix 4: Contraception Guidance for Male Participants with Partner(s) of Child Bearing Potentialprotocols with nivolumab, which 
reflect the lack of nivolumab genotoxicity and no transmission of biologically relevant amounts to women of childbearing potential (WOCBP) partners.  
Section 7.1.1 : Arm A or 
Arm B Rollover €õ
Nivolumab in Combination 
with Ipi[INVESTIGATOR_125]; Section 
7.1.2: Arm B €õNivolumab 
MonotherapyAdded ‚Äúapproximately‚Äù to references of 30-minute intravenous infusions.
Added optional instructions to flush the 
intravenous line with an appropriate amount of diluent.Aligned with current BMS 
guidelines for protocols with 
nivolumab.
Section 7.4.1 : Dose Delay 
CriteriaUpdated to align with CTCAE v5 grading, 
and added new terms (ie, Guillain-Barre, 
myasthenia gravis, hypophysitis/hypopi[INVESTIGATOR_297]).
Updated text to tabular format ( Table 7.4.1-
1) and included criteria to resume and/or 
discontinue treatment. 
Added instruction to delay dosing in 
participants with SARS-CoV-2 infection.Aligned with current nivolumab IB and BMS guidelines for protocols 
with nivolumab using CTCAE v5 for safety assessments; changed to tabular format for greater ease of use.
Aligned with current BMS 
guidelines for protocol updates concerning SARS-CoV-2.
Section 7.4.2 : Criteria to 
Resume TreatmentUpdated and moved criteria to resume 
treatment following specific AEs to Table 
7.4.1-1.
Clarified that participants may resume study 
treatment following steroid taper for AEmanagement.
Added criteria to resume treatment 
following SARS-CoV-2 infection.Aligned with current nivolumab IB and BMS guidelines for protocols with nivolumab.
Aligned with current BMS 
guidelines for protocol updates concerning SARS-CoV-2. 
Section 7.4.4 : Treatment of 
Nivolumab- and Ipi[INVESTIGATOR_125]-Related Infusion ReactionsMade minor updates to treatment guidelines.Aligned with current BMS 
guidelines for protocols with 
nivolumab.
Section 7.4.5 : Management 
Algorithms for Immuno-oncology AgentsMade minor updates to language 
referencing the management algorithms for 
immuno-oncology agents in Appendix 5.Aligned with current BMS guidelines for protocols with nivolumab.
Section 7.7.1 : Concomitant 
Therapy, Prohibited and/or Restricted Treatments;
Section 7.7.2 : Permitted 
TherapyMade minor updates to prohibited therapi[INVESTIGATOR_470222].
Added restrictions on administration of live 
(prohib ited) or not live (permitted) SARS-
CoV-2 vaccines.Aligned with current BMS guidelines for protocols with 
nivolumab.
Aligned with current BMS 
guidelines for protocol updates concerning SARS-CoV-2.
Protocol Amendment No.: 04
Date: 04-May-2021 7
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Section 8.1:
Discontinuation from Study Treatment;
Section 8.1.1 :D o s e  
Discontinuation in 
Nivolumab and Ipi[INVESTIGATOR_90843];
Section 8.1.2 :D o s e  
Discontinuation in 
Nivolumab Monotherapy ArmUpdated and moved criteria to discontinue treatment following specific AEs to  Table 
7.4.1-1 .Aligned with current nivolumab IB and BMS guidelines for protocols 
with nivolumab using CTCAE v5 
for safety assessments.
Section 9: Study 
Assessments and 
ProceduresUpdated to include recommendations for potential cardiac or pulmonary toxicity.Aligned with current nivolumab IB and BMS guidelines for protocols with nivolumab.
Section 9.2.1 : Time Period 
and Frequency for Collecting AE and SAE Information;
Section 9.2.3 : Follow-up of 
AEs and SAEsAdded instruction for collection and follow-
up of SAEs and non-serious AEs associated 
with SARS-CoV-2 infection.Aligned with current BMS 
guidelines for protocol updates 
concerning SARS-CoV-2.
Section 9.2.5 : PregnancyRemoved instruction for reporting of pregnancy occurring in a female partner of a male study participant.Aligned with current nivolumab IB 
and essential protocol elements, 
which reflect the lack of nivolumab genotoxicity and no transmission of biologically relevant amount to  WOCBP partners.  
Section 9.5:Pharmacokinetics, 
Table 9.5-1:
Pharmacokinetic and Immunogenicity Sampling 
Schedule €õArm A or Arm 
B Rollover €õNivolumab in 
Combination with 
Ipi[INVESTIGATOR_125];
Table 9.5-2:
Pharmacokinetic and Immunogenicity Sampling Schedule Arm B €õ
Nivolumab MonotherapyClarified site of blood draw and proper documentation of sample collection and the evaluation of samples for development of anti-drug antibody.
Revised footnote b to clarify end of 
infusion-PK sampling. Aligned with current BMS 
guidelines for protocols with 
nivolumab.
Section 9.10: Patient-
Reported OutcomesRevised text to clarify that alternate 
administration modalities may be used if 
necessary.Aligned with current BMS 
guidelines for protocol updates 
concerning SARS-CoV-2.
Protocol Amendment No.: 04
Date: 04-May-2021 8
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Section 10 : Statistical 
ConsiderationsAdded ‚Äúin the salvage setting‚Äù to 
descriptions of the primary analysis 
populations.
Added ‚Äúand study randomization is 
completed‚Äù to timing of the analyses.Clarified that the primary analysis popul ations include salvage s etting 
participants per inclusion criteria 
updated in Revised Protocol [ADDRESS_602568] after study 
randomization is completed.
Section 10.1: Sample Size Determination; 
Section 10.2 : Populations 
for AnalysesRevised text to clarify that only participants 
in the bTMB high population enrolled prior 
to the closure of the bTMB high group will be included in the final primary bTMB efficacy analysis population.
Added Table 10.2-1.Enrollment into the bTMB high 
population was closed in Dec-2019; 
the primary bTMB efficacy analysis population will include all participants randomized into this group prior to its closure.
Table 10.2-1 clarifies the primary 
analysis populations and timing of the analyses.
Section 10.3.6 : Interim 
AnalysesRevised text to clarify that the primary analysis population for the tTMB interim efficacy analysis will be limited to study 
participants in the tTMB high population 
who were randomized at least [ADDRESS_602569] 12 months prior to the LPLV for the analysis.
Section 11 : ReferencesRemoved references to KEYNOTE-010 and 
KEYNOTE-006 per  Section 5.4.5 update.
Added references for current nivolumab 
USPI [INVESTIGATOR_470223].Aligned with current BMS guidelines for protocols with nivolumab.
Section 12 :Appendix 1: 
Abbreviations and TrademarksAdded abbreviations.Aligned with updated text within 
the protocol body.
Section 12: Appendix 2: 
Study Governance 
Considerations: MonitoringAdded flexible language to allow for remote 
monitoring.  Aligned with current BMS 
guidelines for protocol updates 
concerning SARS-CoV-2.
Protocol Amendment No.: 04
Date: 04-May-2021 9
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04
Section Number & 
TitleDescription of Change Brief Rationale
Section 12 :Appendix 5: 
Management Algorithms 
for Studies Under CTCAE 
Version 5.0Updated treatment management algorithms 
for immuno-oncology agents.Aligned with current nivolumab IB and BMS guidelines for protocols with nivolumab using CTCAE v5 
for safety assessments.
AllMade minor formatting and typographical 
corrections.These changes are minor and
therefore have not been 
summarized.
Protocol Amendment No.: 04
Date: 04-May-2021 10
5.0 Approved 930106993 5.0v Approved 1.0 v
TABLE OF CONTENTS 
  
TITLE PAGE ................................................................................................................  
DOCUMENT HISTORY ..............................................................................................  
OVERALL RATIONALE FOR PROTOCOL AMENDMENT 04: ............................  
SUMMARY OF KEY CHANGES FOR PROTOCOL AMENDMENT 04 ................  
TABLE OF CONTENTS ..............................................................................................  
1 SYNOPSIS .................................................................................................................  
2 SCHEDULE OF ACTIVITIES..................................................................................  
3 INTRODUCTION .....................................................................................................  
3.1 Study Rationale .................................................................................................  
3.1.1 Rationale for Participant Population with TMB-H Tumor ......................  
3.1.2 Rationale for Study in Refractory, Metastatic, or Unresectable Setting .  
3.1.3 Rationale for Inclusion of Adolescent Participants .................................  
3.1.4 Rationale for Key Endpoints ....................................................................  
[IP_ADDRESS] Rationale for Independent Central Review .....................................  
[IP_ADDRESS] Rationale for Investigator Assessed Response ................................  
3.1.5 Rationale for Exploratory Biomarker Assessments .................................  
3.1.6 Rationale for Outcomes Research Assessments .......................................  
3.2 Background .......................................................................................................  
3.2.1 Mechanism of Action of Nivolumab .........................................................  
3.2.2 Ipi[INVESTIGATOR_102261] ............................................................  
3.2.3 Nivolumab Combined with Ipi[INVESTIGATOR_470224] ...........................................................................  
3.2.4 Nivolumab Combined with Ipi[INVESTIGATOR_470225] ..................................................................  
3.2.5 Nivolumab Clinical Pharmacology ..........................................................  
3.3 Benefit/Risk Assessment ..................................................................................  
3.3.1 Adult Patients ...........................................................................................  
3.3.2 Adolescent Patients ..................................................................................  
4 OBJECTIVES AND ENDPOINTS ...........................................................................  
5 STUDY DESIGN.......................................................................................................  
5.1 Overall Design ..................................................................................................  
5.1.1 Data Monitoring Committee and Other External Committees ................  
[IP_ADDRESS] Data Monitoring Committee ...........................................................  
[IP_ADDRESS] Blinded Independent Ce ntral Review Committee ...........................  
5.2 Number of Participants .....................................................................................  
5.3 End of Study Definition ....................................................................................  
5.4 Scientific Rationale for Study Design...............................................................  
5.4.1 TMB Cutoff and Stratification .................................................................  
5.4.2 Stratification with Line of Therapy ..........................................................  
5.4.3 Exclusion of Melanoma, NSCLC and RCC ..............................................  
5.4.4 Rationale for Treatment with Nivolumab and Ipi[INVESTIGATOR_470226] ................................................  
5.4.5 Rationale for Two Year Duration of Treatment .......................................  
5.5 Justification for Dose ........................................................................................  
































Clinical Protocol
BMS-936558CA209848
nivolumab
Protocol Amendment No.: 04Date: 04-May-2021 11
5.0 Approved 930106993 5.0v Approved 1.0 v
5.5.1 Rationale for Nivolumab Monotherapy Dose Selection ..........................  
5.5.2 Nivolumab/Ipi[INVESTIGATOR_470227] ......................................................................................................  
[IP_ADDRESS] Population Pharmacokinetics of Nivolumab ..................................  
[IP_ADDRESS] Population Pharmacokinetics of Ipi[INVESTIGATOR_125] .................................  
[IP_ADDRESS] Pharmacokinetics of Nivolumab and Ipi[INVESTIGATOR_125] ...........................  
5.5.3 Dose for Adolescents................................................................................  
5.5.4 Clinical Pharmacology Summary ............................................................  
5.5.5 Rationale for 30-minute Infusion .............................................................  
6 STUDY POPULATION ............................................................................................  
6.1 Inclusion Criteria ..............................................................................................  
6.2 Exclusion Criteria .............................................................................................  
6.3 Lifestyle Restrictions ........................................................................................  
6.4 Screen Failures ..................................................................................................  
6.4.1 Retesting During Screening Period .........................................................  
7 TREATMENT ...........................................................................................................  
7.1 Treatments Administered ..................................................................................  
7.1.1 Arm A or Arm B Rollover ‚Äì Nivolumab in Combination with Ipi[INVESTIGATOR_125]
.....................................................................................................................  
7.1.2 Arm B ‚Äì Nivolumab Monotherapy ...........................................................  
7.2 Method of Treatment Assignment ....................................................................  
7.3 Blinding.............................................................................................................  
7.4 Dosage Modification .........................................................................................  
7.4.1 Dose Delay Criteria .................................................................................  
7.4.2 Criteria to Resume Treatment ..................................................................  
7.4.3 Nivolumab and Ipi[INVESTIGATOR_470228] .................................................................................................  
[IP_ADDRESS] Treatment with nivolumab and ipi[INVESTIGATOR_470229] (Arm B 
rollover) ................................................................................................  
7.4.4 Treatment of Nivolumab- and Ipi[INVESTIGATOR_222055]-Related Infusion Reactions ..  
7.4.5 Management Algorithms for Immuno-oncology Agents ..........................  
7.5 Preparation/Handling/Storage/Accountability ..................................................  
7.5.1 Retained Samples for Bioavailability / Bioequivalence ...........................  
7.6 Treatment Compliance ......................................................................................  
7.7 Concomitant Therapy........................................................................................  
7.7.1 Prohibited and/or Restricted Treatments.................................................  
7.7.2 Permitted Therapy ...................................................................................  
7.7.3 Palliative Local Therapy ..........................................................................  
7.7.4 Other Restrictions and Precautions .........................................................  
7.7.5 Imaging Restriction and Precautions ......................................................  
7.7.6 Surgical Resection Following Initial Response .......................................  
7.8 Treatment After the End of the Study ...............................................................  
8 DISCONTINUATION CRITERIA ...........................................................................  
8.1 Discontinuation from Study Treatment ............................................................  
8.1.1 Dose Discontinuation in Nivolumab and Ipi[INVESTIGATOR_90843]........  
































Clinical Protocol
BMS-936558CA209848
nivolumab
Protocol Amendment No.: 04Date: 04-May-[ADDRESS_602570] to Follow-Up .............................................................................................  
9 STUDY ASSESSMENTS AND PROCEDURES .....................................................  
9.1 Efficacy Assessments ........................................................................................  
9.1.1 Imaging Assessment for the Study............................................................  
9.1.2 Methods of Measurement .........................................................................  
[IP_ADDRESS] Solid tumors ....................................................................................  
[IP_ADDRESS] Primary CNS Neoplasms ................................................................  
9.1.3 Imaging and Clinical Assessment ............................................................  
[IP_ADDRESS] BICR Confirmation of Radiographic Progression .........................  
9.[ADDRESS_602571] Result Abnormalities .....................................................  
9.2.7 Potential Drug Induced Liver Injury (DILI) ............................................  
9.2.8 Immune-mediated Adverse Events ...........................................................  
9.2.9 Other Safety Considerations ....................................................................  
9.3 Overdose ...........................................................................................................  
9.4 Safety ................................................................................................................  
9.4.1 Physical Examinations .............................................................................  
9.4.2 Vital signs.................................................................................................  
9.4.3 Clinical Safety Laboratory Assessments ..................................................  
9.4.4 Imaging Safety Assessment ......................................................................  
9.5 Pharmacokinetics ..............................................................................................  
9.6 Pharmacodynamics ...........................................................................................  
9.7 Pharmacogenomics ...........................................................................................  
9.8 Biomarkers ........................................................................................................  
9.8.1 Additional Research Collection ...............................................................  
9.8.2 Immunogenicity Assessments ...................................................................  
9.8.3 Blood-based Biomarkers ..........................................................................  
9.8.4 Tissue-based Biomarkers .........................................................................  
9.8.5 Other Assessments ...................................................................................  
9.9 Medical Resource Utilization and Health Economics ......................................  
9.10 Patient-Reported Outcomes ............................................................................  
10 STATISTICAL CONSIDERATIONS ....................................................................  
10.1 Sample Size Determination .............................................................................  
10.2 Populations for Analyses ................................................................................  
10.3 Statistical Analyses .........................................................................................  
10.3.1 Efficacy Analyses ...................................................................................  
10.3.2 Safety Analyses.......................................................................................  
10.3.3 Pharmacokinetics Analysis ....................................................................  





































Clinical Protocol
BMS-936558CA209848
nivolumab
Protocol Amendment No.: 04Date: 04-May-2021 13
5.0 Approved 930106993 5.0v Approved 1.0 v
10.3.4 Outcomes Research Analyses ................................................................  
10.3.5 Other Analyses .......................................................................................  
10.3.6 Interim Analyses .....................................................................................  
11 REFERENCES ........................................................................................................  
12 APPENDICES .........................................................................................................  
APPENDIX 1 ABBREVIATIONS AND TRADEMARKS ........................................  
APPENDIX 2 STUDY GOVERN ANCE CONSIDERATIONS .................................  
APPENDIX 3 ADVERSE EVENTS AN D SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, EVALUATING, 
FOLLOW UP AND REPORTING .........................................................................  
APPENDIX 4 WOMEN OF CHILDBEARI NG POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION .....................................................................  
APPENDIX 5 MANAGEMENT ALGORITHMS FOR STUDIES UNDER CTCAE 
VERSION 5.0 .........................................................................................................  
APPENDIX 6 ECOG PERFORMANCE STATUS .....................................................  
APPENDIX 7 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
GUIDELINES (VERSION 1.1) WI TH BMS MODIFICATIONS ........................  
APPENDIX 8 RADIOGRAPHIC ASSE SSMENT FOR NEURO-ONCOLOGY 
(RANO) CRITERIA FOR HIGH-GRADE GLIOMAS .........................................  
APPENDIX 9 KARNOFSKY AND LANSKY CRITERIA ........................................  
APPENDIX 10 SIMULATION RESULTS..................................................................  
APPENDIX 11 COUNTRY SPE CIFIC AMENDMENTS ..........................................  
APPENDIX 12 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY ......  
 












Clinical Protocol
BMS-936558CA209848
nivolumab
Protocol Amendment No.: 04Date: 04-May-2021 14
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
1 SYNOPSIS
Protocol Title: A Randomized, Open-Label, Phase 2 Study of Nivolumab in Combination 
with Ipi[INVESTIGATOR_470230] (TMB-H)
(CheckMate 848: CHECKpoint pathway and nivoluMAb clinical Trial Evaluation 848)
Study Phase: 2
Rationale: Blockade of the PD-[ADDRESS_602572] anti-tumor 
immune responses. Nivolumab, an anti-PD-1 bloc king antibody, has demonstrated overall survival 
benefit in multiple tumors including non-squamous cell lung cancer, squamous cell lung cancer, 
melanoma, renal cell carcinoma and head and neck cancer. Recent data across multiple tumor types 
support the hypothesis that patients with tumors harboring increased somatic mutations due to 
DNA mismatch-repair deficiencies are more likely to respond to anti-PD-1/PD-L1 and 
anti-CTLA-4 blockade. Tumor mutational burden (TMB) refers to the total number of somatic mutations th at exist within a tumor‚Äôs genome. A subset of these mutations may result in expressed 
proteins that are not recognized by [CONTACT_40689]‚Äôs immune system as self, and therefore has the potential 
to be immunogenic and more susceptible to an immune-mediated anti-tumor response. The primary goal of this study is to demonstrate the clin ical activity of nivolumab in combination with 
ipi[INVESTIGATOR_470231].
Tumors with a high mutational burden may have a higher number of neo-antigens which, in 
principle, would be expected to be more immunogenic than tumors with comparatively low 
mutational burden.1Therefore, high TMB has been hypothesized to correlate with improved 
efficacy in patients treated wi th immune-oncology (IO) therapi[INVESTIGATOR_014]. This hypothesis has been 
supported by [CONTACT_470359][INVESTIGATOR_014], tumor types, and lines of treatment.
The available data suggest that, in addition to PD-L1, TMB is also an important predictive 
biomarker of the clin ical efficacy of IO therapy. Therefore, patients of TMB-H across multiple 
solid tumors will be selected for participation in this clinical study
Study Population:
For entry into the study, the following criteria MUST be met.
Key Inclusion Criteria (See protocol Section 6.[ADDRESS_602573] of criteria)
1) Type of Participant and Target Disease Characteristics
a) Participants with a refractory, metastatic, or unresectable histologically or cytologically 
confirmed solid malignant tumor with TMB-H who are refr actory to sta ndard local 
therapi[INVESTIGATOR_470232], or for which no standard treatment per local 
management guidelines is available (salvage setting).
b) The IRT must be provided with the results of both tissue and blood TMB-H testing for 
eligible participants prior to randomization. Both results are utilized for stratification purposes (see Figure 1 ).
Protocol Amendment No.: 04
Date: 04-May-2021 15
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Figure 1-1: TMB Pre-Screening/Screening
i) Participants must have either tTMB or bTMB ‚â• 10 mut/Mb (tTMB ‚â• [ADDRESS_602574] interim analysis)
ii) Prior results of TMB-H obtained with F1CDx assay (tissue) or bTMB-validated CLIA
assay from Foundation Medicine (blood) are acceptable for eligibility purposes. 
(1) If tTMB result is available, blood sample must be provided for central TMB testing(2) If bTMB result is available, tissue sample must be provided for central TMB testing (3) If neither tTMB nor bTMB result is av ailable, both tissue and blood samples must 
be provided for central TMB testing
iii) TMB results ob tained from any other assays are not acceptable for eligibility.
c) Participants must have measurable disease for response assessment as per RECIST 1.1 for 
solid tumors other than CNS, and RANO criteria for primary CNS malignancies.
2) Age and Reproductive Status
a) Males and Females, ages of 12 years and older. Sites in Belgium and the Netherlands will 
not include adolescents and only enroll participants 18 years or older.
Exclusion Criteria (See protocol Section 6.[ADDRESS_602575] of criteria)
3) Prior/Concomitant Therapy
a) Participants who received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting 
T-cell co-stimulation or checkpoint pathways
Protocol Amendment No.: 04
Date: 04-May-2021 16
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Objectives and Endpoints:
Objectives Endpoints
Primary
‚Ä¢To estimate BICR-assessed objective response rate (ORR) 
in participants of tTMB-H treated with nivolumab 
combined with ipi[INVESTIGATOR_125]‚Ä¢BICR-assessed ORR using RECIST 1.1, 
and Response Assessment for Neuro-Oncology (RANO) criteria in primary CNS 
tumors 
‚Ä¢To estimate BICR-assessed ORR in participants of bTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_125]‚Ä¢BICR-assessed ORR using RECIST 1.1, and 
RANO cr iteria in primary CNS tumors
Secondary
‚Ä¢To estimate the BICR-assessed duration of response 
(DOR) and time to response (TTR) in participants of 
tTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_125]‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To estimate the BICR-assessed DOR and TTR in 
participants of bTMB-H treated with nivolumab combined 
with ipi[INVESTIGATOR_125]‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate the BICR-assessed ORR, DOR and TTR in 
participants of tTMB-H treated with nivolumab 
monotherapy‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate the BICR-assessed ORR, DOR and TTR in 
participants of bTMB-H treated with nivolumab 
monotherapy‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate Investigator-assessed ORR, DOR, TTR in 
participants of tTMB-H treated with  nivolumab combined 
with ipi[INVESTIGATOR_470233]‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed TTR
‚Ä¢To evaluate Investigator-assessed ORR, DOR, TTR in 
participants of bTMB-H treated with nivolumab combined 
with ipi[INVESTIGATOR_470233]‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed TTR
‚Ä¢To evaluate BICR-assessed and investigator-assessed 
clinical benefit rate (CBR) in participants of tTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢BICR-assessed CBR
‚Ä¢Investigator-assessed CBR
‚Ä¢To evaluate BICR-assessed and investigator-assessed CBR in participants of bTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_470233]‚Ä¢BICR-assessed CBR
‚Ä¢Investigator-assessed CBR
‚Ä¢To evaluate BICR-assessed and investigator-assessed 
progression free survival (PFS) in participants of tTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢BICR-assessed PFS
‚Ä¢Investigator-assessed PFS
‚Ä¢To evaluate BICR-assessed and investigator-assessed PFS 
in participants of bTMB-H treated with nivolumab 
combined with ipi[INVESTIGATOR_470233]‚Ä¢BICR-assessed PFS
‚Ä¢Investigator-assessed PFS
‚Ä¢To evaluate overall survival (OS) in participants of tTMB-
H treated with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢Overall survival
Protocol Amendment No.: 04
Date: 04-May-2021 17
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Objectives Endpoints
‚Ä¢To evaluate OS in participants of bTMB-H treated with
nivolumab combined with ipi[INVESTIGATOR_251404]‚Ä¢Overall survival
‚Ä¢To assess overall safety and tolerability ‚Ä¢AEs, clinical laboratory values, or other 
safety biomarkers
Exploratory
‚Ä¢To assess overall health status and health utility ‚Ä¢Mean change from baseline in the 3-level 
version of the EQ-5D (EQ-5D-3L) visual analog scale (VAS) and utility index, 
respectively
‚Ä¢To assess cancer-related symptoms and quality of life ‚Ä¢Mean change from baseline in domains and 
symptoms in the 30-item European 
Organization for Research and Treatment of Cancer Quality of Life Questionnaire 
(EORTC QLQ-C30).
‚Ä¢To characterize the pharmacokinetics of 
nivolumab/ipi[INVESTIGATOR_470235]-response relationships with respect to safety and efficacy‚Ä¢Population pharmacokinetic parameters 
‚Ä¢To assess immunogenicity of nivolumab/ipi[INVESTIGATOR_125] ‚Ä¢Incidence of anti-nivolumab/anti-ipi[INVESTIGATOR_470236]
‚Ä¢To characterize tumor and host biomarkers ‚Ä¢Analysis of genomic, molecular, and immunohistochemical profiles
‚Ä¢To assess OS and BICR-assessed and investigator-
assessed ORR, DOR, PFS in all participants of TMB-H treated with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢OS
‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR 
‚Ä¢BICR-assessed PFS 
‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed PFS 
Overall Design:
The study will enroll participants diagnosed with select advanced or metastatic solid tumors with 
either tissue (tTMB) or blood TMB (bTMB) ‚â• 10 mut/Mb (TMB-H). Both tissue and blood TMB 
will be assessed prior to randomization. 
Participants without a prior known tTMB-H status available via F1CDx assay, or a prior known 
bTMB-validated CLIA result available from Foundati on Medicine, wi ll provide consent for pre-
screening and TMB status determination, but cons ent for further screening procedures and study 
treatment should be deferred until TMB-H status is  established. Screening process can continue 
when the participant‚Äôs status is TMB-H. 
Participants with a prior known result of tTMB-H via F1CDx assay or bTMB-H from 
Foundation Medicine may proceed immediately with  full screening procedures. Both tissue and 
blood TMB will be assessed prior to randomization. Prior results of tTMB or bTMB obtained from 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602576] of three phases: screening, treatment, 
and follow-up. 
Efficacy will be evaluated using tumor specific response criteria, ie, RECIST 1.1 for solid tumors2
and RANO criteria3for primary CNS tumors. 
The primary analysis of BICR-assessed ORR in participants with either bTMB-H or tTMB-H will 
be conducted after a minimum of 12 months following LPFT. This study will end when analysis of the primary endpoint is comp lete. Additional survival analysis may be conducted for up to 
5 years beyond the primary endpoint analysis.
Details regarding the assessments to be pe rformed during these phases are outlined in Section 2
Schedule of Activities. 
The study design schematic is presented below:
Figure 1-2: Study Design Schematic
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will 
not be included in these countries.
Physical examinations, vital sign measurements, ou tcome questionnaires, biomarker collection, 
and clinical laboratory evalu ations will be performed at selected times throughout study 
Protocol Amendment No.: 04
Date: 04-May-2021 19
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
participation. Participants will be closely mo nitored for AEs throughout the study. Blood samples 
will be collected for safety, pharmacokinetic (PK) and biomarker analysis. 
Participants with progressive disease while on treatment with nivolumab monotherapy may be 
allowed to be treated beyond progression with ni volumab and ipi[INVESTIGATOR_125] (Arm B rollover ‚Äì see 
Section 7.4.3 ).
Number of Participants: 
The number of randomized participants will ra nge from approximately 183 to  342 based on 1) the 
actually observed concordance between tTMB-H and bTMB-H, and 2) the new bTMB cutoff 
determined by [CONTACT_470360]. The per tumor type cap is approximately 15% of the total sample size.
A total of 76 TMB-evaluable subjects in the salvage setting treated with nivolumab + ipi[INVESTIGATOR_470237]. The sample size determination was not 
based on power consideration, but to provide precision on the estimation of ORR and DOR for TMB-high participants treated with nivolumab + ipi[INVESTIGATOR_125]. The following table summarizes the exact 95% CIs for a sample size of 76 in the nivol umab + ipi[INVESTIGATOR_470238] 25%-50%.
Sample size Number of responses Response rate 95% Confidence interval
76 19 0.25 (0.16, 0.36)
76 22 0.29 (0.19, 0.40)
76 24 0.32 (0.21, 0.43)
76 26 0.34 (0.24, 0.46)
76 28 0.37 (0.26, 0.49)
76 30 0.39 (0.28, 0.51)
76 32 0.42 (0.31, 0.54)
76 34 0.45 (0.33, 0.57)
76 36 0.47 (0.36, 0.59)
76 38 0.50 (0.38, 0.62)
Treatment Arms and Duration:
Study treatment: 
Study Drugs for CA209848
Medication PotencyIMP/
Non-IMP
Nivolumab
(BMS-936558-01)
Solution for Injection100 mg (10 mg/mL) and 40 mg (10 mg/mL) IMP
Protocol Amendment No.: 04
Date: 04-May-2021 20
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Study Drugs for CA209848
Medication PotencyIMP/
Non-IMP
Ipi[INVESTIGATOR_125]
(BMS-734016) Solution for Injection200 mg
(5 mg/mL)IMP
Treatments Administered
The selection and timing of dose for each participant is as follows:
Selection and Timing of Dose
Treatment 
ArmStudy 
TreatmentParticipant 
Age/WeightUnit dose 
strength(s)/
Dosage level(s)Frequency of 
AdministrationRoute of 
Administration
Arm A or Arm 
B rollover: 
nivolumab in 
combination 
with 
ipi[INVESTIGATOR_470239] 
‚â•40kg240 mgQ2 weeks up to 
24 monthsIV
Adolescents 
<4 0 k g3 mg/kgQ2 weeks up to 
24 monthsIV
Ipi[INVESTIGATOR_470240] 1 mg/kgQ6 weeks up to 
24 monthsIV
Arm B: 
nivolumab 
monotherapyNivolumabAdults and 
adolescents 
‚â•40kg480 mgQ4 weeks up to 
24 monthsIV
Adolescents 
< 40kg6 mg/kgQ4 weeks up to 
24 monthsIV
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will 
not be included in these countries.
Data Monitoring Committee: Yes
To provide independent oversight of safety, efficacy, and study conduct, a data monitoring 
committee (DMC) will be instituted. The DMC will meet regularly to ensure that participant safety 
is carefully monitored. The DMC will convene additional ad hoc meetings if necessary. Following each meeting, the DMC will recommend continu ation, modification, or discontinuation of the 
study based on observed toxicities. The DMC will review the interim analysis results and determine whether the cut-off value for bTMB should be adjusted for the first interim analysis and whether criteria for superiority are met at th at time for the tTMB interim analysis; the DMC will 
also review the bTMB final analysis results. A separate DMC charter w ill describe the activities 
of this committee in more detail.
Blinded Independent Central Review
A Blinded Independent Central Review (BIC R) committee w ill be formed fo r standardized 
response assessment. Images will be submitted to an imaging third-party vendor for central review. 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602577] response assessment, the clinical indicator data will be provided to the BICR
along with imaging data.
REFERENCES
1Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mu tational landscape 
determine sensitivity to PD-1 blockade in non-small cell lung cancer. Science. 2015; 348:124 
8.
2Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (v ersion 1.1). Eur J Cancer 2009;45:228-247.
3Wen PY, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High Grade Gliomas: Response Assessment in Neuro-O ncology Working Group J Clin Oncol 28;1 
3059-3067. 2010.
Protocol Amendment No.: 04
Date: 04-May-2021 22
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
2 SCHEDULE OF ACTIVITIES
Table 2-1: Screening Procedural Outline (CA209848)
Procedure Screening Visit Notes
Pre-screening for TMB-H Participants must have TMB-H status (tissue and/or blood) confirmed via F1CDx assay (tissue) or bTMB-validated 
CLIA assay from Foundation Medicine (blood) prior to signing consent for other eligibility procedures (see details in
Section 6.1 ).
Prior TMB-H results ‚â• 10 mut/Mb obtained from F1CDx assay (tissue) or bTMB-validated CLIA assay from 
Foundation Medicine (blood) are acceptable for eligibility purposes. 
Participants who do not have TMB-H status (tissue or blood) with the assays described above must sign a pre-
screening informed consent form and have tissue and / or blood samples provided for central testing. See 
details below for Biomarkers Collection.
Both tissue and blood results obtained with these assays are required prior to randomization, and both can be done 
under the pre-screening, if not previously available ; as long as at least one of the results is ‚â• 10 mut/Mb (tTMB ‚â• 
10 mut/Mb or the new cutoff value of bTMB determined by [CONTACT_941] 1stinterim analysis), the participant may sign 
the study Informed Consent Form and proceed to additional screening procedures.
Biomarkers Collection
Tumor tissue Refer to 
Table 9.8-1 and 
Table 9.8-2:
Biomarker 
Tissue and 
Blood Samples: 
Arm B 
Nivolumab 
MonotherapyIf prior tTMB results are submitted, the tTMB assay must have been F1CDx. 
Foundation One or any other assays are not acceptable.
For patients without prior tTMB results from F1CDx: A formalin-fixed, paraffin-embedded 
tumor tissue (FFPET) block (preferred) or 25 unstained slides of tumor tissue (archival tissue or 
fresh biopsy) is required. 10 slides are required for TMB eligibility evaluation and 15 slides are 
required for PD-L1 and other tumor-based biomarker evaluations.
For patients with prior tTMB results from F1CDx: A formalin-fixed, paraffin-embedded tumor 
tissue (FFPET) block (preferred) or 15 unstained slides of tumor tissue (archival tissue or fresh 
biopsy) is required from all participants for PD-L1 and other tumor-based biomarker evaluations. 
Fresh biopsies are preferred; however, archival samples are acceptable if obtained within 
9 months of signing the initial consent form ([pre-screening] and no additional intervening 
therapy (excluding palliative therapy) in between).
If a fresh biopsy is warranted, the participant must have a lesion that can be biopsied at an 
acceptable clinical risk as judged by [CONTACT_470361].
Protocol Amendment No.: 04
Date: 04-May-2021 23
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (CA209848)
Procedure Screening Visit Notes
If the required number of slides are not available, the BMS Medical Monitor must be consulted 
upfront , prior to enrollment, to discuss acceptability of the tissue available. 
Collection of blood sample for TMB 
testing Refer to 
Table 9.8-1 and 
Table 9.8-2:
Biomarker 
Tissue and 
Blood Samples: 
Arm B 
Nivolumab 
MonotherapyIf prior bTMB -validated CLIA results are submitted, bTMB testing must have been done by 
[CONTACT_33430]. Any other assays are not acceptable.
A fresh blood sample must be submitted (all participants). 
Eligibility Assessments
Informed consent X For participants 18 years of age or older, and legal representatives of participants age between 12 
and less than 18 years old
Assent form X For participants ages between 12 and less than 18 years old; should be obtained per local laws and 
regulations
Inclusion/Exclusion criteria X All inclusion/exclusion criteria should be assessed at screening and confirmed prior to first dose
Medical history X Including diagnostic pathology report, TMB level, dMMR, and MSI-High status (if previously 
performed), and all previous anti-cancer treatments 
Safety Assessments
Pregnancy test X WOCBP only: Serum or urine (minimum sensitivity 25 IU/L or equivalent units of HCG) to be 
done at screening visit and repeated within [ADDRESS_602578] dose 
Physical examination X Including height and weight within 14 days prior to randomization.
Vital signs X Temperature, blood pressure, and heart rate within 14 days prior to randomization.
Performance Status X Within 14 days prior to randomization. See  Appendix 6 for ECOG performance status (for 
participants ‚â• 16 years old with solid tumors, Appendix 9 for Karnofsky (participants ‚â• 16 years 
old with CNS as primary tumor) and Lansky (for all participants < 16 years old) 
Protocol Amendment No.: 04
Date: 04-May-2021 24
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-1: Screening Procedural Outline (CA209848)
Procedure Screening Visit Notes
Assessment of signs and symptoms X Within 14 days prior to randomization.
Serious adverse events (SAE) 
AssessmentXSAEs collected from time of consent.
All AEs (SAEs or non-serious AEs) associated with SARS-CoV-2 infection collected from time of 
consent.
Electrocardiogram (ECG) X Within 14 days prior to randomization.
Laboratory Tests
Hematology and chemistry X See Section 9.4.3 Clinical Safety Laboratory Assessments 
Hepatitis B and hepatitis C testing XWithin 28 days prior to randomization: Hepatitis B and C testing (HBsAg and anti-HCV [HCV-
RNA, if needed])
HIV Testing X Testing for HIV must be performed at sites where mandated locally.
Thyroid function testing X Thyroid panel including TSH, free T3, and free T4 within 14 days prior to randomization
Efficacy Assessments
Body Imaging XFor Solid Tumors: Contrast enhanced CT of the chest, CT/MRI of the abdomen, pelvis, and all 
other known and/or suspected sites of disease, within [ADDRESS_602579] dose.
Brain Imaging XFor Primary CNS Tumor: MRI of the brain without and with gadolinium-based contrast should be 
performed during screening period.
For Solid Tumors: Participants with known or suspected brain metastases, MRI of the brain 
without and with contrast is required unless participant has completed an imaging study of the 
brain within [ADDRESS_602580] can be 
performed if MRI is contraindicated. See Section 9.1.1 for further details
Other: Bone Scan As clinically indicated per local standards. See Section 9.1.1 for further details. 
IRT/Clinical Drug Supplies
Contact [CONTACT_470362]:
For participant number assignment at the time informed consent is obtained.
Within 3 days prior to dosing for study drug vial assignment.
Protocol Amendment No.: 04
Date: 04-May-2021 25
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Note: Some of the assessments referred to in this section may not be captured as data in the eCRF. They are intended to be used  as safety monitoring by [CONTACT_30780]. Additional testing or assessments may be performed as clinically necessary or where required by [CONTACT_343765].
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will not be in cluded in these countries.
Protocol Amendment No.: 04
Date: 04-May-2021 26
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-2: On Study Assessments Treatment Phase - Arm A - Nivolumab in Combination with Ipi[INVESTIGATOR_125] 
(CA209848)
Procedure Day 1Every 2 weeks (i.e., 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every [ADDRESS_602581] X X (see  note)WOCBP only: Serum or urine pregnancy 
test (minimum sensitivity 25 IU/L or 
equivalent units of HCG) to be done 
within 24h prior to first dose of study 
treatment, and then every 4 weeks 
(¬±1 week) regardless of dosing schedule. 
Weight X X (see note) X (see note)Weight must be assessed within 72h prior 
to dosing for adolescents < 40kg, and 
every 6 weeks (i.e., every 3 cycles) for 
adults and adolescents ‚â• 40kg
Physical examination and 
ECOG, Karnofsky or Lansky 
Performance Status XWithin 72h prior to dosing. See Appendix 
6 for ECOG performance status (for 
participants ‚â• 16 years old with solid 
tumors), and Appendix 9 for Karnofsky 
(participants ‚â• 16 years old with CNS as 
primary tumor) and Lansky (for all 
participants < 16 years old)
Targeted physical examination 
and ECOG, Karnofsky or 
Lansky Performance Status XMust be performed within 72h prior to 
dosing and include at a minimum the 
cardiovascular, gastrointestinal, and 
pulmonary body systems. See Appendix 6 
for ECOG performance status (for 
participants ‚â• 16 years old with solid 
tumors), and Appendix 9 for Karnofsky 
(participants ‚â• 16 years old with CNS as 
primary tumor) and Lansky (for all 
participants < 16 years old)
Protocol Amendment No.: 04
Date: 04-May-2021 27
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-2: On Study Assessments Treatment Phase - Arm A - Nivolumab in Combination with Ipi[INVESTIGATOR_125] 
(CA209848)
Procedure Day 1Every 2 weeks (i.e., 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every [ADDRESS_602582] be performed prior to dosing.
Concomitant medication Continuously
Adverse events (including 
serious and non-serious)
assessmentContinuouslyRecord at each visit. All AEs (SAEs or 
non-serious AEs), including those 
associated with SARS-CoV-[ADDRESS_602583] be 
performed within 72h prior to dosing.
Thyroid function testing X X (see note)Thyroid function testing should be done 
every 4 weeks (i.e., Day 1 of every other 
cycle) for the first [ADDRESS_602584] be performed within 72h 
prior to dosing.
Pharmacokinetic Assessment See Section 9.5
Immunogenicity Assessment See Section 9.5
Biomarker assessment See Section 9.8
Collection of tumor tissue for 
biomarkers upon disease 
progressionSee Section 9.8If a biopsy has been performed and tissue 
is available, participants are requested to 
submit fresh tumor tissue for biomarker 
Protocol Amendment No.: 04
Date: 04-May-2021 28
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-2: On Study Assessments Treatment Phase - Arm A - Nivolumab in Combination with Ipi[INVESTIGATOR_125] 
(CA209848)
Procedure Day 1Every 2 weeks (i.e., 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every 2 weeks
research. Tissue submission is optional 
and biopsy is not required by [CONTACT_990].
Additional research collection See Section 9.8.1
Efficacy Assessments
Body Imaging X (see note)For Solid Tumors: Tumor Assessments 
should occur every 12 weeks ( ¬±7 days) 
until BICR confirmation of disease 
progression or treatment 
discontinuation(including treatment 
beyond progression), whichever comes 
later. 
See Section 9.1.1 for further details.
Brain Imaging X (see note)For Primary CNS neoplasms: MRI without 
and with contrast; should have MRI of the 
brain approximately every 12 weeks ( ¬±7 
days) until BICR confirmation of disease 
progression or treatment 
discontinuation(including treatment 
beyond progression), whichever comes 
later. 
For Solid Tumors: Participants with a 
history of brain metastasis or symptoms 
should have a surveillance brain MRI per 
standard of care (approximately 12 weeks) 
or sooner if clinically indicated. 
See Section 9.1.1 for further details.
Protocol Amendment No.: 04
Date: 04-May-2021 29
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-2: On Study Assessments Treatment Phase - Arm A - Nivolumab in Combination with Ipi[INVESTIGATOR_125] 
(CA209848)
Procedure Day 1Every 2 weeks (i.e., 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every 2 weeks
Other: Bone Scan X (see note)As clinically indicated per local standards. 
See Section 9.1.1 for further details.
Outcomes Research
EORTC QLQ-C30 and EQ-5D 
questionnairesXXEach assessment should be completed at 
the start of the clinic visit prior to dosing 
or any study-related procedures. Only
applies to participants ‚â•[ADDRESS_602585] IRT X XWithin 3 days prior to dosing for study 
drug vial assignment
Nivolumab 240 mg Q2W 
(adults and adolescents ‚â• 
40kg)XXParticipants should be dosed within 3 days 
from the scheduled dose. Participants may 
be dosed no less than 12 days from the 
previous dose.
Nivolumab 3 mg/kg Q2W (adolescents < 40 kg)XXParticipants should be dosed within 3 days 
from the scheduled dose. Participants may 
be dosed no less than 12 days from the 
previous dose.
Ipi[INVESTIGATOR_125] 1 mg/kg Q6W (all 
participants)X X (see note)Ipi[INVESTIGATOR_470241] 
6 weeks (i.e., every 3 cycles, Day 1). 
Participants should be dosed within 3 days 
from the scheduled dose
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will not be in cluded in these countries.
Protocol Amendment No.: 04
Date: 04-May-2021 30
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-3: On Study Assessments Treatment Phase - Arm B - Nivolumab Monotherapy (CA209848)
Procedure Day 1Every 4 weeks
(i.e. each subsequent 
cycle Day 1)
(¬±3 Days)Every 12 weeks 
(i.e. every 3 cycles 
Day 1)
(¬±7 Days)Notes
For the purposes of this table, a cycle refers to nivolumab every 
[ADDRESS_602586] X XWOCBP only: Serum or urine pregnancy test (minimum sensitivity 
25 IU/L or equivalent units of HCG) to be done within 24h prior to 
first dose of study treatment, and then every 4 weeks ( ¬±1 week) 
regardless of dosing schedule. 
Weight X X Weight must be assessed within 72h prior to dosing 
Physical examination 
and ECOG, Karnofsky 
or Lansky Performance StatusXWithin 72 hours prior to dosing. See Appendix 6 for ECOG 
performance status (for participants ‚â• 16 years old with solid 
tumors), and Appendix 9 for Karnofsky (participants ‚â• 16 years old 
with CNS as primary tumor) and Lansky (for all participants < 16 
years old)
Targeted physical examination and ECOG, Karnofsky or Lansky Performance StatusXTargeted examination must be performed within 72 hours prior to 
dosing and include at a minimum the cardiovascular, 
gastrointestinal, and pulmonary body systems. See Appendix 6 for 
ECOG performance status (for participants ‚â• 16 years old with 
solid tumors), and Appendix 9 for Karnofsky (participants ‚â• 16 
years old with CNS as primary tumor) and Lansky (for all 
participants < 16 years old)
Vital signs X XTemperature, blood pressure, and heart rate. Must be performed 
prior to study drug administration. 
Concomitant medication Continuously
Adverse events 
(including serious and 
non-serious) assessmentContinuouslyRecord at each visit. All AEs (SAEs or non-serious AEs), including 
those associated with SARS-CoV-[ADDRESS_602587] be collected 
continuously throughout the treatment period. Adverse events and 
laboratory values will be graded according to the NCI-CTCAE 
version 5.
Protocol Amendment No.: 04
Date: 04-May-2021 31
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-3: On Study Assessments Treatment Phase - Arm B - Nivolumab Monotherapy (CA209848)
Procedure Day 1Every 4 weeks
(i.e. each subsequent 
cycle Day 1)
(¬±3 Days)Every 12 weeks 
(i.e. every 3 cycles 
Day 1)
(¬±7 Days)Notes
For the purposes of this table, a cycle refers to nivolumab every 
[ADDRESS_602588] be 
performed within 72h prior to study drug administration.
Thyroid function testing X X (see notes)Thyroid function testing should be done every 4 weeks (i.e., Day 1 
of every cycle) for the first 5 cycles, and then every 8 weeks (i.e., 
Day 1 of every other cycle) until completion of study treatment.
Must be performed within 72h prior to study drug administration.
Pharmacokinetic 
AssessmentSee Section 9.5
Immunogenicity AssessmentSee Section 9.5
Biomarker assessments See Section 9.8
Collection of tumor tissue for biomarkers 
upon disease progressionSee Section 9.8If a biopsy has been performed and tissue is available, participants 
are requested to submit fresh tumor tissue for biomarker research. 
Tissue submission is optional and biopsy is not required by 
[CONTACT_990].
Additional research collectionSee Section 9.8
Efficacy Assessments
Body Imaging XFor Solid Tumors: Tumor Assessments should occur every 12 
weeks ( ¬±7 days) until BICR confirmation of disease progression or
treatment discontinuation(including treatment beyond progression), 
whichever comes later. 
See Section 9.1.1 for further details.
Protocol Amendment No.: 04
Date: 04-May-2021 32
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-3: On Study Assessments Treatment Phase - Arm B - Nivolumab Monotherapy (CA209848)
Procedure Day 1Every 4 weeks
(i.e. each subsequent 
cycle Day 1)
(¬±3 Days)Every 12 weeks 
(i.e. every 3 cycles 
Day 1)
(¬±7 Days)Notes
For the purposes of this table, a cycle refers to nivolumab every 
4 weeks
Brain Imaging XFor Primary CNS neoplasms: MRI without and with contrast 
should have MRI of the brain approximately every 12 weeks (¬± 7 
days) until BICR confirmation of disease progression or treatment 
discontinuation (including treatment beyond progression), 
whichever comes later.
For solid tumor: Participants with a history of brain metastasis or 
symptoms should have a surveillance brain MRI per standard of 
care (approximately 12 weeks) or sooner if clinically indicated. 
See Section 9.1.1 for further details.
Other: Bone Scan XAs clinically indicated per local standards. See Section 9.1.1 for 
further details.
Outcomes Assessments
EORTC QLQ-C30 and 
EQ-5D questionnairesXXEach assessment should be completed at the start of the clinic 
visit prior to dosing or any study-related procedures. Only applies 
to participants ‚â•[ADDRESS_602589] IRT X X Within 3 days prior to dosing for study drug vial assignment
Nivolumab 480 mg Q4W (adults and 
adolescents ‚â• 40 kg)XXParticipants should be dosed within 3 days from the scheduled 
dose. The minimum interval between doses is 22 days.
Nivolumab 6 mg/kg Q4W (adolescents < 
40 kg)XXParticipants should be dosed within 3 days from the scheduled 
dose. The minimum interval between doses is 22 days.
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will not be in cluded in these countries.
Protocol Amendment No.: 04
Date: 04-May-2021 33
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-4: On Study Assessments Treatment Phase ‚Äì Arm B Rollover ‚Äì Participants Treated with Nivolumab in 
Combination with Ipi[INVESTIGATOR_470242] (CA209848)
Procedure Day 1Every 2 weeks (i.e. 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every [ADDRESS_602590] X X (see  note)WOCBP only: Serum or urine pregnancy 
test (minimum sensitivity 25 IU/L or 
equivalent units of HCG) to be done 
within [ADDRESS_602591] dose of study 
treatment, and then every 4 weeks 
(¬±1 week) regardless of dosing schedule. 
Weight X X (see note) X (see note)Weight must be assessed within 72h prior 
to dosing for adolescents < 40 kg, and 
every 6 weeks for adults and adolescents ‚â• 
40 kg
Physical examination and 
ECOG, Karnofsky or Lansky Performance Status XWithin 72 hours prior to dosing. See 
Appendix 6 for ECOG performance status 
(for participants ‚â• 16 years old with solid 
tumors), and Appendix 9 for Karnofsky 
(participants ‚â• 16 years old with CNS as 
primary tumor) and Lansky (for all 
participants < 16 years old)
Targeted physical examination 
and ECOG, Karnofsky or 
Lansky Performance Status XTargeted examination must be performed 
within 72 hours prior to dosing and 
include at a minimum the cardiovascular, 
gastrointestinal, and pulmonary body 
systems. See Appendix 6 for ECOG 
performance status (for participants ‚â• 16 
years old with solid tumors), and
Appendix 9 for Karnofsky (participants ‚â• 
16 years old with CNS as primary tumor) 
and Lansky (for all participants < 16 years 
old)
Protocol Amendment No.: 04
Date: 04-May-2021 34
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-4: On Study Assessments Treatment Phase ‚Äì Arm B Rollover ‚Äì Participants Treated with Nivolumab in 
Combination with Ipi[INVESTIGATOR_470242] (CA209848)
Procedure Day 1Every 2 weeks (i.e. 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every [ADDRESS_602592] be performed prior to dosing. 
Concomitant medication Continuously
Adverse events (including 
serious and non-serious) 
assessmentContinuouslyRecord at each visit. All AEs (SAEs or 
non-serious AEs), including those 
associated with SARS-CoV-[ADDRESS_602593] be 
performed within 72h prior to dosing.
Thyroid function testing X X (see note)Thyroid function testing should be done 
every 4 weeks (i.e., Day 1 of every other 
cycle) for the first [ADDRESS_602594] be performed within 72h 
prior to dosing.
Pharmacokinetic Assessment See Section 9.5
Immunogenicity Assessment See Section 9.5
Biomarker assessment See Section 9.8
Collection of tumor tissue for 
biomarkers upon disease 
progressionSee Section 9.8If a biopsy has been performed and tissue 
is available, participants are requested to 
submit fresh tumor tissue for biomarker 
Protocol Amendment No.: 04
Date: 04-May-2021 35
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-4: On Study Assessments Treatment Phase ‚Äì Arm B Rollover ‚Äì Participants Treated with Nivolumab in 
Combination with Ipi[INVESTIGATOR_470242] (CA209848)
Procedure Day 1Every 2 weeks (i.e. 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every 2 weeks
research. Tissue submission is optional 
and biopsy is not required by [CONTACT_990].
Additional research collection See Section 9.8.1
Efficacy Assessments
Body Imaging X (see note)For Solid Tumors: Tumor Assessments 
should occur every 12 weeks ( ¬±7 days) 
until BICR confirmation of disease 
progression or treatment discontinuation
(including treatment beyond progression), 
whichever comes later. 
See Section 9.1.1 for further details.
Brain Imaging X (see note)For Primary CNS neoplasms: MRI without 
and with contrast; should have MRI of the 
brain approximately every 12 weeks ( ¬±7 
days) until BICR confirmation of disease 
progression or treatment discontinuation
(including treatment beyond progression), 
whichever comes later.
For solid tumors: Participants with a 
history of brain metastasis or symptoms 
should have a surveillance brain MRI per 
standard of care (approximately 12 weeks) 
or sooner if clinically indicated. 
See Section 9.1.1 for further details.
Other: Bone Scan X (see note)As clinically indicated per local standards. 
See Section 9.1.1 for further details.
Protocol Amendment No.: 04
Date: 04-May-2021 36
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-4: On Study Assessments Treatment Phase ‚Äì Arm B Rollover ‚Äì Participants Treated with Nivolumab in 
Combination with Ipi[INVESTIGATOR_470242] (CA209848)
Procedure Day 1Every 2 weeks (i.e. 
every subsequent cycle 
Day 1) 
(¬±¬±3 Days)Every 6 weeks 
(i.e. every 3 cycles 
Day 1 ( ¬±3 Days)Every 12 weeks 
(i.e. every 6 
cycles Day 1) 
(¬±7 Days)Notes
For the purposes of this table, a cycle 
refers to nivolumab every 2 weeks
Outcomes Research
EORTC QLQ-C30 and EQ-5D 
questionnairesXXEach assessment should be completed at 
the start of the clinic visit prior to dosing 
or any study-related procedures. Only 
applies to participants ‚â• [ADDRESS_602595] IRT X XWithin 3 days prior to  dosing for study 
drug vial assignment
Nivolumab 240 mg Q2W (adults and adolescents 
‚â•40kg)XXParticipants should be dosed within 3 days 
from the scheduled dose. Participants may 
be dosed no less than 12 days from the 
previous dose.
Nivolumab 3 mg/kg Q2W (adolescents < 40 kg)XXParticipants should be dosed within 3 days 
from the scheduled dose. Participants may 
be dosed no less than 12 days from the 
previous dose.
Ipi[INVESTIGATOR_125] 1mg/kg Q6W (all participants)X X (see note)Ipi[INVESTIGATOR_470241] 
6 weeks (i.e., every 3 cycles, Day 1). 
Participants should be dosed within 3 days 
from the scheduled dose
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will not be in cluded in these countries.
Protocol Amendment No.: 04
Date: 04-May-2021 37
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-5: Follow-up Assessments CA209848
ProcedureFollow-up Visits 
X01 (Day 30) ( ¬±¬±7 Days) 
and X02 (Day 100)a
(¬±7D a ys) after Last DoseSurvival
Follow-up Visitsb
Every 3 months
(¬± 14 Days)Notes
Safety Assessments
Targeted Physical Examination XTargeted examination must include the cardiovascular, 
gastrointestinal, and pulmonary body systems and examination to 
specific malignancy. 
To assess for potential late emergent study drug related findings. 
Adverse events assessment XRecord at each visit. All AEs and SAEs must be collected 
continuously up to [ADDRESS_602596] (as defined in Section 9 ), and all AEs (SAEs and 
non-serious AEs) associated with confirmed or suspected SARS-
CoV-[ADDRESS_602597] to follow-up (as 
defined in Section 8.3 ), or for suspected cases, until SARS-CoV-[ADDRESS_602598] X WOCBP only: serum or urine
Outcome Research Assessment
EORTC QLQ-C30 questionnaire X Only participants ‚â• 18 years of age at baseline. See Section 9.10
for more details.
Protocol Amendment No.: 04
Date: 04-May-2021 38
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2-5: Fo llow-up Assessments CA209848
ProcedureFollow-up Visits 
X01 (Day 30) ( ¬±¬±7 Days) 
and X02 (Day 100)a
(¬±7 Days) after Last DoseSurvival
Follow-up Visitsb
Every 3 months
(¬± 14 Days)Notes
EQ-5D questionnaire X X May be obtained through a telephone call or clinic visit. Only 
participants ‚â• 18 years of age at baseline. See Section 9.10 for 
more details.
Efficacy Assessments
Body Imaging X (See note) X (See note)Only for solid tumor participants without progression.
Tumor Assessments should occur every 12 weeks ( ¬±7 days) from
date of first dose until BICR confirmation of disease progression 
and treatment discontinuation (including treatment beyond 
progression), whichever comes later. 
See Section 9.1 for further details.
Brain Imaging X (See note) X (See note)Primary CNS neoplasms: MRI without and with contrast should 
have MRI of the brain approximately every 12 weeks ( ¬±7 days)
until BICR confirmation of disease progression or treatment 
discontinuation (including treatment beyond progression), 
whichever comes later.
For Solid Tumors: Participants with a history of brain metastasis or 
symptoms should have a surveillance brain MRI per standard of 
care (approximately 12 weeks) or sooner if clinically indicated.
See Section 9.1for further details.
Other: Bone Scan X (See note) X (See note)As clinically indicated per local standards.
See Section 9.1for further details.
Participa nt status XEvery 3 months after X02; may be accomplished by [CONTACT_470363], to update survival information 
Collect all subsequent anti-cancer treatment.
aParticipants must be followed for at least [ADDRESS_602599] dose of study treatment. Follow-up visit #1 (FU1) occurs approximately 3 0d a y s  ( ¬±7 days) after the 
last dos e or coinciding with the date of discontinuation (¬± 7 days) if date of discontinuation is gr eater than [ADDRESS_602600] dose. Follow -up visit #2 (FU2) 
occurs approximately 100 days ( ¬±7 days) from last dose. Both FU1 and FU2 should be conducted in person.
Protocol Amendment No.: 04
Date: 04-May-2021 39
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
bSurvival Follow-up visits to occur every 3 months ¬± [ADDRESS_602601], each participant will be contact[CONTACT_470364]. Survival follow-up may be conducted in person or by [CONTACT_756].
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602602] anti-tumor immune 
responses. Nivolumab, an anti-PD-1 blocking an tibody, has demonstrated overall survival benefit 
in multiple tumors including non-squamous cell lung cancer, squamous cell lung cancer, 
melanoma, renal cell carcinoma and head and neck cancer. Recent data across multiple tumor types support the hypothesis that patients with tumors harboring increased somatic mutations due to 
DNA mis match-repair deficiencies are more likely to respond to anti-PD-1/PD-L1 and anti-CTLA-
4 blockade. Tumor mutational burden (TMB) refers to the total number of somatic mutations that 
exist within a tumor‚Äôs genome. A subset of these mutations may result in expressed proteins that 
are not recognized by [CONTACT_40689]‚Äôs immune system as  self, and therefore has the potential to be 
immunogenic and more susceptible to immune-mediated anti-tumor response. The primary goal of this study is to demonstrate the clinical activity of nivolumab in combination with ipi[INVESTIGATOR_470231].
3.[ADDRESS_602603] a higher number of neo-antigens which, in 
principle, would be expected to be more immunogenic than tumors with comparatively low 
mutational burden.
1Therefore, high TMB has been hypothesized to correlate with improved 
efficacy in patients treated wi th immune-oncology (IO) therapi[INVESTIGATOR_014]. This hypothesis has been 
supported by [CONTACT_470359][INVESTIGATOR_014], tumor types, and lines of treatment. The 
first published study of TMB as a biomarker of clinical ou tcomes was reported by [CONTACT_102432], 
where high TMB (TMB-H) was found to be associated with efficacy in metastatic melanoma 
patients treated with anti-CTLA-[ADDRESS_602604] of TMB on efficacy of a PD-1/L1 inhibitor.
3This analysis demonstrated that in patients 
with TMB-H, the ORR was numerically higher in the nivolumab arm versus the chemotherapy 
arm (47% vs 28%) and the median PFS was longer in the nivolumab arm compared to the chemotherapy arm (9.7 vs 5.8 mo., HR 0.62; 95% CI 0.38, 1.00). OS was notable, though similar (18.3 vs 18.8 mo. and 1 year OS rates of 64% vs 60%, respectively), between the arms in patients 
with TMB-H, although of note, 68% of patients in the chemotherapy arm received subsequent 
nivolumab.
4Interestingly, the ORR and mPFS rates observed in the TMB-H subgroup in the 
nivolumab arm within CheckMate [ADDRESS_602605] line NSCLC study 
of pembrolizumab (K eynote-024), where ORR and mPFS were 45% and 10.3 months, 
respectively, in patients with ‚â• 50% PD-L1 expression treated with pembro lizumab monotherapy.[ADDRESS_602606] line treatment 
in patients with metastatic NSCLC of TMB ‚â•10 mut/Mb, demonstrated significantly better and 
durable clinical response a nd progression-free survival benefit compared to chemotherapy, 
Protocol Amendment No.: 04
Date: 04-May-2021 41
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
including ORR 45.3% vs 26.9%, DOR ‚â•1 yr 68% vs 25%, PFS rate at 1 yr 43% vs 13%, and mPFS 
of 7.2 vs 5.4 months. Preliminary analysis on OS wa s also encouraging, and the clinical benefits 
are independent of PD-L1 expression. These findings further support TMB as an important, 
predictive and independent biomarker for clinical efficacy.
Recently, Yarchoan M, et al suggested a s ignificant positive linear c orrelation between higher 
TMB and increased ORR after analyzing 27 tumor types/subtypes treated with anti-PD-1/PD-L1 
monotherapy, which highlights the potential st rong relationship between TMB and the clinical 
activity of anti-PD-1/PD-L1 therapi[INVESTIGATOR_470243].6
Figure 3.1.1-1: Correlati on between Tumor Mutational Burden and Objective 
Response Rate with Anti‚ÄìPD-1 or Anti‚ÄìPD-L1 Therapy
Taken together, the available data suggest that,  in addition to PD-L1, TMB is also an important 
predictive biomarker of the clin ical eff icacy of IO therapy. Therefore, patients of TMB-H across 
multiple solid tumors will be selected for participation in this clinical study.
Protocol Amendment No.: 04
Date: 04-May-2021 42
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Prevalence of TMB-H tumor: Selected tumors and their c orresponding prevalence by [CONTACT_470365]: 
Figure 3.1.1-2: Tumor Mutational Burden in Various Tumor Types
Analyzed using an algorithm developed to extract mutational signatures from catalogues of somatic mutations in 7042 
primary cancers. Source: adapted from Alexandrov LB, et al. Nature 2013;500:415-[ADDRESS_602607] supportive 
care. The low prevalence of TMB-H in these tumor types limits the feasibility of traditional large-
scale randomized trials. As a result, a high un met medical need exists for these patients, with no 
less expectation for immunotherapy activity.
3.1.3 Rationale for Inclusion of Adolescent Participants
The majority of pediatric patients with cancer are enro lled in clinical trials; however, enrollment
has been shown to decrease with age, and only 10% to 15% of older adolescents (ages 12 to 19) 
with cancer participate in clinical trials and is cons idered an unmet need. Much of the more than 
50% decrease in overall childhood cancer mortality since [ADDRESS_602608] problemat ically, a d elay in new efficacious therapi[INVESTIGATOR_470244]. It has been reco mmended that adolescents be considered for trials in adult populations 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602609] the option of opting out of adolescent eligibility.
This section is not app licable for sites in Belgium or the Netherlands as adolescents will not be 
included in these countries.
3.1.4 Rationale for Key Endpoints
Objective response rate (ORR) assessed by a blinded independent central review committee is the 
primary e ndpoint of this study. ORR is a v alidated clinical endpoint in many tumors, and in patients 
in whom a durable tumor response is achieved can be expected to derive a survival benefit from 
therapy.10
[IP_ADDRESS] Rationale for Independent Central Review 
The primary endpoint of ORR will be based on centrally-assessed radiologic tumor measurements 
(and additional clinical indicators, where applicable) using standard disease-specific response 
criteria. A centrally -assessed ORR will provide standardized assessment of progression and 
response using disease-specific response criteria. For this purpose, radiologic imaging from this study will be trans mitted to an imaging core lab for analysis by a Blinded Independent Central 
Review (BICR) committee. Please see Section 9.1 and CA209848 Imaging Manual for additional 
information.
[IP_ADDRESS] Rationale for Investigator Assessed Response
Investigator-assessed radiologic tumor measuremen ts (and additional clinical indicators, where 
applicable) using standard disease-specific response criteria will closely reflect observed clinical 
practice responses, and w ill allow for real-time tr eatment decisions based on the most 
comprehensive, available, clinical information for the individual participant.
3.1.5 Rationale for Exploratory Biomarker Assessments 
An effective anti-tumor immune response relies on a number of interactions, beginning with the 
immune system recognizing the tumor cell as fo reign. One important means of recognition is the 
expression of unique tumor-specific peptides (i.e ., neoantigens) that are processed, presented via 
the major histocompatibility complex (MHC), and subsequently recognized by T cells as 
immunologic targets. This triggers an immune response driven by T-cell activation, cytokine 
production, peripheral expansion, and infiltration of effector cells that ultimately k ill the tumor 
cell.
A number of factors can suppress an effective anti-tumor response, including a lack of str ong 
tumor neoantigens recognized by T cells, downregulation of the MHC on cancer cells, minimal 
activation or inactivation of  T cells, poor infiltration of effector cells into tumors, and the actions 
of immune checkpoint proteins (e.g., programmed cell death protein 1 [PD-1], programmed death 
ligand 1 [PD-L1], cytotoxic T-lymphocyte- associated protein 4 [CTLA-4]) and tumor 
microenvironment modulators (e.g., regulatory T c ells [TRegs] and myelo id-derived suppressor 
cells [MDSCs]), which limit the strength and duration of immune responses.
Protocol Amendment No.: 04
Date: 04-May-2021 44
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
As described by [CONTACT_470366].,11requirements for T-cell-mediated tumor control (and targets for 
potential biomarker selection for immuno-oncology therapy) include: tumor foreignness, general 
immune status, immune cell infiltration, absence of checkpoints, absence of soluble inhibitors, absence of inhibitory tumor metabolism, and tumor sensitivity to immune effectors. 
Tumor PD-L1 is already an established clinically validated biomarker with available 
complementary/companion dia gnostic tests for anti-PD-1/L1 therapi[INVESTIGATOR_470245]. The 
utility of tumor PD-L1 as the sole predictive biomarker is limited by [CONTACT_470367]-off value for PD-L1 expression that reliably selects all patients likely to benefit from immuno-
oncology therapy. For example, in SCCHN study CA209141, while improved efficacy was 
observed with increasing PD-L1 expression, durable responses were also observed in patients with 
PD-L1 non-expressing tumors.
Due to the complexity of the immune system and its response to immuno-oncology therapy, 
additional biomarkers beyond PD-L1 are being i nvestigated to help clinicians to select therapy for 
patients most likely to benefit (e.g., those ‚Äòimmune-primed‚Äô patients with one or more 
tumor/immune characteristics that indicate a positive response to immuno-oncology therapy) or to 
suggest alternative combinations beyond immuno-oncology therapy alone. Exploratory biomarkers that may be assessed in this study include but are not limited to: tumor gene expression 
profiling, PD-L2, CD8, and myeloid derived suppressor cells (MDSCs). 
3.1.[ADDRESS_602610] of tr eatment from 
the participant‚Äôs perspective and offer insights into patient experience that may not be captured 
through physician reporting. Additionally, generic health-related quality of life measures provide data needed for calculating utility valu es to inform health economic models.
3.2 Background
OPDIVO
¬Æ(nivolumab), is a human programmed death receptor-1 (PD-1)12blocking antibody 
approved for unresectable or metastatic melanoma, previously tr eated metastatic squamous non-
small cell lung cancer (NSCLC), advanced renal cell carcinoma, and classical Hodgkin lymphoma 
in the [LOCATION_002] and in Japan for unresectable melanoma, kidney cancer, and NSCLC, and is 
in clinical development for the treatment of other malignancies. Nivolumab has also demonstrated 
clinical activity as combination therapy with ipi[INVESTIGATOR_195176], NSCLC, RCC, and Hodgkin lymphoma. The majority of responses were durable and exceeded 6 months. 
The overall safety experience with nivolumab, as a monotherapy or in combination with other 
therapeutics, is based on experience in approximately 224,573 participants treated to date. Overall, 
the safety profile of nivolumab monotherapy is manageable and generally consistent across 
completed and ongoing clinical trials with no maximum tolerated dose (MTD) reached at any dose tested up to 10 mg/kg. There was no pattern in the incidence, severity, or causality of AEs to 
nivolumab dose level. Most AEs were low grade (Grade 1 - 2) with relatively few related high grade (Grade 3 - 4) AEs. 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602611] that ar e potentially associated with the use of 
nivolumab, Bristol-Myers Squibb (BMS) has identified select AEs based on the following 
principles: AEs that may differ in type, frequency, or severity from AEs caused by [CONTACT_2111][INVESTIGATOR_470246]-modulating; AEs that may requi re immunosuppression  (e.g. corticosteroids) as 
part of their management; AEs whose early recognition and management may mitigate severe 
toxicity; AEs for which multiple event terms may be used to describe a single type of AE, thereby [CONTACT_368473]. 
Based on these principles and taking into account the types of AEs already observed across studies 
of nivolumab monotherapy, pneumonitis, interstitial nephritis, diarrhea/colitis, hepatitis, rash, endocrinopathies, and hypersensitivi ty/infusion reaction events are currently considered to be 
select AEs. The majority of these AEs have been managed successfully with supportive care and, 
in more severe cases, a combination of dose delay, permanent discontinuation, and/or initiation of systemic corticosteroids. 
This protocol will generate efficacy and safety data on nivolumab in combination with ipi[INVESTIGATOR_470247], metastatic and unresectable select tumor types 
of TMB-H (excluding melanoma, RCC, NSCLC a nd hematologic malignancies), some of which 
have not been previously examined in clinical trials.
3.2.1 Mechanism of Action of Nivolumab 
Cancer immunotherapy rests on the premise that tumors  can be recognized as foreign rather than 
as self and can be effectively attacked by [CONTACT_20397]. An effective immune 
response in this setting is thought to rely on immune surveillance of tumor antigens expressed on 
cancer cells that ultimately results in an  adaptive immune response and cancer cell death. 
Meanwhile, tumor progression may depend upon acquisition of traits that allow cancer cells to 
evade immunosurveillance and escape effective innate and adaptive immune responses. 
13,14,15. 
Current immunotherapy efforts attempt to br eak the apparent tolerance of the immune system to 
tumor cells and antigens by [CONTACT_470368]. T-cell stimulation is a complex process 
involving the integration of numerous positive as well as negative co-s timulatory signals in 
addition to antigen recognition by [CONTACT_941] T- cell r eceptor (TCR).16Collectively, these signals govern 
the balance between T-cell activation and tolerance. 
PD-1 is a member of the CD28 family of T-cell co-s timulatory receptors that also includes CD28, 
CTLA 4, ICOS, and BTLA.17PD-1 signaling has been shown to inhibit CD-28-mediated 
upregulation of IL-2, IL-10, IL- 13, interferon- Œ≥ (IFN-Œ≥) and Bcl-xL. PD-[ADDRESS_602612] genetic factors. Thus, PD-1 deficiency or inhibition is not accompanied by a universal loss of 
tolerance to self-antigens.
Protocol Amendment No.: 04
Date: 04-May-2021 46
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
In vitro, nivolumab (BMS-936558) binds to PD-1 with high affinity (EC50 0.39-2.62 nM), and 
inhibits the binding of PD-1 to its ligands  PD-L1 and PD-L2 (IC50 1 nM). Nivolumab binds 
specifically to PD-[ADDRESS_602613] by [CONTACT_102428] a reproducible enhancement 
of both proliferation and IFN- Œ≥ release in the mixed lymphocyte reaction (MLR). Using a 
cytomegalovirus (CMV) re-stimulation assay with human peripheral blood mononuclear cells 
(PBMC), the effect of nivolumab on antigen specific recall response indicates that nivolumab 
augmented IFN- Œ≥ secretion from CMV specific memory T cells in a dose-dependent manner versus 
isotype-matched control. In vivo blockade of PD-1 by a murine analog of nivolumab enhances the 
anti-tumor immune response and resu lts in tumor rejection in several immunocompetent mouse 
tumor models (MC38, SA1/N, and PAN02).19
3.2.2 Ipi[INVESTIGATOR_102289]-4, an activation-induced T-cell surface molecule, is a member of the CD28:B7 
immunoglobulin superfamily that competes with  CD28 for B7. CTLA-4 mediated signals are 
inhibitory and turn off T cell-dependent immune responses.20Ipi[INVESTIGATOR_142] a fully human 
monoclonal IgG1Œ∫  that binds to the CTLA-4 antigen expressed on a subset of T cells from human 
and nonhuman primates. The proposed mechanism of action for ipi[INVESTIGATOR_470248]-4 with B7 molecules on APCs, with subsequent blockade of the inhibitory 
modulation of T-cell activation promoted by [CONTACT_102429] 4/B7 interaction.
3.2.[ADDRESS_602614] been studied concomitantly 
with ascending doses of ipi[INVESTIGATOR_470249].In each arm in this multi-arm study, ipi[INVESTIGATOR_460527] 3 weeks for 4 
doses with nivolumab administered once every 3 weeks for 8 doses. Starting at week 24,
ipi[INVESTIGATOR_251369] 12 weeks for 8 doses. The threeinitial dose-escalatio n cohorts consisted of Cohort 1 (nivolumab 0.3 mg/kg + ipi[INVESTIGATOR_125] 3 
mg/kg; n=14), Cohort 2 (nivolumab 1.0 g/kg + ipi[INVESTIGATOR_125] 3 mg/kg; n =17) and Cohort 3 
(nivolumab 3.0 mg/kg + ipi[INVESTIGATOR_125] 3 mg/kg; n = 6). Later, the study was amended to include 
Cohort 2a which evaluated nivolumab 3 mg/ kg + ipi[INVESTIGATOR_125] 1 mg/kg (n - 16). The primary 
objective was to assess safety/tolerability; th e secondary objective was to assess preliminary 
efficacy.
Of the 52 participants evaluable for response as of the 15-Feb-2013 clinical cut-off in CA209004,
21 participants (40%) had an objective response by [CONTACT_470369](mWHO) criteria. In an additional 2 participants (4%) there was an unconfirmed objective response. In Cohort 1 (0.1 mg/kg nivolumab + 3 mg/kg ipi[INVESTIGATOR_125]), 3 out of 14 evaluable
Protocol Amendment No.: 04
Date: 04-May-2021 47
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
participants had an objective response by [CONTACT_143884] (21%), including 1 CR and 2 PRs. In Cohort
2 (1 mg/kg nivolumab + 3 mg/kg ipi[INVESTIGATOR_125]), 9 out of 17 (53%) evaluable participants had anobjective response by [CONTACT_143884], including 3 CRs (18%) and 6 PRs (35%). In Cohort 2a (3 
mg/kg nivolumab + 1 mg/kg ipi[INVESTIGATOR_125]), 6 out of 15 ( 40%) response evaluable participants
had an objective response by [CONTACT_143884], incl uding 1 CR (7%) and 5 PRs (33%). In Cohort 3 (3 
mg/kg nivolumab + 3 mg/kg ipi[INVESTIGATOR_125]), 3 out of 6 (50%) evaluable participants had an objectiveresponse by [CONTACT_143884], all 3 of which were PRs (50%).
Preliminary analysis revealed 16 of the 52 evaluable participants (31%) had > 80% reduction in
the size of target tumor lesions by [CONTACT_68069] 12 evaluation. This is compared to < 2% for 3 mg/kg ipi[INVESTIGATOR_143721]184020 (N=540) and < 3% for nivolumabmonotherapy based on CA209003 (N=94, 0.1-10 mg/kg).
The following dose limiting toxicities ( DLTs) were observed: in Cohort 1, Grade [ADDRESS_602615]/ALT (1 participant) ; in Cohort 2, Grade 3 uveitis (1 par ticipant) and Grade [ADDRESS_602616]/ALT (1 participant) and in Cohort 3, Grad e 4 elevated lipase (2 participants) and Grade 3
elevated lipase (1 participant). Bas ed on these data, Cohort 2 was identified as the m a x i m u m
tolerated dose (MTD) and Cohort [ADDRESS_602617] 1 adverse event (AE) regardless of causalityhas been reported in 98% of participants treated. The most common (reported at 10% incidence)
treatment related AEs (any Grade 9 3%; Grade 3-4 5 3 %:) are rash (55%; 4%), pruritus (47%;
0%), vitiligo (11%; 0%), fatigue (38%; 0%), pyrexia (21%, 0%), diarrhe a (34%; 6%), nausea (21%,
0%), vomiting (11%, 2%), ALT increased (21%; 11%), AST increased (21%; 13%), lipase
increased (19%; 13%), amy lase increased (15%, 6%), headache (11%, 0%), and cough (13%, 0%).
The majority of AEs leading to discontinuation (regardless of causality) were Grade 3 or 4 (reported in 11 of 53 participants, 21%). Grade [ADDRESS_602618]
increased. No drug-related deaths were reported.
21
The combination of nivolumab with ipi[INVESTIGATOR_470250] 1 study CA209016.
Participants with metastatic RCC (mRCC; Karnofsky performance status (KPS) ‚â• 80%; untreated 
or any number of prior therapi[INVESTIGATOR_014]) were randomized to receive nivolumab 3 mg/kg + ipi[INVESTIGATOR_125] 1 
mg/kg (arm N3 + I1) or nivolumab 1 mg/kg + ip ilimumab 3 mg/kg (arm N1 + I3) IV Q3W for 4 
doses followed by [CONTACT_20382] 3 mg/kg IV Q2W until progression/toxicity. The primary objective was to assess safety/tolerability; secondary objective was to assess antitumor activity. 
Participants were randomized to N3 + I1 (n = 47) and N1 + I3 (n = 47). Approximately half (n = 
46; 51%) had prior systemic therapy (N3 + I1: 22; N1 + I3: 26). 
After a median follow-up of 22.[ADDRESS_602619] 1.1 (R esponse 
Evaluation Criteria in Solid Tumors) was 40.4% (N = 47) in both Arms N3 + I1 and N1 + I3; 
Protocol Amendment No.: 04
Date: 04-May-2021 48
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
42.1% (n = 8) and 36.8% (n = 7) had an ongoing response, with a median DOR of 88.7 weeks 
(95% CI: 37.14, NA) and 85.9 weeks (95% CI: 35.14, NA ), respectively. Median PFS was 7.7 
months (95% CI: 3.71, 14.29) and 9.4 mont hs (95% CI: 5.62, 18.63) in Arms N3 + I1 and N1 + 
I3, resp ectively. OS at 12 months was 80.9% and 85.0% in Arms N3 + I1 and N1 + I3, respectively, 
and at 24 months was 67.3% and 69.6%, respectively.
The safety of nivolumab combined with ipi[INVESTIGATOR_143723]209016. Treatment-
related AEs were seen in 88/94 pts (94%), including 43/47 (92%) in N3 + I1 and 45/47 (96%)
in N1 + I3.The most frequently reported drug-related AEs in N3 + I1 included fatigue (66%), 
cough (53.2%), and arthralgia (51.1%); the majority were Grade 1- 2. The most frequently reporteddrug-related AEs in N1 + I3 included fati gue (74.5%), nausea (55.3%), and diarrhea (53.2%). The
majority were Grade 1-2.
Treatment-related AEs leading to discontinuation ( 31.9% versus 10.6%), and treatment-related
serious adverse events (SAEs) (34% versus 23.4%) occurred more commonly in participants
in the N1 + I3 arm than in the N3 + I1 arm, respectively. 
22
CA209012 was a multi-arm Phase 1b trial evaluating the safety and tolerability of nivolumab in 
patients with chemotherapy-na√Øve advanced non-small cell lung cancer (NSC LC), as either a 
monotherapy or in combination with other agents including ipi[INVESTIGATOR_125], at different doses and 
schedules. The primary endpoint of the study was safety with secondary endpoints of ob jective 
response rate (ORR) per RECIST 1.1 and 24-week progression-free survival (PFS). Participants 
were assigned to receive nivolumab 3 mg/kg Q2W + ipi[INVESTIGATOR_125] 1mg/kg Q12W (n=38), 
nivolumab 3mg/kg Q2W + ipi[INVESTIGATOR_125] 1 mg/kg Q6W (n = 39) and nivolumab 3 mg/kg Q2W 
(n=52). The confirmed ORR was 47% (N3 q2w + I1 q12w), 39% (N3 q2w + I1q6w) and 23% (N3 
Q2W). The median duration of response (DOR) was not reached in any of these groups. 
The rate of treatment-related adverse events (AEs) in the Q12W (82%) and Q6W (72%) arms were 
comparable to monotherapy (72%). In the study, Grade 3/4 adverse events were 37%, 33%, and 
19% for the Q12W, Q6W and nivolumab monotherapy arms, respectively. Treatment-related Grade 3-4 AEs led to discontinuation in 5% and 8% of participants in the Q12W and Q6W cohorts, respectively, and were  similar to nivolumab monotherapy. There were no tr eatment-related deaths. 
The treatment-related select AEs in patients administered the optimized dosing schedule (3 mg/kg 
of nivolumab Q2W plus 1 mg/kg of ipi[INVESTIGATOR_125] Q6W) were skin related (36%), gastrointestinal 
(23%), endocrine (20%), and pulmonary (5%) and there were ‚â§ 5% treatment related Grade [ADDRESS_602620] line melanoma patients. In this study, combination of nivolumab 1 mg/kg and ipi[INVESTIGATOR_125] 3 mg/kg for 4 doses,
followed by [CONTACT_20382] 3 mg/kg, Q2W (NIVO+IPI), compared with ipi[INVESTIGATOR_125] 3 mg/kg, Q3W x
4 doses (IPI) demonstrated a s ignificant improvement in OS and PFS, with mOS not r eached in 
the NIVO+IPI [INVESTIGATOR_470251] 19.98 months in the IPI [CONTACT_19313], and mPFS 11.7 months in the NIVO+IPI [INVESTIGATOR_470251] 2.9 months in the IPI [CONTACT_19313]. When NIVO+IPI [INVESTIGATOR_470252] 3 mg/kg group (NIVO), a numeric difference in OS and improved PFS 
Protocol Amendment No.: 04
Date: 04-May-2021 49
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
(mPFS of 11.73 vs 6.87 months) were observed in fa vor of the combination. The ORR in NIVO+IPI 
(58.9%) was significantly higher than the IPI [CONTACT_19313] (19.0%) and numerically higher than NIVO 
group (44.6%). The overall safety profile of NIVO+IPI [INVESTIGATOR_470253]. In
general, the frequency of AEs was lowest acro ss AE categories in th e NIVO group an d highest
in the NIVO+IPI [CONTACT_19313]. Treatment-related AEs of Grade 3 or 4 occurred in 59% patients of the 
NIVO+IPI [CONTACT_19313], 21% of the NIVO group and 34% of the IPI [CONTACT_19313]. Analyses of immune-mediated 
AEs (IMAE) showed that most IMAEs were Grade 1-2. The majority of IMAEs in the IMAE categories of diarrhea/colitis, and hepatitis were Grade 3-4. The majority of IMAEs resolved
and were manageable using the recommended treatment guidelines for early evaluation and 
intervention.
[ADDRESS_602621] line patients with RCC. Among the 
intermediated/poor-risk participants, combination of nivolumab and ip ilimumab therapy 
(NIVO+IPI, nivolumab 3 mg/kg and ipi[INVESTIGATOR_125] 1 mg/kg, Q3W for 4 doses then followed by 
[CONTACT_20382] 3 mg/kg, Q2W) demonstrated a sta tistically significant h igher ORR (41.6%) than
sunitinib (26.5%). CR was achieved  in 9.4% vs 1.2% in NIVO+IPI [INVESTIGATOR_470254],
respectively. Responses in the NIVO+IPI [INVESTIGATOR_470255] (media n TTR of 2.79 months)
and were durable (median DOR not reached). In the sunitinib group, mTTR (3.04 months) was 
similar but responses were less durable (18.17 months). NIVO+IPI [INVESTIGATOR_470256] (mOS was not reached) compared with 
sunitinib (mOS of 25.95 months). The overall safety profile of NIVO+IPI [INVESTIGATOR_470257] . Treatment-related AEs occurred in 93% of patients receiving 
NIVO+IPI, and 97% receiving sunitinib; Grade 3 or 4 AEs occurred in 46% and 63%, and treatment-related AEs leading to discontinu ation occurred in 22% and 12%, respectively. Most 
IMAEs were Grade 1-2, and the majority of IMAEs resolved and were manageable using the 
recommended treatment guidelines for early evaluation and intervention.
25
3.2.4 Nivolumab Combined with Ipi[INVESTIGATOR_470258]. A pediatric 
phase 1 trial of ipi[INVESTIGATOR_321205] 1, 3, 5, and 10 mg/m2doses concluded that ipi[INVESTIGATOR_470259].26A multi-center phase 2 trial of ipi[INVESTIGATOR_125] 3 
mg/kg and 10 mg/kg Q4 weeks x 4 doses in adolescents with metastatic melanoma 
([STUDY_ID_REMOVED]) has recently closed e nrollment, and the study report is being prepared. Another 
phase 1 study with ip ilimumab in children and adolescents  with treatment-resistant cancer 
([STUDY_ID_REMOVED]) was reported as completed recently, and study results have not been released.
Nivolumab and nivolumab in combination with ipi[INVESTIGATOR_470260]‚Äôs Oncology Group (COG) Phase 1/2 st udy ( ADVL 1412; 
CA209070; [STUDY_ID_REMOVED]), including part icipants with relapsed refractory solid tumors and 
lymphoma. Good tole rability was demons trated in safety lead-in phase for both tr eatment arms, 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602622] been studied to date (Spring 2017 COG Meeting; personal communication), of which 78 received nivolumab mo notherapy and 32 received the combination. 
Of 58 currently evaluable in the monotherapy arm, only 3 DLTs were recorded. Clin ical benefit
has not been reported in solid tumors in this trial, and this study is continuing to enroll into multiplecohorts using treatment with both nivolumab monotherapy and combination therapy of nivolumaband ipi[INVESTIGATOR_125]. Additional BMS-s ponsored clinical trials in children/adolescent are ongoing, 
including nivolumab in children with recurrent Hodgkin Lymphoma (CA209744), and nivolumab and nivolumab in combination with ipi[INVESTIGATOR_470261] (CA209908). The Pediatric Brain Tumor Consortium recently opened a safety and preliminary efficacy study (PBTC-045, [STUDY_ID_REMOVED]) of anti-PD1 antibody pembrolizumab 
in children with recurrent/refractory high-grade astrocytoma, DIPG, or hypermutated tumors; data are not yet available from this trial.
Recently, FDA has approved tr eatment of adolescent ( ‚â•12 yr old) participants with MSI-H CRC 
and MSI-H pan tumor, respectively.
This section is not app licable for sites in Belgium or the Netherlands as adolescents will not be 
included in these countries.3.2.5 Nivolumab Clinical Pharmacology
Nivolumab pharmacokinetics (PK) was assessed using a population PK approach for both single-
agent OPDIVO and OPDIVO with ipi[INVESTIGATOR_125].
OPDIVO as a single agent: The PK of single-agent nivolumab was studied in patients over a dose 
range of 0.1 to 20 mg/kg administered as a singl e dose or as multiple doses of OPDIVO as a 60-
minute intravenous infusion every 2 or 3 w eeks. Nivolumab clearance (CL) decreases over time, 
with a mean maximal reduction (% coefficient of variation [CV%]) from baseline values of 24.5% 
(47.6%) resulting in a geometric mean stead y-state clearance (CLss) (CV%) of 8.2 mL/h (53.9%) 
in patients with metastatic tumors; the decrease in CLss is not considered clinically r elevant. 
Nivolumab clearance does not decrease over time in pa tients with completely resected melanoma, 
as the geometric mean population clearance is 24% lower in this patient population compared with patients with metastatic melanoma at steady state. The geometric mean volume of distribution at 
steady state (Vss) (CV%) is  6.8 L (27.3%), and geometric mean elimination half-life (t1/2) is 25 
days (77.5%). Steady-state concentr ations of nivolumab were reached by 12 weeks when 
administered at 3 mg/kg every 2 weeks, and systemic accumulation was 3.7-fold. The exposure to nivolumab increases dose proportionally over the dose range of 0.1 to 10 mg/kg administered every 2 weeks. The predicted exposure (Cavg and Cmax) of nivolumab after a 30-minute infusion is 
comparable to that observed with a 60-minute infusion.
OPDIVO with ipi[INVESTIGATOR_125]: When OPDIVO 1 mg/kg was administered in combination with 
ipi[INVESTIGATOR_125] 3 mg/kg, the CL of nivolumab was increased by 29%, and the CL of ipi[INVESTIGATOR_470262]. When OPDIVO 3 mg/kg was administered 
in combination with ipi[INVESTIGATOR_125] 1 mg/kg, the CL of nivolumab and ipi[INVESTIGATOR_470263].
When OPDIVO was administerd in combination with ipi[INVESTIGATOR_125], the presence of anti-nivolumab 
Protocol Amendment No.: 04
Date: 04-May-2021 51
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
antibodies increased the CL of nivolumab by 20% and the CL of ip ilimumab was unchanged in 
presence of anti-ipi[INVESTIGATOR_470236].
Specific Populations: The population PK analysi s suggested that the following factors had no 
clinically important effect on the clearance of nivolumab: age (29 to 87 years), weight (35 to 160 
kg), gender, race, baseline LDH, PD-L1 expression, solid tumor type, tumor size, renal 
impairment, and mild hepatic impairment. 
Renal Impairment: The effect of renal impairment on the clearance of nivolumab was evaluated 
by a population PK analysis in patients with mild (eGFR 60 to 89 mL/min/1.73 m2), moderate 
(eGFR 30 to 59 mL/min/1.73 m2), or severe (eGFR 15 to 29 mL/min/1.73 m2) renal impairment. 
No clinically important differences in the clearance of nivolumab were found between patients 
with renal impairment and patients with normal renal function .
Hepatic Impairment: The effect of hepatic impairment on the clearance of nivolumab was 
evaluated by [CONTACT_470370] (total bilirubin [TB] less than or equal to the ULN and AST greater than 
ULN or TB greater than [ADDRESS_602623]) and in HCC patients with moderate hepatic impairment (TB greater than 1.[ADDRESS_602624]). No clinically important differences in the clearance of nivolumab were found between patients with mild/moderate hepaticimpairment.
Full details on the clinical pharmacology aspects of  nivolumab can be found in the Investigator 
Brochure (IB).3.3 Benefit/Risk Assessment
Extensive details on the safety profile of nivolumab are available in the Investigator Brochure and 
will not be repeated herein.
Overall, the safety profile of nivolumab monotherapy as well as in combination with ipi[INVESTIGATOR_470264] 10 mg/kg. Most AEs were low-grade (Grade 1 to 2) with relatively 
few related high-grade (Grade 3 to 4) AEs. Th ere was no pattern in the incidence, severity, or 
causality of AEs with respect to nivolumab dose level.
A pattern of immune-r elated adverse events has been defined, for which management al gorithms 
have been developed; these are provided in  Appendix [ADDRESS_602625] high-grade events were manageable 
with the use of corticosteroids or hormone re placement therapy (endocrinopathies) as instructed 
in these algorithms. Additional details on the safety profile of nivolumab, including results from other clinical studies, 
are also available in the nivolumab IB.
3.3.[ADDRESS_602626] indicated that tumors of TMB-H are likely to may be more sensitive to IO 
therapi[INVESTIGATOR_014], thus eliciting improved efficacy in patients treated with IO therapi[INVESTIGATOR_470265]. Of the tumor types included in this trial, despi[INVESTIGATOR_470266].: 04
Date: 04-May-[ADDRESS_602627] AEs were low-grade 
(Grade 1 to 2) with relatively few related high-grade (Grade 3 to 4) AEs (see Section 3.2.3 . 
Nivolumab Combined with Ipi[INVESTIGATOR_470267]). Extensive details on the safety 
profile of nivolumab and the combination of nivolumab and ipi[INVESTIGATOR_470268]. 
3.3.2 Adolescent Patients
The PK characteristics (e.g., steady-state peak and trough concentrations and terminal half-life) of 
many antibody-based therapeutic proteins are e ssentially comparable between pediatrics and 
adults once the effect of body size on PK is taken into consideration.27,28Research on
immunotherapy for chil dhood tumors is still preliminary, but av ailable data suggested similar PK 
profile of nivolumab to adult patients, and did not reveal significant safety concerns that are 
different from adult population (see Section 5.5.3 ). A report of the ongoing COG trial
ADVL1412 (See Section 3.2.4 ) indicated good tolerability among the [ADDRESS_602628] been -studiedand found to be well-tolerated. The potential benefit is that some or all of the TMB-H tumor
types in this study will be sensitive to nivolumab alone and/or in combination with ipi[INVESTIGATOR_125], 
thus yielding clinical benefit in these adolescent patients.
The benefit-risk information regarding adolescen t participants is not applicable for sites in 
Belgium or the Netherlands as adolescents will not be included in these countries.
4 OBJECTIVES AND ENDPOINTS
Table 4-1: Objectives and Endpoints
Objectives Endpoints
Primary
‚Ä¢To estimate BICR-assessed objective response rate 
(ORR) in participants of tTMB-H treated with 
nivolumab combined with ipi[INVESTIGATOR_125] ‚Ä¢BICR-assessed ORR using RECIST 1.1, and 
Response Assessment for Neuro-Oncology 
(RANO) criteria in primary CNS tumors 
‚Ä¢To estimate BICR-assessed ORR in participants of 
bTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_125] ‚Ä¢BICR-assessed ORR using RECIST 1.1, and RANO cr iteria in primary CNS tumors
Secondary
Protocol Amendment No.: 04
Date: 04-May-2021 53
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
‚Ä¢To estimate the BICR-assessed duration of response 
(DOR) and time to response (TTR) in participants of 
tTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_125]‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To estimate the BICR-assessed DOR and TTR in participants of bTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_125] ‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate the BICR-assessed ORR, DOR and TTR 
in participants of tTMB-H treated with nivolumab 
monotherapy‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate the BICR-assessed ORR, DOR and TTR 
in participants of bTMB-H treated with nivolumab 
monotherapy‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR
‚Ä¢BICR-assessed TTR
‚Ä¢To evaluate Investigator-assessed ORR, DOR, TTR 
in participants of tTMB-H treated with nivolumab 
combined with ipi[INVESTIGATOR_470233]‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed TTR
‚Ä¢To evaluate Investigator-assessed ORR, DOR, TTR 
in participants of bTMB-H treated with nivolumab 
combined with ipi[INVESTIGATOR_470233]‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed TTR
‚Ä¢To evaluate BICR-assessed and investigator-assessed clinical benefit rate (CBR) in participants of 
tTMB-H treated with nivolumab combined with 
ipi[INVESTIGATOR_470233]‚Ä¢BICR-assessed CBR
‚Ä¢Investigator-assessed CBR
‚Ä¢To evaluate BICR-assessed and investigator-
assessed CBR in participants of bTMB-H tr eated 
with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢BICR-assessed CBR
‚Ä¢Investigator-assessed CBR
‚Ä¢To evaluate BICR-assessed and investigator-assessed progression free survival (PFS) in participants of tTMB-H treated with nivolumab combined with ipi[INVESTIGATOR_251404]‚Ä¢BICR-assessed PFS
‚Ä¢Investigator-assessed PFS
‚Ä¢To evaluate BICR-assessed and investigator-assessed PFS in participants of bTMB-H treated with 
nivolumab combined with ipi[INVESTIGATOR_470233]‚Ä¢BICR-assessed PFS
‚Ä¢Investigator-assessed PFS
‚Ä¢To evaluate overall survival (OS) in participants of 
tTMB-H treated with nivolumab combined with 
ipi[INVESTIGATOR_470233]‚Ä¢Overall survival
Protocol Amendment No.: 04
Date: 04-May-2021 54
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 4-1: Objectives and Endpoints
Objectives Endpoints
‚Ä¢To evaluate OS in particip ants of bTMB-H treated 
with nivolumab combined with ipi[INVESTIGATOR_470234]‚Ä¢Overall survival
‚Ä¢To assess overall safety and tolerability ‚Ä¢AEs, clinical laboratory values, or other safety 
biomarkers
‚Ä¢Exploratory
‚Ä¢To assess overall health status and health utility ‚Ä¢Mean change from baseline in the 3-level version of the EQ-5D (EQ-5D-3L) visual analog scale 
(VAS) and utility index, respectively
‚Ä¢To assess cancer-related symptoms and quality of 
life ‚Ä¢Mean change from baseline in domains and symptoms in the 30- item European Organization 
for Research and Treatment of Cancer Quality of 
Life Questionnaire (EORTC QLQ-C30).
‚Ä¢To characterize the pharmacokinetics of 
nivolumab/ipi[INVESTIGATOR_470235]-
response relationships with respect to safety and efficacy‚Ä¢Population pharmacokinetic parameters 
‚Ä¢To assess immunogenicity of nivolumab/ipi[INVESTIGATOR_125] ‚Ä¢Incidence of anti-nivolumab/anti-ipi[INVESTIGATOR_143778]
‚Ä¢To characterize tumor and host biomarkers ‚Ä¢Analysis of genomic, molecular, and 
immunohistochemical profiles
‚Ä¢To assess OS and BICR-assessed and investigator-assessed ORR, DOR, PFS in all participants of 
TMB-H treated with nivolumab combined with 
ipi[INVESTIGATOR_470233]‚Ä¢OS
‚Ä¢BICR-assessed ORR
‚Ä¢BICR-assessed DOR 
‚Ä¢BICR-assessed PFS 
‚Ä¢Investigator-assessed ORR
‚Ä¢Investigator-assessed DOR
‚Ä¢Investigator-assessed PFS 
[ADDRESS_602629] advanced or metastatic solid tumors with 
either tissue (tTMB) or blood TMB (bTMB) ‚â• 10 mut/Mb. Both tissue and blood TMB will be 
assessed prior to randomization. 
Participants without a prior known tTMB-H status available via F1CDx assay, or a prior known 
bTMB-validated CLIA result available from Foundati on Medicine, wi ll provide consent for pre-
screening and TMB status determination, but consent for further screening procedures and study 
treatment should be deferred until TMB-H status is  established. Screening process can continue 
when the participant is TMB-H. 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602630] of three phases: screening, treatment, 
and follow-up. 
Efficacy will be evaluated using tumor specific response cr iteria, ie, RECIST 1.1 for solid tumors29
and RANO criteria30for primary CNS tumors. 
The primary analysis of BICR-assessed ORR in participants with either bTMB-H or tTMB-H will 
be conducted after a minimum of 12 months following LPFT. This study will end when analysis 
of the primary endpoint is complete. Additional survival analysis may be conducted for up to 5 years beyond the primary endpoint analysis.
Details regarding the assessments to be pe rformed during these phases are outlined in Section 2
Schedule of Activities.The study design schematic is presented in Figure 5.1-1 .
Figure 5.1-1: Study Design Schematic
Protocol Amendment No.: 04
Date: 04-May-2021 56
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Note: Mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants will 
not be included in these countries.
Physical examinations, vital sign measurements, ou tcome questionnaires, biomarker collection, 
and clinical laboratory evaluations will be pe rformed at selected times throughout  study 
participation. Participants will be closely mo nitored for AEs throughout the study. Blood samples 
will be collected for safety, pharmacokinetic (PK) and biomarker analysis. 
Participants with progressive disease while on treatment with nivolumab monotherapy may be 
allowed to be treated beyond progression wi th nivolumab and ipi[INVESTIGATOR_125] (see Section 7.4.3 ).
5.1.1 Data Monitoring Committee and Other External Committees
When required, adjudicated events will be submitted to the DMC and Health Aut horities for review 
on a specified timeframe in accordance with the adjudication documentation.
[IP_ADDRESS] Data Monitoring Committee
To provide independent oversight of safety, efficacy, and study conduct, a data monitoring 
committee (DMC) will be instituted. The DMC will meet regularly to ensure that participant safety 
is carefully monitored. The DMC will convene additional ad hoc meetings if necessary. Following each meeting, the DMC will recommend continu ation, modification, or discontinuation of the 
study based on observed toxicities. The DMC will review the interim analysis results and determine whether the cut-off value for bTMB should be adjusted for the first interim analysis and whether criteria for superiority are met at th at time for the tTMB interim analysis; the DMC will 
also review the bTMB final analysis results. A separate DMC charter w ill describe the activities 
of this committee in more detail.
[IP_ADDRESS] Blinded Independent Central Review Committee
A Blinded Independent Central Review (BICR) Co mmit tee w ill be formed fo r standardized 
response assessment. Images will be submitted to an imaging third-party vendor for central review. 
Imaging acquisition guidelines and submission  process w ill be ou tlined in the CA209848 Study 
Imaging Manual to be provided by [CONTACT_470371]. For tumor types which require clinical indicators 
as part of the standard response assessment, the clinical indicator data will be provided to the BICR
along with imaging data.
5.2 Number of Participants
The number of randomized participants will rang e from approximately 183 to 342 based on 1) the 
actually obse rved concordance between tTMB-H and bT MB-H, and 2) the new bTMB cut off 
determined by [CONTACT_470372] (see Section 10.3.6 ). The per tumor type cap is
approximately 15% of the total sample size.
5.[ADDRESS_602631] 
Protocol Amendment No.: 04
Date: 04-May-2021 57
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
participant. Study completion is defined as the final date on which data for the pr imary endpoint 
was or is expected to be collected, if this is not the same.
5.4 Scientific Rationale for Study Design
The aim of this basket trial is to evalu ate the efficacy of nivolumab in combination with ipi[INVESTIGATOR_470269]-H advanced or metastatic solid tumors excluding melanoma, NSCLC and RCC. The 
clinical benefit of nivolumab and nivolumab in combination with ipi[INVESTIGATOR_470270] n with ipi[INVESTIGATOR_470271], 
particularly in tumors with TMB-H which are hypothesized to be more sensitive to immune checkpoint targeted therapi[INVESTIGATOR_014]. CA209848 study w ill explore the clinical response and safety in 
participants with TMB-H. 
5.4.1 TMB Cutoff and Stratification
High level of TMB is an emerging predictive biomarker for favorable clinical benefit in response 
to IO therapy, however a universal definition of ‚ÄúTMB high‚Äù has not been established. Most 
melanomas have a mutational load greater than 10 mutants/megabase (mut/Mb), and a large body 
of evidence demonstrated higher clinical efficacy in melanoma treated with IO therapy compared to many other tumor types which have less than 10 mut/Mb. In melanoma, nivolumab in 
combination with ipi[INVESTIGATOR_470272]. In CA209568, in response to the treatment of nivolumab combined with ipi[INVESTIGATOR_470273], the ORR increased with higher TMB, and peaked at 10 mut/Mb (9% at <5 mut/Mb, 15% at ‚â•5-<10 mut/Mb, 44% at ‚â• 10-<15 mut/Mb, and 39% at ‚â•15 mut/Mb). These 
findings suggest that TMB at 10 mut/Mb is an optimal cutoff for first line NSCLC patients.Recently, in CA209227, a phase [ADDRESS_602632] lin e NSCLC patients, nivolumab combined with 
ipi[INVESTIGATOR_470274]-H at a cutoff of ‚â•10 mut/Mb. Goodman A et al showed that with a TMB cut off of ‚â•20 mut/Mb, 
diverse tumor types, including melanoma, NSCLC and some rare tumors, responded well to anti-
PD-1/anti-CTLA-[ADDRESS_602633] chosen the TMB-H cut off for enrollment as ‚â• 10 mut/Mb to maximize the probability of 
inclusion of potential responders. Participants at enrollment will also be stratified by [CONTACT_470373] 16 
mut/Mb to ensure even distribution of participants  with relatively low TMB and relatively high 
TMB between the [ADDRESS_602634] line vs second line and beyond between the 2 arms. This is to minimize 
potential imbalance of differential response underlined by [CONTACT_470374], and allow possible TMB‚Äìresponse analysis based on stratification of prior line of therapy.
Protocol Amendment No.: 04
Date: 04-May-2021 58
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
5.4.3 Exclusion of Melanoma, NSCLC and RCC
Currently, multiple anti-PD-1/PD-L1 and/or anti-CTLA4 have been approved for Melanoma and 
NSCLC as first or second line tr eatment. D ata from CA209227 highlighted superior clinical 
benefit of nivolumab combined with ipi[INVESTIGATOR_470275], which may provide additional effective treatment option for this population. The 
probability of identifying IO na√Øve participants with  these two tumor types is considerably low. 
RCCs are characterized by [CONTACT_470375], and have relatively low overall TMB.32,33Several 
analyses suggest that clinical response to IO therapy in RCC patients is independent of TMB, thus 
RCC is excluded from this study.34,35
5.4.4 Rationale for Treatment with Nivolumab and Ipi[INVESTIGATOR_470276]. To maximize the potential clinical bene fit for the patient, upon confirmed disease 
progression, patients who are initially randomized to the nivolumab monotherapy (arm B) have the option to receive nivolumab in combination ipi[INVESTIGATOR_125], at the discretion of the investigator 
and upon discussion with the BMS Medical Monitor.
5.4.[ADDRESS_602635] of the responses occur early, with a median time to response of 2-4 months, and emerging data suggests that benefit can be maintained in the absence of continued 
treatment. A recent analysis in a melanoma study s uggests the majority of patients who discontinue 
nivolumab and/or ipi[INVESTIGATOR_470277].
36Furthermore, a limited duration of ipi[INVESTIGATOR_125], includi ng only [ADDRESS_602636] that 2 years of PD-1 checkpoint inhibitor treatment may be sufficient 
for long term benefit. CA209003, a dose-escalation cohort expansion trial evaluating the safety 
and clinical activity of nivo lumab in patients with previously  treated advanced solid tumors 
(including 129 participants with NSCLC ), specified a maximum treatment duration of 2 years.
Among 16 participants with non-small cell lung cancer (NSCLC) who discontinued nivolumab 
after completing 2 years of treatment, 12 par ticipants were alive >5 years and remained 
progression-free without any subsequent ther apy. In the CA209003 NSCLC cohort, the overall 
survival (OS) curve begins to plateau after 2 years, with an OS rate of 25% at 2 years and 18% at 
3 years.38These survival outcomes are similar to phase 3 studies in previously treated NSCLC, in 
which nivolumab treatment was con tinued until progressi on or unacceptable tox icity (2 year OS 
Protocol Amendment No.: 04
Date: 04-May-2021 59
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
rates of 23% and 29%, and 3 year OS rates of 16% -18% for squamous and non-squamous NSCLC 
respectively).[ADDRESS_602637], a shorter duration of nivolumab of only 1 year was associated with increased risk of 
progression in previously tr eated patients with NSCLC, s uggesting that treatment beyond 1 year 
is likely needed. In CA209153, patients with previously treated advanced NSCLC who completed1 year of nivolumab therapy were randomized to either continue or stop treatment, with the option 
of retreatment upon progression. Am ong 163 patients  still on tr eatment at 1 year and without 
progression, those who were randomized to continue nivolumab had significant improvement in 
progression-free survival (PFS) compared to thos e who were randomized to  stop treatment, with 
median PFS (post-ra ndomization) not reached  vs 10.3 months, respectively; HR=0.42 (95% CI, 
0.25 to 0.71). With a median follow-up of 14.[ADDRESS_602638]-randomization, there also was a trend for patients on continued treatment to live longer (OS HR = 0.63 [95% CI: 0.33, 1.20]). Of note, 
the PFS curves in both groups plateau approximately 1 year after randomization (i .e., 2 years after 
treatment initiation), suggesting that there may be minimal benefit in extending treatment beyond 
a total of [ADDRESS_602639] that there is minimal if any benefit derived from continuing IO 
treatment beyond two years in advanced tumors. However, even though immunotherapy is well 
tolerated, patients will be at risk for additional toxicity with l onger term tr eatment. There fore, in 
this study, treatment will be given for a maximum of 2 years from the start of study treatment.
5.5 Justification for Dose
5.5.1 Rationale for Nivolumab Monotherapy Dose Selection
Nivolumab monotherapy has been extensively studied in multiple tumor types, including 
melanoma, NSCLC, renal cell carcinoma (RCC), classical Hodgkin‚Äôs lymphoma (cHL), head and 
neck (H&N) and urothel ial carcinoma (UC), using body weight normalized dosing (mg/kg), and 
has been safely administered at doses up to 10 mg/kg Q2W. Nivolumab is currently approved for the treatment of various tumors, including melanoma, NSCLC, RCC, cHL, SCCHN, and UC, 
using a regimen of either nivolumab 240 mg Q2W or nivolumab 480 mg Q4W.
The nivolumab 480 mg Q4W dose was selected for this study based on clinical data and modeling 
and simulation approaches using population pharmacokinetics (PPK) and exposure response (ER) analyses examining relationships between nivolumab exposures and efficacy (eg. OS, OR) and 
safety responses, using data from studies in multiple tumor types (melanoma, NSCLC, and RCC) 
with body weight-normalized dosing (mg/kg).
41The PPK analyses have shown that exposure to 
nivolumab increased dose proportionally over the dose range of 0.1 to 10 mg/kg administered 
Q2W, and no clinically meaningful differences in PK across ethnicities and tumor types were 
observed. Nivolumab clearance and volume of dist ribution were found to increase as body weight 
increases but less than proportionally with increasing weight, ind icating that milligram-per-
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602640] of body weight on nivolumab PK. 
Using the PPK and ER models, nivolumab exposures and probabilities of efficacy responses and risks of AEs were predicted following nivolumab  480 mg Q4W and compared to those following 
nivolumab 3 mg/kg Q2W, the initially approved dose. The overall distributions of average nivolumab steady-state exposures (Cavgss) are comparable following administration with either 
nivolumab 3 mg/kg Q2W or nivolumab 480 mg Q4W. Nivolumab 480 mg Q4W is predicted to result in approximately 43% greater steady-stat e peak concentrations (Cmaxss) compared to 
nivolumab 3 mg/kg Q2W; however, these exposures are predicted to be lower than the exposure ranges observed at doses up to nivolumab 10 mg/ kg Q2W used in the nivolumab clinical program. 
Although the Cmaxss of nivolumab is expected to be greater following nivolumab 480 mg Q4W compared to nivolumab 3 mg/kg Q2W, the predicted Cmaxss following nivolumab 480 mg Q4W 
is well below the median Cmaxss achieved following administration of nivolumab 10 mg/kg Q2W, a safe and tolerable dose level ( Figure 5.5.1-1 ).
Figure 5.5.1-1: Predicted  Nivolumab Cmax (with 90% PI) versus Time by [CONTACT_470376]-safety analysis demonstrated that the exposure margins for safety are maintained following nivolumab 480 mg Q4W, and the predicted  risks of AE-DC/D, AE Grade 3+, and AE-
IM Grade 2+, are predicted to be similar following nivolumab 480 mg Q4W relative to nivolumab 3 mg/kg Q2W across tumor types. Safety analyses using available data following nivolumab 
3 mg/kg Q2W and 10 mg/kg Q2W administration i ndicated there were no differences in AE 
profiles across body weight  groups. Fin ally, initial evidence demonstr ates that following 
administration of nivolumab 480 mg Q4W, nivolumab has been shown to be well tolerated.
42
Nivolumab 480 mg Q4W is predicted to be  approximately 16% lower steady-state trough 
concentrations (Cminss) compared to nivolu mab 3 mg/kg Q2W. Wh ile these e xposures are 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602641] efficacy, Exposure-efficacy  analyses of multiple PK measures and efficacy endpoints (eg, 
OS, OR) indicated that following administration of nivolumab 480 mg Q4W efficacy is predicted 
to be similar to that following administration of nivolumab 3 mg/kg Q2W across multiple tumor types. Based on these data, nivolumab [ADDRESS_602642] similar efficacy and safety profiles to nivolumab 240 mg Q2W or nivolumab 3 mg/kg Q2W.
5.5.2 Nivolumab/Ipi[INVESTIGATOR_470278]. In addition, the Clinical 
Pharmacology Section of the product labels  for ipi[INVESTIGATOR_45762], as w ell as the 
Investigator Brochures, have additional details.
43,44,45 ,46
[IP_ADDRESS] Population Pharmacokinetics of Nivolumab
The PK, clinical activity, and safety of nivolu mab has been assessed in completed and ongoing 
Phase 1, 2, and 3 studies in adult subjects with non-small cell lung cancer (NSCLC), melanoma, 
and renal cell carcinoma (RCC) in addi tion to other tumor types.47
The PK of nivolumab as monotherapy was characterized by [CONTACT_470377]. Nivolumab clearance 
increased with bas eline body weight, es timated glomerular f iltration (eGFR), and Eastern 
Cooperative Oncology Group (ECOG) performance status > 0. The PPK analysis was performed 
using data from 1908 subjects who received nivol umab from the following studies: nivolumab 
monotherapy data from studies MDX- 1106-01, ONO-4538-01, ONO-4538- 02, MDX- 1106-03, 
CA209010, CA209063, and CA209037. Studies CA209004, CA209069, CA209066, and CA209067 provided PK data of nivolumab monotherapy as w ell as in combination with 
ipi[INVESTIGATOR_470279] (advanced melanoma) who received the proposed dosing 
regimens. The data from these studies also allowed for an evaluation of potential drug interactions between nivolumab and ipi[INVESTIGATOR_470280]. Thus, for 
this analysis, the covariates assessed included ADA status, baseline ECOG status, baseline eGFR, baseline body weight (BW), gender and co-administration of ipi[INVESTIGATOR_125].
Co-administration with ipi[INVESTIGATOR_125] 3 mg/kg resulted in a modest increase in nivolumab CL of 
35% whereas co-administration with ipi[INVESTIGATOR_125] 1 mg/kg did not appear to have an effect on nivolumab CL. Presence of anti-nivolumab anti bodies increased nivolu mab CL by 25%, consistent 
with prior findings. In subjects with an ECOG performance status of > 0, nivolumab CL was 22% 
higher (based on median values). Male subjects had a median of 12% higher volume of distribution 
of central compartment (VC) than females. Ba seline body weight was identified as a signif icant 
covariate for both CL and VC and the magnitude of the effect of baseline eGFR on CL was not 
considered clinically relevant. Th e geometric mean CL, Vss, and terminal half-life of nivolumab 
were 9.83 mL/h, 7.62 L, and 24.1 days, respectively. When administered in combination, the CL of nivolumab was increased by 35%, whereas there was no effect on the clearance of ipi[INVESTIGATOR_125].
Protocol Amendment No.: 04
Date: 04-May-2021 62
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
[IP_ADDRESS] Population Pharmacokinetics of Ipi[INVESTIGATOR_470281] 1345 subjects in 4 Phase 2 studies with 
ipi[INVESTIGATOR_79285] (CA184004, CA184007, CA184008, and CA184022), as w ell as one 
Phase 1 study (CA209004), one Phase 2 study (CA209069) and one Phase 3 study (CA209067) 
with ipi[INVESTIGATOR_470282]. The ipi[INVESTIGATOR_470283]209004, CA209069, and CA209067 are included as they p rovide ip ilimumab PK 
samples that were collected in combination with nivolumab in the target population. The data from 4 ipi[INVESTIGATOR_470284] (CA184004, CA184007, CA184008, and CA184022) were included in the PPK analysis, to enable the assessment of the potential nivolumab effect on ipi[INVESTIGATOR_90886].
The co-administration of ipi[INVESTIGATOR_125] (3 mg/kg) with nivolumab 0.3 mg/kg and nivolumab 
3.0 mg/kg resulted in minimal changes in ipi[INVESTIGATOR_470285] (- 7.5% and 11%, respectiv ely); however, 
sample sizes at these doses were small. The CL of ipi[INVESTIGATOR_90904]-administered with 1 mg/kg nivolumab was estimated to be 1% higher (95% CI: 97.8 - 106) relative to the CL of ipi[INVESTIGATOR_470286], demonstrating that ipi[INVESTIGATOR_470287]-administration of 1 mg/kg nivolumab. Ipi[INVESTIGATOR_470288] 6% (95% CI: 96.5 - 115) in the presence of ipi[INVESTIGATOR_90889], as measured by [CONTACT_470378] (2nd generation) assay. This effect is not considered to be statist ically signif icant (95% CI includes 1). Ip ilimumab CL and VC increased 
with increasing baseline body weight, and ipi[INVESTIGATOR_470289].
[IP_ADDRESS] Pharmacokinetics of Nivolumab and Ipi[INVESTIGATOR_470290], when adminis tered in combination, were characterized by 
[CONTACT_470379]209004 and by [CONTACT_470380]209004, CA209069 and CA209067.
A dose-related increase in nivolumab peak and t rough concentrations was observed after the first 
dose in Study CA209004. Peak and trough concentrations after the first dose for 1 mg/kg of 
nivolumab in combination with 3 mg/kg of ipi[INVESTIGATOR_125] Q3W were in the range of 
18.1 - 21.5 Œºg/mL and 3.2 - 4.8 Œºg/mL, resp ectively. Ipi[INVESTIGATOR_470291] 3 mg/kg 
in combination with 1 mg/kg nivolumab after  the first dose were in the range of 63.5 - 68.5 Œºg/mL. 
Ipi[INVESTIGATOR_470292] 3 mg/kg in combination with 1 mg/kg nivolumab after the first dose were in the range of 9.8 - 11.9 Œºg/mL.
5.5.[ADDRESS_602643] dose in pediatric patients are available from CA209-908 and ADVL 1412 / 
CA209-070, where patients were treated with nivolumab 3 mg/kg and ipi[INVESTIGATOR_125] 1 mg/kg Q3W 
followed by [CONTACT_53930]. Serum peak and trough concentrations (geometric means 
[CV%]) after the first dose of nivolumab and ipi[INVESTIGATOR_125], in adolescent patients are presented inTable 5.5.3-1 . These values are very similar to geometric mean peak and trough concentrations in 
Protocol Amendment No.: 04
Date: 04-May-2021 63
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
adults who received similar dose regimen for nivolumab and ipi[INVESTIGATOR_125], including NSCLC 
(n=501) with nivolumab (peak = 61.8 and trough = 17.5 Œº g/mL), and RCC (n = 497) with
nivolumab (peak = 62 Œºg/mL, and trough = 15.3 Œºg/mL) and ipi[INVESTIGATOR_125] (peak = 19.7 Œºg/mL, and 
trough=3.93 Œºg/mL) (BMS internal data).
Table 5.5.3-1: Pharmacokinetics data aft er first dose in adolescents (12 -
<18 years) patients from CA209-908 and CA209-070 (COG) study 
who received Nivolumab 3 mg/kg + Ipi[INVESTIGATOR_125] 1 mg/kg Q3W
CA209-908 study CA209-070 (COG) study
Nivolumab 3 mg/kg
Cmax 1a(Œºg/mL)72.4 (34.5)
N=655.3 (13)
N=5
Cmin 1b(Œºg/mL)18.3 (40.6)
N=315.9 (23.8)
N=8
Ipi[INVESTIGATOR_125] 1 mg/kg
Cmax 1 (Œºg/mL)20.4 (48.2)
N=619.1 (24.1)
N=16
Cmin 1 (Œº g/mL)3.4 (50.1)
N=33.53 (33.6)
N=7
aCmax1 = Peak concentration after first dose.
bCmin1 = Trough concentration after first dose.
Population PK m odel based simulation has shown that exposures produced by [CONTACT_20382] 480 mg 
Q4W and 240 mg Q2W were well below the simulated exposure range of a 10 mg/kg Q2W 
regimen, a previously established clinically safe dos e. The body weight range  for adults subjects 
that established the population PK model used for simulation was 34- 180 kg. Therefore, a 
minimum body weight threshold in adolescents ( ‚â• 40 kg) is defined to receive the same adult flat 
dose to prevent exceeding target adult exposures.
Adolescent participants < 40 kg body weight will be given weight-based dose that is equivalent to 
the adult dose (typi[INVESTIGATOR_470293] 80-kg body weight). Adolescents with body weight ‚â• 40 kg 
will be administered nivolumab 240 mg Q2W in nivo/ipi [INVESTIGATOR_216], and nivolumab 480 mg Q4W in the monotherapy arm. Adolescents < 40 kg will be administered body weight adjusted nivolumab dose 
of 3 mg/kg Q2W in the nivolumab in combinatio n with ipi[INVESTIGATOR_44772], and 6 mg/kg Q4W in the 
monotherapy arm.
This section is not applicable for sites in Belgium or the Netherlands as adolescent participants
will not be included in these countries.
5.5.4 Clinical Pharmacology Summary
Nivolumab pharmacokinetics (PK) was assessed using a population PK approach for both single-
agent nivolumab and nivolumab with ipi[INVESTIGATOR_125].
Protocol Amendment No.: 04
Date: 04-May-2021 64
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Nivolumab as a single agent: The PK of single-agent nivolumab was studied in participants over 
a dose range of 0.1 to 20 mg/kg administered as a single dose or as multiple doses of nivolumab 
as a 60-minute intravenous infusion every 2 or 3 weeks. Nivolumab clearance (CL) decreases 
over time, with a mean maximal reduction (% coefficient of variation [CV%]) from baseline 
values of 24.5% (47.6%) resulting in a geometric mean steady-state clearance (CLss) (CV%) of 8.2 mL/h (53.9%) in patients with metastatic tumors; the decrease in CLss is not considered clinically relevant. Nivolumab CL does not decrease over time in patients with completely 
resected melanoma, as the geometric mean population clearance is 24% lower in this patient 
population compared with patients with metastatic me lanoma at steady state. The geometric 
mean volume of distribution at steady state (Vss) (CV%) is 6.8 L (27.3%), and geometric mean elimination half-life (t1/2) is 25 days (77.5%). Steady-state concentrations of nivolumab were 
reached by 12 weeks when administered at 3 mg/kg every 2 weeks, and systemic accumulation 
was 3.7-fold. The exposure to nivolumab increases dose proportionally over the dose range of 0.1 to 10 mg/kg administered every 2 weeks. The predicted exposure (Cavg and Cmax) of nivolumab after a 30-minute infusion is compar able to that observed with a 60-minute infusion.
Nivolumab with ipi[INVESTIGATOR_125]: When nivolumab 1 mg/kg was administered in combination with 
ipi[INVESTIGATOR_125] 3 mg/kg, the CL of nivolumab was increased by 29%, and the CL of ipi[INVESTIGATOR_470294]. When nivolumab 3 mg/kg was administered in combination with ipi[INVESTIGATOR_125] 1 mg/kg, the CL of nivolumab and ipi[INVESTIGATOR_470295]. When nivolumab was administered in combination with ipi[INVESTIGATOR_125], the 
presence of anti-nivolumab antibodies increased the CL of nivolumab by 20%, and the CL of ipi[INVESTIGATOR_470296]-ipi[INVESTIGATOR_470236].
Specific Populations: The population PK analysis suggested that the following factors had no 
clinically important effect on the clearance of nivolumab: age (29 to 87 years), weight (35 to 160 
kg), gender, race, baseline LDH, PD-L1 expressi on, solid tumor type, tumor size, renal
impairment, and mild hepatic impairment. 
Renal Impairment: The effect of renal impairment on the clearance of nivolumab was evaluated 
by a population PK analysis in patients with mild (eGFR 60 to 89 mL/min/1.73 m
2), moderate 
(eGFR 30 to 59 mL/min/1.73 m2), or severe (eGFR 15 to 29 mL/min/1.73 m2) renal impairment. 
No clinically important differences in the clearance of nivolumab were found between patients 
with renal impairment and patients with normal renal function.
Hepatic Impairment: The effect of hepatic impairment on the clearance of nivolumab was 
evaluated by [CONTACT_470381] (total bilirubin [TB] less than or equal to the ULN and AST greater than ULN or TB greater than [ADDRESS_602644]) and in patients with HCC with 
moderate hepatic impairment (TB greater than 1.[ADDRESS_602645]). No clinically 
important differences in the clearance of nivolumab were found between patients with mild/moderate hepatic impairment.
Full details on the clinical pharmacology aspects of nivolumab can be found in the IB and 
product label.
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602646] a burden on patients and treatment centers. Establishing that nivolumab 
and ipi[INVESTIGATOR_470297] 30 minutes‚Äô duration 
will dimin ish the burden, provided that there is no change in the safety profile. Previous clinical 
studies of nivolumab and ipi[INVESTIGATOR_470298] a 60-minute infusion duration for nivolumab and a 90-minute infusion 
duration for ipi[INVESTIGATOR_125] (1 - 3 mg/kg dosing for bot h). However, both nivolumab and ipi[INVESTIGATOR_448138] 10 mg/kg with  the same infusion duration (ie, 60 minutes).
Establishing that nivolumab can be safely administered using a shorter infusion time (30 minutes) 
is under investigation. Previous clinical studies of nivolumab monotherapy have used a 60-minute 
infusion duration wherein, nivolumab has been safely administered up to 10 mg/kg over long 
treatment periods. Infusion r eactions including high-grade hypersensitivity reactions have been 
uncommon across nivolumab clinical program. In CA209010, a dose association was observed for 
infusion site reactions and hypersensitivity reactions (1.7% at 0.3 m g/kg, 3.7% at 2 mg/kg and 
18.5% at 10 mg/kg). All the events were Grade 1-2 and were manageable. An infusion duration of 30 minutes for 3 mg/kg nivolumab (30% of the dose provided at 10 mg/kg) is not expected to 
present any safety concerns compared to the prior experience at 10 mg/kg nivolumab dose infused over a 60-minute duration. The safety of nivolumab  3 mg/kg administered as a 30-min infusion 
was assessed in CA209153 in patients (n = 322) with previously  treated advanced NSCLC. 
Overall, there were no clinically meaningful  differences in the frequency of 
hypersensitivity/infus ion-related r eactions (of any cause or tr eatment-related) in patients 
administered nivolumab over a 30-minute infusion compared with that re ported for patients with 
the 60-minute infusion. Thus, it was shown that nivolumab can be safely infused over 30 minutes. 
Similarly, ipi[INVESTIGATOR_170] 10 mg/kg has been safely administered over 90 minutes. In participants 
with advanced Stage II or Stage IV melanoma (CA184022 Study), where ipi[INVESTIGATOR_470299] a dose of 10 mg /kg, on-study drug related hypersen sitivity events (Grade 1/2) 
were reported in 1 participant (1.4%) in the 0.3 mg/kg and in 2 participan ts (2.8%) in the 10 mg/kg 
group. There were no drug-r elated hypersensitivity events re ported in the 3 mg/kg group. Across 
the 3 treatment groups, no Grade 3/4 drug-related hypersen sitivity events were reported and there 
were no reports of infusion reactions. Ipi[INVESTIGATOR_125] 10 mg/kg monotherapy has also been safely 
administered as a 90-minute infusion in a la rge Phase 3 study in prostate cancer (CA184043) and 
as adjuvant therapy for Stage III melan oma (CA184029), with  infusion reactions occ urring in 
participants. Administering 3 mg/kg of ipi[INVESTIGATOR_470300]-third of the 
10 mg/kg dose.
Overall, infusion reactions including high-grade hypersensitivity reactions have been uncommon 
across clinical studies of nivolumab, ipi[INVESTIGATOR_125], and nivolumab/ipi[INVESTIGATOR_470301]. Overall, a change in safety profile is not anticipated with 30-minute i nfusions of nivolumab, 
ipi[INVESTIGATOR_470302].
In addition, nivolumab is approved as 30-minute i nfusion (as monotherapy or combination 
therapy) for the treatment of various tumor types.
48Ipi[INVESTIGATOR_125] 1 mg/kg Q6W is approved as a
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602647] be met.
6.1 Inclusion Criteria
1) Signed Written Informed Consent
a) Prior to study participation, written i nformed consent from participants, or in the case of 
minors, written permission (informed consent) from parents (both, if required by [CONTACT_1769]), 
guardians, or legally acceptable representatives must be obtained according to local laws 
and regulations
b) Assent from minor participants s hould be obtained per local laws and regulations and 
should be documented in accordance with local requirements.
c) Written informed consent and HIPAA authorization (applies to covered entities in the [LOCATION_003] 
only) obtained from the par ticipant/legal representative prior to performing any 
protocol-related procedures, including screening evaluations
d) Participants must be willing and able to comply with scheduled visits, treatment schedule, 
laboratory tests, and other requirements of the study.
2) Type of Participant and Target Disease Characteristics
a) Participants with a refractory, metastatic, or unresectable histologically or cytologi cally
confirmed solid malignant tumor with TMB-H who are refr actory to standard therapi[INVESTIGATOR_470303], or for which no standard treatment per local 
management guidelines is available (salvage setting).
i) Treatment with botanical preparations alone (e.g. herbal supplements or traditional 
Chinese medicines) are not considered a line of therapy. 
b) Either a formalin-fixed, paraffin-embedded (FFPE) tissue block or unstained tumor tissue 
sections, obtained within 9 months and no additional intervening therapy (excluding the 
current line of therapy and palliative local therapy) prior to enrollment, with an associated 
pathology report, must be submitted to the core laboratory for inclusion. Palliative lo cal 
therapy includes palliative radiation therapy and palliative surgical resection to symptomatic non pr imary bone lesions, skin lesions, or CNS lesions (only for peripheral 
solid tumors, not applicable for CNS primary tumor). Radiation to the primary lesions and systemic chemotherapy are not considered palliat ive therapy. Biopsy should be excisional, 
incisional or core needle. Fine needle aspi[INVESTIGATOR_103982]
i) If a fresh biopsy is warranted, the participant must have a lesion that can be biopsied at 
an acceptable clinical risk as judged by [CONTACT_470382].: 04
Date: 04-May-2021 67
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
c) The IRT must be provided with the results of both tissue and blood TMB-H testing for 
eligible participants prior to randomization. Both results are utilized for stratification 
purposes (see Figure 6.1-1 ).
Figure 6.1-1: TMB Pre-Screening/Screening
i) Participants must have either tTMB or bTMB ‚â• 10 mut/Mb (tTMB ‚â• 10 mut/Mb or the 
new cutoff value of bTMB determined by [CONTACT_941] 1st interim analysis). Should one of the 
two populations (tTMB-H or bTMB-H) reach the targeted sample size before the other,then enrollment will continue only with participants for the other TMB-H population
(bTMB-H or tTMB-H, see details in Section 10.1 ).
ii) Prior results of TMB-H obtained with F1CDx assay (tissue) or bTMB-validated CLIA
assay from Foundation Medicine (blood) are acceptable for eligibility purposes. 
(1) If tTMB result is available, blood sample must be provided for central TMB testing(2) If bTMB result is available, tissue sample must be provided for central TMB testing 
(3) If neither tTMB nor bTMB result is av ailable, both tissue and blood samples must 
be provided for central TMB testing
iii) TMB results ob tained from any other assays are not acceptable for eligibility.
d) Participants must have an Eastern Cooperative Oncology Group (ECOG) Performance 
Status of ‚â§1 (participants > 16 years old with solid tumors), Karnofsky Performance Score 
(KPS) ‚â•80 (participants > 16 years old with primary CNS tumors) or Lansky Performance 
Score (LPS) ‚â•80 (participants 12 to 16 years old ONLY). For details, see Appendix 6  
and9.
e) Participants must have measurable disease for response assessment as per RECIST 1.1 for 
solid tumors other than CNS, and RANO criteria for primary CNS malignancies.
Protocol Amendment No.: 04
Date: 04-May-2021 68
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
3) Age and Reproductive Status
a) Males and Females, ages of 12 years and older
i) If adolescents are not allowed to participate, then ‚â• 18 years applies
b) Women of childbearing potential (WOCBP) must have a negative serum or urine 
pregnancy test (minimum sensitivity 25 IU/L or equivalent units of HCG) within 24 hours 
prior to the start of study treatment.
c) Women must not be breastfeeding
d) WOCBP must agree to follow instructions for method(s) of contraception for the duration 
of study treatment and [ADDRESS_602648] dose of study treatment (i.e., 30 days 
[duration of ovulatory cycle] plus the time required for the investigational drug to undergo 
approximately five half-lives). 
e) Not Applicable per Protocol Amendment 04: Males who are sexually active with WOCBP 
must agree to follow instructions for method(s) of contraception for the duration of study 
treatment and [ADDRESS_602649] dose of  study treatment (i.e., 90 days [duration of 
sperm turnover] plus the time required for the investigational drug to undergo approximately five half-lives). In addition, male participants must be willing to refrain 
from sperm donation during this time. 
f) Azoospermic males are exempt from contraceptive requir ements. WOCBP who are 
continuously not heterosexually act ive are also exempt from contr aceptive requirements, 
and still must undergo pregnancy testing as described in this section.
Investigators shall counsel WOCBP on the importance of pregnancy prevention and the 
implications of an unexpected pregnancy. Investigators shall advise on the use of highly effective 
methods of contraception ( Appendix 4) which have a failure rate of < 1% when used consistently 
and correctly.
The inclusion of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent 
participants will not be included in these countries. Participants in these countries must be 18 years 
of age or older.
6.2 Exclusion Criteria
1) Medical Conditions
a) Women with a positive pregnancy test at enrollment or prior to administrati on of study 
medication.
b) Participants with melanoma, non-small cell lung cancer, renal cell carcinoma or 
hematological malignancy as primary site of disease are not eligible for this study.
c) Active brain metastases (excluding primary CNS malignancies) or leptomeningeal 
metastases. Participants with brain metastases  are eligible if these have been treated and 
there is no magnetic resonance imaging (MRI) evidence of progression for at least [ADDRESS_602650] also be no requirement for immunosuppressive doses of 
systemic corticosteroids (> 10 mg/day prednis one equivalents for adults, or > 0.25 mg/kg
daily prednisone equivalent for adolescents) for at least 2 weeks prior to study drug 
administration.
Protocol Amendment No.: 04
Date: 04-May-2021 69
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
d) Prior malignancy active within the previous [ADDRESS_602651].
e) Participants with an active, known or suspect ed autoimmune disease. Participants with 
type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin 
disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or 
conditions not expected to recur in the absence of an external trigger are permitted to enroll.
f) Excluding participants with serious or uncontrolled medical disorders.
2) Prior/Concomitant Therapy
a) Participants with a condition requiring sy stemic treatment with eith er corticosteroids 
(> 10 mg daily prednisone equivalents for adults, or > 0.25 mg/kg daily prednisone
equivalent for adolescent) or other immunosuppressive medications within 14 days of study 
treatment. Inhaled or topi[INVESTIGATOR_198216] > 10 mg daily 
prednisone equivalents for adults, or > 0.25 mg/kg daily prednis one equivalent for 
adolescents are permitted, in the absence of active autoimmune disease.
b) Participants who received prior treatment with an anti-PD-1, anti-PD-L1, anti-PD-L2, 
anti-CD137, or anti-CTLA-4 antibody, or any other antibody or drug specifically targeting 
T-cell co-stimulation or checkpoint pathways
c) All toxicities attributed to prior anti-cancer thera py other than alopecia and fatigue must 
have resolved to Grade 1 (NCI CTCAE version 5) or baseline before administration of 
study drug. Participants with toxicities attribu ted to prior anti-cancer therapy which are not 
expected to resolve and result in long lasting sequelae, such as neuropathy after platinum 
based therapy, are permitted to enroll.
d) Treatment with any chemotherapy, radiation therapy, biologics for cancer, or 
investigational therapy within 28 days (or, for pr imary CNS tumors, within 12 weeks of 
completion of radiation therapy) of first administration of study treatment (participants 
with prior cytotoxic or investigational products (IP) < [ADDRESS_602652] been resolved to Grade 1 (NCI CTCAE version 5).
e) Treatment with botanical preparations (e.g. herbal supplements or traditional Chinese 
medicines) intended for general health support or to treat the disease under study within 2 
weeks prior to randomization/treatment. Refer to Section 7.7.1 for prohibited therapi[INVESTIGATOR_014].
f) Known history of positive test for human immunodeficiency virus (HIV) or known 
acquired immunodeficiency syndrome (AIDS). NOTE: Testing for HIV must be performed 
at sites where mandated locally.
g) Participants must not have received a live / attenuated vaccine within [ADDRESS_602653] 
treatment.
3) Physical and Laboratory Test Findings
Participants with any of the following lab criteria will be excluded from the study:
a) WBC < 2000/ŒºL
b) Neutrophils <1500/ŒºL
c) Platelets < 100x103/ŒºL
Protocol Amendment No.: 04
Date: 04-May-2021 70
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
d) Hemoglobin < 9.0 g/dL
e) Serum creatinine:
‚àíFor participants ‚â• 18 years old: Serum creatinine > 1.[ADDRESS_602654] unless creatinine clearance 
‚â•40 mL/min (measured or calculated using the Cockcroft Gault formula): 
Female CrCl = ([140 - age in years] x weight in kg x 0.85)/
(72 x serum creatinine in mg/dL)
Male CrCl = ([140 - age in years] x weight in kg x 1.00)/
(72 x serum creatinine in mg/dL)
‚àíFor participants ‚â• 12 years old and < 18 years old, consider a serum creatinine based the 
table below, unless creatinine clearance ‚â•70 ml/min/1.73 m2calculated using the 
Schwartz formula:
Ped CrCl = (k x Ht)/Cr
Age Maximum Serum Creatinine (mg/dL)
Male Female
12 to < 13 years 1.2 1.2
13 to < 16 years 1.5 1.4
16 to < 18 years 1.7 1.4
Note: the threshold values in this table were derived from the Schwartz formula for estimating GFR,50utilizing 
child length and stature data published by [CONTACT_165086]
f) AST or ALT > 3.[ADDRESS_602655] 
g) Total Bilirubin > 1.[ADDRESS_602656] (except participants with Gilbert Syndrome who must have a 
total bilirubin level of < 3.[ADDRESS_602657])
h) Any positive test result for hepatitis B virus or hepatitis C virus indicating presence of 
virus, eg, hepatitis B surface antigen (HBsA g, Australia antigen) positive, or hepatitis C 
antibody (anti-HCV) positive (except if HCV-RNA negative).
4) Allergies and Adverse Drug Reaction
a) History of severe hypersensitivity reactions to other monoclonal antibodies
b) History of allergy or hypersensitivity to study drug components
5) Other Exclusion Criteria
a) Prisoners or participants who are involunt arily incarcerated. (Not e: under certain specific 
circumstances a person who has been imprisoned may be included or permitted to continue 
as a participant. Strict conditions apply and Bristol-Myers Squibb approval is required.
b) Participants who are compulsorily detained for treatment of either a psychiatric or physical 
(e.g. infectious disease) illness
Eligibility criteria for this study have been carefu lly considered to ensure the safety of the study 
participants and that the results of the study can be used. It is imperative that participants fully 
meet all eligibility criteria.
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602658] be 18 years of age or older.
6.3 Lifestyle Restrictions
Not applicable. No restrictions are required
6.4 Screen Failures
Screen failures are defined as participants who consent to participate in the clinical study but who 
are not subsequently entered in the study/included in the analysis population. A min imal set of 
screen failure information is required to ensure transparent reporting of screen failure participants, 
to meet the Consolidated Standards of Reporting Trials (CONSORT) publishing requirements, as 
applicable, and to respond to queries from regul atory authorities. Minimal information includes 
date of consent, demography, screen failure details, eligibility criteria, and any serious AEs.
6.4.1 Retesting During Screening Period
Participant Re-enrollment: This study permits the re-enrollment of a participant that has 
discontinued the study as a pre -treatment f ailure (i.e. participant has not been rando mized / has not 
been treated). If re-enrolled, the part icipant must be re-consented.
The most current result prior to Randomization is the value by [CONTACT_35853], as it represents the participant‚Äôs most current, clinical state.
Laboratory parameters and/or assessments that are included in Table 2-1 , Screening Procedural 
Outline may be repeated in an effort to find all possible well-qu alified participan ts. Consultation 
with the Medical Monitor may be needed to identify whether repeat testing of any particular 
parameter is clinically relevant.
7 TREATMENT
Study treatment is defined as any investigatio nal treatment(s), marketed  product(s), placebo or 
medical device intended to be administered to a st udy participant acc ording to the st udy 
randomizatio n or treatment allocation
Study treatment includes both Investigatio nal [Medicinal] Product (IP/IMP) and 
Non-investigational [Medicinal] Product (Non-IP/Non-IMP) and can consist of the following:
An IP, also known as investigational med icinal product in some regions, is defined a 
pharmaceut ical form of an active substance or placebo being tested or used as a reference in a 
clinical study, including products already with a marketing authori zation but used or assembled 
(formulated or package d) differently than the authorized form, or used for an unauthorized 
indication, or when used to gain further information about the authorized form.Other medications used as support or escape medication for preventative, diagnostic, or therapeutic 
reasons, as components of the standard of care for a given diagnosis, may be considered as non-
IP.
IPs used in this trial are provided in Table 7-1. There are no non-IPs in this study.
Protocol Amendment No.: 04
Date: 04-May-2021 72
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
For body weight-based dosing, the dosing calculat ions should be based on the body weight 
assessed at baseline. It is not necessary to re-calcu late subsequent doses if the participant weight 
is within 10% of the weight used to calculate the previous dose. All doses should be rounded up 
or to the nearest milligram per institutional standard.
Protocol Amendment No.: 04
Date: 04-May-2021 73
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 7-1: Study treatments for CA209848
Product Description / 
Class and Dosage 
FormPotencyIMP/
Non-IMPBlinded or 
Open LabelPackaging / 
AppearanceStorage Conditions
(per label)
Nivolumab
(BMS-936558-01)
Solution for Injection100 mg (10 mg/mL) 
and 40 mg (10 mg/mL)IMP Open labelVial or various 
packaging 
configurationsRefer to the label on con tainer and/or pharmacy 
manual
Ipi[INVESTIGATOR_125]
(BMS-734016) 
Solution for Injection200 mg
(5 mg/mL)IMP Open labelVial or various 
packaging 
configurationsRefer to the label on container and/or pharmacy 
manual
Protocol Amendment No.: 04
Date: 04-May-2021 74
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
7.1 Treatments Administered
The selection and timing of dose for each participant is as follows:
Table 7.1-1: Selection and Timing of Dose
Treatment 
ArmStudy 
TreatmentParticipant 
Age/WeightUnit dose 
strength(s)/
Dosage level(s)Frequency of 
AdministrationRoute of 
Administration
Arm A or Arm 
B Rollover: 
nivolumab in 
combination 
with 
ipi[INVESTIGATOR_470239] 
‚â•40kg240 mgQ2 weeks up to 
24 monthsIV
Adolescents 
<4 0 k g3 mg/kgQ2 weeks up to 
24 monthsIV
Ipi[INVESTIGATOR_470240] 1 mg/kgQ6 weeks up to 
24 monthsIV
Arm B: 
nivolumab 
monotherapyNivolumabAdults and 
adolescents 
‚â•40kg480 mgQ4 weeks up to 
24 monthsIV
Adolescents 
< 40kg6 mg/kgQ4 weeks up to 
24 monthsIV
Note: The mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent participants 
will not be included in these countries.
7.1.1 Arm A or Arm B Rollover ‚Äì Nivolumab in Combination with Ipi[INVESTIGATOR_470304] 2 week s. Adult participants and adolescents ‚â• 40kg will 
receive nivolumab at a dose of 240 mg, and adolescents < 40kg will receive nivolumab at a dose 
of 3mg/kg; in both cases, nivolumab will be administered as an approximately 30-minut e infusion 
on Day 1 of each treatment cycle. Ipi[INVESTIGATOR_470305] 6 weeks; all participants 
will receive ip ilimumab at a dose of 1mg/kg. If needed, flush the intravenous line with an 
appropriate amount of diluent (e.g. 0.9% sodium chlori de or 5% dextrose in water) to ensure that 
the complete dose is administered over approximately 30 minutes. Participants should begin study treatment within 3 calendar days of rando mization.
When study treatments (nivolumab  and ipi[INVESTIGATOR_125]) are to be administered on the same day, 
nivolumab is to be administered first. Nivolumab infusion must be promptly followed by a flush 
of diluent to clear the line of nivolumab before starting the ipi[INVESTIGATOR_182]. The second infusion will always be the ipi[INVESTIGATOR_470306] i nfusion line has 
been flushed, filters changed and patient has b een observed to ensure no infusion reaction has 
occurred.
Nivolumab and ipi[INVESTIGATOR_470307], discontinuation due 
to unacceptable toxicity, withdrawal of consent, or study closure. Participants will be treated up to 24 months in the absence of disease progression or unacceptable toxicity. Maximum 24 months of 
treatment also applies to treatment beyond progression.
Protocol Amendment No.: 04
Date: 04-May-2021 75
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Ipi[INVESTIGATOR_470308]. The assessment 
for discontinuation of nivolumab should be made separ ately from the assessment made for 
discontinuation of ipi[INVESTIGATOR_125]. Although there is overlap among the discontinuation criteria, if 
discontinuation criteria are met for ipi[INVESTIGATOR_45773], treatment with nivolumab 
may continue at the same dose and schedule if ipi[INVESTIGATOR_45774]. If a participant meets 
criteria for discontinuation and investigator is unable to determine whether the event is related to all or any one study d rug, the participant should discontinue  all study drugs and be taken off the 
treatment phase of the study. 
For ipi[INVESTIGATOR_470309], refer to ipi[INVESTIGATOR_162549]
51and/or pharmacy 
manual.
Separate infusion bags and filters should be used when administering nivolumab and ip ilimumab 
on the same day.Ipi[INVESTIGATOR_470310] 30-minute IV infusion and may be infused 
using a volumetric pump with a 0.[ADDRESS_602659] does not contain any antimicrobial 
preservatives or bacteriostatic agents. At the end of  the infusion, flush the line with a sufficient 
quantity of diluent.
The mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent 
participants will not be included in these countries.
7.1.2 Arm B ‚Äì Nivolumab Monotherapy
Adult participants and adolescents ‚â• 40kg will receive nivolumab at a dose of 480 mg. Adolescents 
< 40kg will receive nivolumab at a dose of 6mg/kg. In both cases, nivolumab will be administered 
as an approximately 30-minute i nfusion on Day [ADDRESS_602660]. If needed, flush the intravenous line with  an appropriate amount of 
diluent (e.g. 0.9% sodium chloride or 5% dextrose in water) to ensure that the complete dose is 
administered over approximately 30 minutes. Participants should begin study treatment within 3 
calendar days of randomization.
For nivolumab preparation and storage instructions, please refer to the nivolumab IB and/or 
pharmacy manual.
All participants will be monitored continuous ly for AEs while on study treatment. Treatment 
modifications (e.g. dose delay, reduction, retreatment, or discontinuation) w ill be based on specific 
laboratory and adverse event criteria, as described in  Sections 7.4.1 and Section 8 .
The mention of adolescents is not applicable for sites in Belgium or the Netherlands as adolescent 
participants will not be included in these countries.
Protocol Amendment No.: 04
Date: 04-May-2021 76
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
7.2 Method of Treatment Assignment
All participants will be assigned to treatment using an Interactive Response Technology (IRT). 
Before the study is initia ted, each user will receive log in information and dir ections on how to 
access the IRT.
Study treatment will be dispensed at the study visits as listed in Schedule of Activities ( Section 2 ).
7.3 Blinding
This is an open-label study, blinding procedures are not applicable.
7.4 Dosage Modification
Dose escalations or reductions of nivolumab or ipi[INVESTIGATOR_470311]. Participants may be 
dosed no less than 12 days from the previous dose during Q2W cycles. For Q4W dosing cycles, 
participants may be dosed within a ¬±[ADDRESS_602661] dose of nivolumab or nivolumab 
combined with ipi[INVESTIGATOR_125].
Participants should be carefully monitored for infusion r eactions during nivolumab and 
ipi[INVESTIGATOR_288]. If an acute infusion reaction is noted, part icipants should be managed 
according to Section 7 .
Doses of nivolumab and ipi[INVESTIGATOR_104000], delayed, or discontinued depending on 
how well the participant tolerates the treatment. Dosing visits are not skipped, only delayed.
7.4.1 Dose Delay Criteria 
Delay administration of both nivolumab and ipi[INVESTIGATOR_470312] S ection 7.4.1
are met. Delay nivolumab and ipi[INVESTIGATOR_470313], laboratory a bnormality, 
or intercurrent illness which, in the judgment of  the investigator, warrants delaying the dose of 
study medication.
Delay dosing for severe acute respi[INVESTIGATOR_6507] 2 (SARS-CoV-2) infection, either 
confirmed or suspected.
For participants who require delay of nivolumab and ipi[INVESTIGATOR_125], re-evaluate weekly or more 
frequently if clinically indicated and resume dosing when criteria to resume treatment are met (see 
Section 7.4.2 ). 
Continue tumor assessments per protocol even if dosing is delayed.
Protocol Amendment No.: 04
Date: 04-May-2021 77
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 7.4.1-1: Adverse Event C riteria for Delay, Resumption, and Discontinuation of Nivolumab and Ipi[INVESTIGATOR_470314]-related Adverse Event 
(AE) per CTCAE V5Severity Action Taken Clarifications, Exceptions, and Resumption
Criteria
Gastrointestinal
Colitis or diarrheaGrade 2 Delay dose Dosing may resume when AE resolves to baseline.
Grade 3 Nivolumab monotherapy: Delay dose Dosing may resume when AE resolves to baseline.
When administered with ipi[INVESTIGATOR_125]: 
Permanently discontinue ipi[INVESTIGATOR_470315]. If Grade 3 diarrhea or colitis 
recurs while on nivolumab monotherapy, 
permanently discontinue.
Grade 4 Permanently discontinue
Renal
Serum creatinine increased Grade 2 or 3 Delay dose Dosing may resume when AE resolves to Grade ‚â§ 1 
or baseline value.
Grade 4 Permanently discontinue
Pulmonary
Pneumonitis Grade 2 Delay dose Dosing may resume after pneumonitis has resolved 
to Grade‚â§ 1.
Grade 3 or 4 Permanently discontinue
Hepatic
Aspartate aminotransferase 
(AST), alanine 
aminotransferase (ALT), or 
total bilirubin (T.bili) increasedAST or ALT > 3√ó and ‚â§5√ó
upper limit of normal (ULN) or T.bili  > 1.5√ó and ‚â§3√ó
ULN, regardless of baseline valueDelay dose Dosing may resume when laboratory values return 
to baseline.
AST or ALT > 5 √ó ULN or T. bili > 3 √ó ULN, regardless 
of baseline valueDelay dose or 
permanently discontinue In most cases o fAST or ALT > 5√ó ULN, study 
treatment will be permanently discontinued. If the investigator determines a possible favorable 
benefit/risk ratio that warrants continuation of study 
Protocol Amendment No.: 04
Date: 04-May-2021 78
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 7.4.1-1: Adverse Event C riteria for Delay, Resumption, and Discontinuation of Nivolumab and Ipi[INVESTIGATOR_470314]-related Adverse Event 
(AE) per CTCAE V5Severity Action Taken Clarifications, Exceptions, and Resumption
Criteria
treatment, a discussion between the investigator and the Medical Monitor/designee must occur and 
approval from the Medical Monitor must be 
obtained prior to resuming therapy.
Concurrent AST or ALT > [ADDRESS_602662] and T.bili > [ADDRESS_602663], 
regardless of baseline valuePermanently discontinue 
Endocrinopathy
Adrenal insufficiency Grade 2 adrenal insufficiency Delay dose Dosing may resume after adequately controlled 
with hormone replacement.
Grade 3 or 4 adrenal 
insufficiency or adrenal crisisDelay dose or permanently discontinue Mandatory discussion with and approval from the 
Medical Monitor needed prior to resuming therapy. 
If adrenal insufficiency resolves or is adequately 
controlled with physiologic hormone replacement, 
participant may not require discontinuation of study 
drug.
Hyperglycemia Hyperglycemia requiring 
initiation or change in daily management (Grade 2 or 3)Delay dose Dosing may resume if hyperglycemia resolves to 
Grade ‚â§1 or baseline value, or is adequately 
controlled with glucose-controlling agents.
Grade 4 Delay dose or permanently discontinue Mand atory discussion with and approval from the 
Medical Monitor needed prior to resuming therapy. 
If hyperglycemia resolves, or is adequately 
controlled with glucose-controlling agents, 
participant may not require discontinuation of study 
drug.
Hypophysitis/Hypop ituitarism Sympto matic Grade 1-3 that is 
also associated with 
corresponding abnormal lab 
and/or pi[INVESTIGATOR_470316], or is adequately controlled with 
only physiologic hormone replacement.
Grade 4 Delay dose or permanently discontinue Mandatory discussion with and approval from the 
Medical Monitor needed prior to resuming therapy. 
If endocrinopathy resolves or is adequately 
controlled with physiologic hormone replacement, 
participant may not require discontinuation of study 
drug.
Protocol Amendment No.: 04
Date: 04-May-2021 79
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 7.4.1-1: Adverse Event C riteria for Delay, Resumption, and Discontinuation of Nivolumab and Ipi[INVESTIGATOR_470314]-related Adverse Event 
(AE) per CTCAE V5Severity Action Taken Clarifications, Exceptions, and Resumption
Criteria
Hyperthyroidism or  HypothyroidismGrade 2 or 3 Delay dose Dosing may resume if endocrinopathy resolves to 
be asymptomatic, or is adequately controlled with 
only physiologic hormone replacement or other 
medical management.
Grade 4 Delay dose or permanently discontinue Mandatory discussion with and approval from the 
Medical Monitor needed prior to resuming therapy. If endocrinopathy resolves or is adequately 
controlled with physiologic hormone replacement
or other medical management, participant may not 
require discontinuation of study drug.
Skin
Rash Grade 2 rash covering >30% 
body surface area or Grade 3 
rashDelay dose Dosing may resume when rash reduces to ‚â§10% 
body surface area.
Suspected Stevens-Johnson syndrome (SJS), toxic 
epi[INVESTIGATOR_194] (TEN), or drug reaction with eosinophilia 
and systemic symptoms 
(DRESS)Delay dose Dosing may resume if SJS, TEN, or DRESS is ruled 
out and rash reduces to is ‚â§10% body surface area.
Grade 4 rash or confirmed SJS,TEN, or DRESSPermanently discontinue
Neurological
Guillain-Barre Syndrome (GBS)Any grade Permanently discontinue
Myasthenia Gravis (MG) Any grade Permanently discontinue
Encephalitis Any grade encephalitis Delay dose After workup for differe ntial diagnosis, (ie,
infection, tumor-related), if encephalitis is not drug related, then dosing may resume when AE resolves.
Any grade drug-related 
encephalitis Permanently discontinue
Myelitis Any grade myelitis Delay dose After  workup for differential diagnosis, (ie,
infection, tumor-related), if myelitis is not drug 
related, then dosing may resume when AE resolves.
Protocol Amendment No.: 04
Date: 04-May-2021 80
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 7.4.1-1: Adverse Event C riteria for Delay, Resumption, and Discontinuation of Nivolumab and Ipi[INVESTIGATOR_470314]-related Adverse Event 
(AE) per CTCAE V5Severity Action Taken Clarifications, Exceptions, and Resumption
Criteria
Any grade drug-related myelitisPermanently discontinue
Neurological (other than GBS, 
MG, encephalitis, or myelitis)Grade [ADDRESS_602664] or with 
minimal activity or exertion, 
and/or where intervention 
indicatedPermanently discontinue
Other Clinical AEs
Pancreatitis: 
Amylase or lipase increasedGrade 3 with symptoms Delay dose Note: Grade 3 increased amylase or lipase without 
signs or symptoms of pancreatitis does not require 
dose delay. 
Dosing may resume when patient becomes 
asymptomatic.
Grade 4 Permanently discontinue
Uveitis Grade 2 uveitis Delay dose Dosing may resume if uveitis responds to topi[INVESTIGATOR_186691] (eye drops) and after uveitis resolves to 
Grade ‚â§ 1 or baseline. If patient requires oral 
steroids for uveitis, then permanently discontinue study drug.
Grade 3 or 4 uveitis Permanently discontinue
Other drug-related AE (not 
listed above)Grade 2 non-skin AE, except 
fatigueDelay dose Dosing may resume when AE resolves to Grade ‚â§ [ADDRESS_602665] occurrence lasting ‚â§ 7 daysDelay dose Dosing may resume when AE resolves to Grade ‚â§ [ADDRESS_602666] occurrence lasting > 7 daysPermanently discontinue
Protocol Amendment No.: 04
Date: 04-May-2021 81
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 7.4.1-1: Adverse Event C riteria for Delay, Resumption, and Discontinuation of Nivolumab and Ipi[INVESTIGATOR_470314]-related Adverse Event 
(AE) per CTCAE V5Severity Action Taken Clarifications, Exceptions, and Resumption
Criteria
Recurrence of Grade 3 AE of any durationPermanently discontinue
Grade 4 or life-threatening 
adverse reactionPermanently discontinue
Other Laboratory Abnormalities 
Other drug-related laboratoryabnormality (not listed above)Grade 3 Delay dose Exceptions:
No delay required for: Grade 3 lymphopenia 
Permanent discontinuation for: Grade 3 
thrombocytopenia > 7 days or associated withbleeding
Grade 4 Permanently discontinue Exceptions: The following events do not require 
discontinuation of study drug: 
‚Ä¢Grade 4 neutropenia ‚â§ 7 days
‚Ä¢Grade 4 lymphopenia or leukopenia
‚Ä¢Grade 4 isolated electrolyte 
imbalances/abnormalities that are not associated 
with clinical sequelae and are responding to supplementation/appropriate management within 
72 hours of their onset
Infusion Reactions (manifested by [CONTACT_411], chills, rigors, headache, rash, pruritus, arthralgia, hypotension, hypertension, bronc hospasm, or other allergic-like 
reactions)
Hypersensitivity reaction or infusion reactionGrade 3 or 4 Permanently discontinue Refer to  Section 7.4.4 .
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602667] completed AE management (ie,
corticosteroid taper) or are on ‚â§ 10 mg prednisone or equivalent and meet the requirements per 
Table 7.4.1-1 .
Participants with SARS-CoV-2 infection (eit her confirmed or suspecte d) may resume treatment 
after all of the following :
1) At least 10 days (20 days for severe/critical illness) have passed since symptoms first appeared 
or positive test result (e.g. reverse transcription polymerase chain reaction [RT-PCR] or viral 
antigen),
2) Resolution of acute symptoms (including at least [ADDRESS_602668] fever without 
fever reducing medications), 
3) Evaluation by [CONTACT_104128] a higher risk of receiving investigational treatment, and
4) Consultation by [CONTACT_470383]. 
For suspected cases, treatment may also resume if SARS-CoV-2 infection is ruled-out and other 
criteria to resume treatment ar e met.Prior to re-initiating tr eatment in a participant with a dosing 
delay lasting > 6 weeks for nivolumab or > 12 weeks for ipi[INVESTIGATOR_125], the Medical Monitor (or 
designee) must be consulted. Continue tumor asse ssments per protocol even if dosing is delayed. 
Continue periodic study visits to assess safe ty and laboratory studies every [ADDRESS_602669] be discontinued due to toxicity 
attributed to that agent alone.
7.4.3 Nivolumab and Ipi[INVESTIGATOR_470317] a minority of participants treated with immunotherapy may 
derive clinical benefit despi[INVESTIGATOR_470318] (PD).52Participants treated 
with nivolumab in combination with ipi[INVESTIGATOR_470319], assessed by [CONTACT_093], as long as they 
meet the following criteria:
‚Ä¢Investigator-assessed clinical benefit.
‚Ä¢Tolerance of study treatment
‚Ä¢Stable performance status
‚Ä¢Treatment beyond progression will not d elay an imminent intervention to prevent serious 
complications of disease progression (e.g. CNS m etastases)
Protocol Amendment No.: 04
Date: 04-May-2021 83
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
‚Ä¢Participants provides written informed consent prior to receiving additional nivolumab in 
combination with ipi[INVESTIGATOR_470320]. All other elements of the main consent 
including description of reasonably foreseeable risks or discomforts, or other alternative 
treatment options will still apply.
‚Ä¢The maximum period allowed of st udy treatment is [ADDRESS_602670] dose, including 
treatment beyond progression
‚Ä¢If the investigator feels that the participant continues to achieve clinical benefit by [CONTACT_166862], the participant should remain on the trial and continue to receive monitoring according to the Schedule of Activities in Section 2 .
A radiographic assessment/scan should be performed within 6 weeks of init ial investigator-
assessed progression to determine whether there has been a decrease in the tumor size or continued 
PD. The assessment of clinical benefit should be ba lanced by [CONTACT_470384][INVESTIGATOR_120992].
For the participants who continue nivolumab in combination with ipi[INVESTIGATOR_470321], further progression is defined as following: 
1) For solid tumors, an additional 10% increase in tumor burden with a minimum 5 mm absolute 
increase from time of initial PD, this includes an increase in the sum of diameters of all target 
lesions and/or the diameters of new measurable les ions compared to the time of initial PD.  
2) For CNS tumors, an additional approximately 12.5 % increase in tumor burden with a minimum 
5 mm absolute increase of either diameter from time of initial PD; this includes an increase in 
the sum of the products of perpendicular diameters (SPD) and the sum of one diameter with 
larger increase of all target lesions and/or new measurable lesions compared to the time of initial PD. 
New lesions are considered  measureable at th e time of init ial progression if th e longest diameter
is at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 
15 mm). Any new lesion considered non-measureable at the time of initial progression may 
become measureable and therefore included in the tumor burden if the longest diameter increases 
to at least 10 mm (except for pathological lymph nodes which must have a short axis of at least 
15 mm). In situations where the relative increase in total tumor burden by 10% is solely due to 
inclusion of new lesions which become measurable, these new lesions must demonstrate an absolute increase of at least 5 mm.
Nivolumab in combination with ipi[INVESTIGATOR_470322].
Protocol Amendment No.: 04
Date: 04-May-2021 84
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
[IP_ADDRESS] Treatment with nivolumab and ipi[INVESTIGATOR_470323] (Arm B rollover) 
Participants who have progressed after treatment with nivolumab monotherapy may be allowed to 
receive tr eatment with nivolumab in combination with ipi[INVESTIGATOR_125]. Besides complying with all 
criteria described above, the following criteria must be met:
‚Ä¢Investigator-assessed clinical benefit by [CONTACT_470385][INVESTIGATOR_125];
‚Ä¢Eligibility must be confirmed within [ADDRESS_602671] TMB ‚â• [ADDRESS_602672] infusio n of nivolumab 480mg (or 6mg/ kg). Refer to Sections 7.1.[ADDRESS_602673] wi th fever, chills, rigors, headache, rash, pruritus, 
arthralgias, hypo- or hypertension, bronchospasm, or other allergic-like reactions. All Grade 3 or 
4 infusion r eactions should be reported within 24 hours as SAEs if criteria are met. Infusion 
reactions should be graded according to NCI CTCAE (Version 5.0) guidelines.
Treatment recommendations are provided below based on CTCAE v5 grading definitions and may 
be modified based on local treatment standards and guidelines, as appropriate:
For Grade 1 symptoms: (mild reaction; infusion interruption not indicated; intervention not 
indicated)
‚Ä¢Remain at bedside and monitor participant until recovery from symptoms. The following 
prophylactic premedications are r ecommended for future i nfusions: diphe nhydramine 50 mg 
(or equivalent) and/or acetaminophen/paracetamol [ADDRESS_602674] 30 minutes before 
additional nivolumab or ipi[INVESTIGATOR_45782].
Protocol Amendment No.: 04
Date: 04-May-2021 85
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
For Grade 2 symptoms: (moderate reaction requ ires therapy or infusion interruption but 
responds promptly to symptomatic treatment [eg, antihistamines, non-steroidal 
anti-inflammatory drugs, narcotics, IV fluids]; prophylactic medications indicated for ‚â§‚â§24 
hours)
‚Ä¢Stop the nivolumab or ipi[INVESTIGATOR_182], begin an IV infusion of normal saline, and tr eat 
the participant with diphenhydramine 50 mg IV (or equivalent) and/or 
acetaminophen/paracetamol 325 to 1000 mg; remain at bedside and monitor participant until 
resolution of symptoms. Corticosteroi d and/or bronchodilator therapy may also be 
administered as appropriate. If the i nfusion is inte rrupted, then restart the i nfusion at 50% of 
the original infusion rate when symptoms re solve; if no further complications ensue after 
30 minutes, the rate may be increased to 100% of the original infusion rate. Monitor participant
closely. If symptoms recur, then no further nivolumab or ipi[INVESTIGATOR_114569]. Administer diphenhydramine [ADDRESS_602675] be recorded 
on the electronic case report form (eCRF).
‚Ä¢For future infusions, the following prophylactic premedications are recommended: 
diphenhydramine 50 mg (or equivalent) a nd/or acetaminophen/paracetamol [ADDRESS_602676] 30 minutes before nivolumab or ip ilimumab infusions. If 
necessary, corticosteroids (up to 25 mg of  hydrocortisone or equivalent) may be used.
For Grade 3 or 4 symptoms: (severe reaction, Grade 3: prolonged [ie, not rapi[INVESTIGATOR_77984]/or brief in terruption of infusion ]; recurrence of symptoms 
following initial improvement; hospi[INVESTIGATOR_14138] [eg, renal 
impairment, pulmonary infiltrates]. Grade 4: Life threatening; urgent pressor or ventilatory 
support indicated)
‚Ä¢Immediately discontinue infusion of nivolumab or ipi[INVESTIGATOR_125]. Begin an IV infusion of normal 
saline and tr eat the participant as follows: Reco mmend bronchodilators, epi[INVESTIGATOR_238] 0.2 to 1 
mg of a 1:1000 solution for subcutaneous  administration or 0.1 to  0.25 mg of  a 1:10,000 
solution injected slowly for IV administration, and/or diphenhydramine 50 mg IV with 
methylprednisolone 100 mg IV (or equivalent), as needed. Participant should be monitored 
until the investigator is comfortable that the symptoms will not recur. Nivolumab or 
ipi[INVESTIGATOR_102341]. Investigators s hould follow their institutional 
guidelines for the treatment of  anaphylaxis. Remain at bedside and monitor participant until 
recovery of the symptoms.
In case of late-occurring hypersensitivity symptoms (eg, appearance of a localized or generalized 
pruritus within 1 week after treatment), symptomatic treatment may be given (eg, oral antihistamine or corticosteroids).
7.4.5 Management Algorithms for Immuno-oncology Agents
Immuno-oncology (IO) agents are associated with AEs that can differ in severity and duration
from AEs caused by [CONTACT_20451]. Nivolumab and ipi[INVESTIGATOR_470324].: 04
Date: 04-May-2021 86
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
agents, and the management algorithms in Appendix 5 provide guidance on assessing and 
managing the following groups of AEs:
‚Ä¢Gastrointestinal
‚Ä¢Renal
‚Ä¢Pulmonary
‚Ä¢Hepatic
‚Ä¢Endocrinopathy
‚Ä¢Skin
‚Ä¢Neurological
‚Ä¢Myocarditis
Treatment management algorithms are found in the nivolumab IB47and in Appendix 5. 
7.5 Preparation/Handling/Storage/Accountability
The IP should be stored in a secure area according to local regulations. It is the responsibility of 
the investigator to ensure that IP is only dispensed to study Participants. The IP must be dispensed 
only from official study sites by [CONTACT_470386].
The product storage manager should ensure that the study treatment is stored in accordance with the environmental conditions (temperature, lig ht, and humidity) as determined by [CONTACT_20444]. If 
concerns regarding the quality or appearance of the study tr eatment arise, the st udy tr eatment 
should not be dispense d and contact [CONTACT_20445].
Study treatment not supplied by [CONTACT_53972].
IP documentation (whether supplied by [CONTACT_20447] ) must be maintain ed that in cludes all processes 
required to ensure drug is accurately administered. This includes documen tation of drug storage, 
administration and, as applicable, storage temper atures, reconstitution, and use of required 
processes (eg, required diluents, administration sets).Further guidance and information for final disposition of unused study tr eatment are provided in
Appendix 2 and CA209848 Pharmacy Manual. 
7.5.1 Retained Samples for Bioavailability / Bioequivalence
Not applicable.
7.[ADDRESS_602677] ug accountability. Drug 
accountability s hould be reviewed by [CONTACT_102441]. Sites should discuss discrepancies with the participant at each on-tr eatment study 
visit.
Protocol Amendment No.: 04
Date: 04-May-2021 87
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
7.7 Concomitant Therapy
7.7.1 Prohibited and/or Restricted Treatments
The following medications are prohibited during the study (unless utilized to treat a drug-related 
adverse event). Medications taken within [ADDRESS_602678] be recorded on the CRF.
‚Ä¢Immunosuppressive agents 
‚Ä¢Immunosuppressive doses of systemic corticosteroids (except as stated in Section 7.7.2 )
‚Ä¢Any concurrent antineoplastic therapy (ie, chemotherapy, hormonal therapy, immunotherapy, 
extensive, non-p alliative rad iation therapy, or standard or investigational agents for treatment 
of cancer)
‚Ä¢Any complementary medications (eg, herbal supplements or traditional Chinese medicines) 
intended to treat the disease under study or provi de supportive care. Use of marijuana and its 
derivatives for treatment of symptoms relate d to cancer or cancer treatment are permitted if 
obtained by [CONTACT_102437] (even without a medical prescription) has been 
legalized locally.
‚Ä¢Any live / attenuated vaccine (eg varicella, zoster, yellow fever, rotavirus, oral polio and measles, mumps, rubella (MMR)) during treatment and until [ADDRESS_602679] dose.
‚Ä¢Use of any additional noninvasive medical dev ice treatment of glioblastoma multiforme (eg, 
NovoTTF‚Ñ¢, Optune¬Æ).
‚Ä¢Administration of a live (replication comp etent) coronavirus disease 2019 (COVID-19)
vaccine within 30 days prior to randomization (or screening). Live COVID-[ADDRESS_602680] 
dose of IP.
7.7.2 Permitted Therapy
Participants are permitted the use of topi[INVESTIGATOR_2855], ocular, intra-articular, intranasal, and inhalation 
corticosteroids (with minimal system absorption). Adrenal replacement steroid doses > 10 mg daily prednisone are permitted. A brief (less than 3 weeks) course of corticosteroids for 
prophylaxis (eg, for contrast dye allergy) or for treatment of non-autoimmune conditions (eg, 
delayed-type hypersensitivity reaction cau sed by a contact [CONTACT_20435]) is permitted. Prior p alliative 
radiotherapy must have been completed at least [ADDRESS_602681] dose of IP.
COVID-19 vaccines that are NOT live (not rep lication competent) are pe rmitted during the study 
and after the last dose of IP. No data are available on the response to COVID-[ADDRESS_602682] the Clinical Trial 
Physician/Medical Monitor (or designee) with any questions related to COVID-19 vaccines.
7.7.3 Palliative Local Therapy
Palliative local therapy, including palliative rad iation therapy- and palliative surgical resection, to 
symptomatic non-target bone lesions, skin lesions, or CNS lesions (only for peripheral solid 
tumors, not applicable for CNS primary tumor) is permitted prior to discontinuation of study 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602683] meet criteria to 
continue treatment beyo nd progression in order to resume immunotherapy after p alliative lo cal 
therapy.
The potential for overlappi[INVESTIGATOR_470325]; 
however, anecdotal data suggests that it is tolerable. As concurrent radiotherapy and nivolumab 
have not been formally evaluated, in cases where p alliative radiotherapy is required for a tumor 
lesion, then nivolumab should be withheld for at least 1 week before, during, and 1 week after 
radiation. Participants should be closely monitored for any potential toxicity during and after 
receiving radiotherapy, and AEs should resolve to Grade ‚â§1 prior to resuming nivolumab.
7.7.4 Other Restrictions and Precautions
Participants with a condition requiring systemic treatment with either corticosteroids (> 10 mg 
daily prednisone equivalent) or other immunos uppressive medications within 14 days of treatment 
assignment are excluded. Inhaled or topi[INVESTIGATOR_470326], and adrenal replacement steroid doses 
> 10 mg daily prednisone equivalent, are permitted in the absence of active autoimmune disease.
7.7.5 Imaging Restriction and Precautions
It is the local imaging facility‚Äô s responsibility to determine, based on participant attributes (eg, 
allergy history, diabetic history and renal status), the appropriate imaging mod ality and contrast 
regimen for each participant. Imaging contraindications and contrast risks should be considered in 
this assessment. Participants with renal insufficiency s hould be assessed as to whether or not they 
should receive contrast and if so, what type and dose of contrast is appropriate. Specific to MRI, participants with severe renal insufficiency (i e, estimated glomerular filtration rate (eGFR) 
< 30 mL/min/1.73 m
2) are at increased risk of nephrogenic systemic fibrosis. MRI contrast should 
not be given to this participant population. In a ddition, participants are excluded from MRI if they 
have tattoos, met allic imp lants, pacemakers, etc. The ultimate decision to perform MRI in an 
individual participant in this study rests with th e site radiologist, the investigator and the standard 
set by [CONTACT_61857].
7.7.[ADDRESS_602684] solitary lesions in participants with 
metastatic disease and render the patient free of macroscopic disease. Participants enrolled in this 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602685] 
4 weeks after previous scan and following consultation with the BMS Medical Monitor. If tumor shrinkage of the solitary lesion is noted on the re-staging assessment, it is highly encouraged that 
surgical resection be delayed until subsequent scans fail to demonstrate further shrinkage.
7.8 Treatment After the End of the Study
At the conclusion of the study, participants who continue to demons trate clinical benefit will be 
eligible to receive BMS-supplied study treatment for the maximum tr eatment duration specified 
in protocol Section 7.1 . Study treatment will be provided via an extension of the study, a rollover
study requiring approval by [CONTACT_470387].
BMS reserves the right to terminate access to BMS supplied study treatment if any of the following 
occur: a) the study is terminated due to safety concerns; b) the development of nivolumab or 
ipi[INVESTIGATOR_102359], including but not limited to lack of efficacy and/or not meeting the study objectives; c) the participant can obtain  medication from a government 
sponsored or private health program. In all cas es BMS will follow local regulations.
8 DISCONTINUATION CRITERIA
8.1 Discontinuation from Study Treatment
Nivolumab and/or ipi[INVESTIGATOR_470327] 7.4.1. Discontinue nivolumab and/or ipi[INVESTIGATOR_143802], laboratory 
abnormality, or intercurrent illness that, in the judgment of the Investigator, presents a substantial 
clinical risk to the participant with continued nivolumab and/or ipi[INVESTIGATOR_45770].
Participants MUST discontinue IP (and non-IP at the discretion of the investigator) for any of the 
following reasons:
‚Ä¢Participant‚Äôs request to stop study tr eatment. Par ticipants who request to discontinue study 
treatment w ill remain in the study and must continue to be followed for protocol specified 
follow-up procedures. The only exception to this is when a participant specifically withdraws 
consent for any further contact [CONTACT_35859]/her or persons previously authorized by [CONTACT_104135]
‚Ä¢Any clinical adverse event (AE), labor atory abnormality or intercurrent illness which, in the 
opi[INVESTIGATOR_871], indicates that continued participation in the study is not in the best interest of the participant
‚Ä¢Confirmed disease progression after treatment beyond initial study cr iteria defined
progression (see 7.4.3) for Arm A (combination of nivolumab and ipi[INVESTIGATOR_125])
‚Ä¢Confirmed disease progression after treatment beyond initial study cr iteria defined
progression (s ee 7.4.3) for Arm B unless the par ticipants choose and are eligible for rollover to
receive nivolumab in combination with ipi[INVESTIGATOR_125])
‚Ä¢Termination of the study by [CONTACT_414]-Myers Squibb (BMS)
‚Ä¢Loss of ability to fr eely provide consent through imprisonment or involuntarily incarceration 
for treatment of eith er a psychiatric or physical (eg, infectious di sease) illness. (Note: Under 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602686] conditions  apply and BMS approval is required.)
Refer to the Schedule of Activities for data to be collected at the time of treatment discontinuation 
and follow-up and for any further evaluations that can be completed.
In the case of pregnancy, the investigator mu st immediately, within 24 hours of awareness of the 
pregnancy, notify the BMS Medical Monitor/design ee of this event. In most cases, the study 
treatment w ill be permanently discontinued in an appropri ate manner (e.g. dose tapering if 
necessary for participant safety). Refer to Section 9.2.[ADDRESS_602687]-treatment study follow-up or loses the 
ability to consent freely (i.e., is imprisoned or involuntarily incarcerated for the treatment of either a psychiatric or physical illness).
If study treatment is discontinued prior to the participant‚Äôs completion of the study, the reason for 
the discontinuation must be documented in th e participant‚Äôs medical records and entered on the 
appropriate case report form (CRF) page.
The assessment for discontinuation of nivolumab should be made separately from the assessment 
made for discontinuation of ipi[INVESTIGATOR_125]. Although there is overlap among the discontinuation 
criteria, if discontinuation criteria are met fo r ipi[INVESTIGATOR_470328], treatment with 
nivolumab may continue if ipi[INVESTIGATOR_45774].
If a participant in the nivolumab/ipi[INVESTIGATOR_470329], the 
participant should discontinue both nivolu mab and ipi[INVESTIGATOR_470330].
8.1.1 Dose Discontinuation in Nivolumab and Ipi[INVESTIGATOR_470331] > 6 weeks for nivolumab or > 12 weeks for 
ipi[INVESTIGATOR_470332], with the following exceptions:
‚àíDosing delays to allow for prolonged steroid tap ers to manage drug-related adverse events 
are allowed. 
‚àíDosing delays from the previous dose that occur for non-drug-related reasons may be allowed if approved by [CONTACT_102440] (or designee). 
Prior to re-initiating treatment in a participant with a dosing delay lasting > 6 weeks for nivolumab 
or >12 weeks for ipi[INVESTIGATOR_125], the BMS Medical Moni tor (or designee) must be consulted. Tumor 
assessments should continue as per protocol even if dosing is delayed. Periodic study visits to 
assess safety and laboratory studies should also continue every 6 weeks or more frequently if clinically indicated during such dosing delays.
Protocol Amendment No.: 04
Date: 04-May-2021 91
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Any adverse event, laboratory abnormality, or intercurrent illness which, in the judgment of the 
Investigator, presents a substantial clinical risk to the participant with continued nivolumab dosing.
The assessment for discontinuation of nivolumab should be made separately from the assessment 
made for discontinuation of ipi[INVESTIGATOR_125]. Although there is overlap among the discontinuation 
criteria, if discontinuation criteria are met for ipi[INVESTIGATOR_45773], treatment with nivolumab may continue if ipi[INVESTIGATOR_45774].
If a participant in the nivolumab/ipi[INVESTIGATOR_470333], 
the participant should discontinue both nivolumab and ipi[INVESTIGATOR_45775].
8.1.2 Dose Discontinuation in Nivolumab Monotherapy Arm
Any event that leads to delay in dosing lasting > 10 weeks from the previous dose requires
discontinuation, with the following exceptions:
‚àíDosing delays to allow for prolonged steroid tap ers to manage drug-related adverse events 
are allowed. 
‚àíDosing delays that occur for non -drug-related reasons may be allowed if approved by [CONTACT_349395] (or designee). 
Prior to re-initiating treatment in a participant with a dosing delay lasting > 10 weeks, the BMS Medical Monitor (or designee) must be consulted. Tumor assessments should continue as per 
protocol even if dosing is delayed. Periodic study visits to assess safety and laboratory studies 
should also continue every [ADDRESS_602688] continue to be followed for collection of 
outcome and/or survival follow-up data as required and in line with Section [ADDRESS_602689] that survival data be collected on all treated/randomized participants outside of 
the protocol defined window (See Table 2-5 in Schedule of Activities). At the time of this request, 
each participant will be con tacted to deter mine their survival s tatus unless the participant has 
withdrawn consent for all contacts or is lost to follow-up.8.[ADDRESS_602690] with  him/her or persons 
previously authorized by [CONTACT_102446]. 
Protocol Amendment No.: 04
Date: 04-May-2021 92
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
‚Ä¢Participants should notify the investigator of the decision to withdraw consent from future 
follow-up in writing , whenever possible.
‚Ä¢The withdrawal of consent should be explained in  detail in the medical rec ords by [CONTACT_1275], as to whether the withdrawal is from further treatment with  study treatment only 
or also from study proce dures and/or post treatment study follow-up, and entered on the 
appropriate CRF page.
‚Ä¢In the event that vital status (whether the participant is alive or dead) is being measured, 
publicly available information s hould be used to determine vital status only as appropriately 
directed in accordance with local law.
‚Ä¢If the participant withdraws consent for disclosure of future information, the sponsor may 
retain and continue to use any data collected before such a withdrawal of consent.
8.[ADDRESS_602691] to Follow-Up
‚Ä¢All reasonable efforts must be made to locate pa rticipants to determine and report their ongoing 
status. This includes follow-up with persons authorized by [CONTACT_2299].
‚Ä¢Lost to follow-up is defined by [CONTACT_470388] a minimum of three
documented phone calls, faxe s, or emails as well as lack of response by [CONTACT_102448]. All attempts should be documented in the participant‚Äôs medical records.
‚Ä¢If it is determined that the participant has died, the site w ill use permissible local methods to 
obtain date and cause of death.
‚Ä¢If investigator‚Äôs use of third-party representative to assist in the follow-up portion of the study 
has been included in the par ticipant‚Äôs informed consent, then the investigator may use a 
Sponsor retained third-party representative to assi st site staff with obtaining participant‚Äôs 
contact [CONTACT_193611] s tatus data n ecessary to complete the follow-up 
portion of the study. 
‚Ä¢The site staff and representative will consult publicly available sources, such as public h ealth 
registries and databases, in orde r to obtain updated contact [CONTACT_3031].
‚Ä¢If after all attempts, the participant remains lost to follow-up, then the last known alive date as 
determined by [CONTACT_102449]‚Äôs medical 
records.
9 STUDY ASSESSMENTS AND PROCEDURES
‚Ä¢Study procedures and timing are summarized in the Schedule of Activities. 
‚Ä¢Protocol waivers or exemptions are not allowed.
‚Ä¢All immediate safety concerns must be  discussed with the Sponsor immediately upon 
occurrence or awareness to determine if the participant should continue or discontinue 
treatment.
‚Ä¢Adherence to the study design requirements, including those specified in the Schedule of 
Activities, is essential and required for study conduct.
‚Ä¢All screening evaluations must be completed and reviewed to confirm that potential 
participants meet all eligibility criteria be fore randomization. The investigator will maintain a 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602692] 
reasons for screening failure, as applicable.
‚Ä¢Procedures conducted as part of the participant‚Äôs routine clinical management (eg, blood count) 
and obtained before signing of  informed consent may be u tilized for screening or baseline 
purposes provided the procedure meets the protocol-defined criteria and has been performed 
within the timeframe defined in the Schedule of Activities.
Additional measures, including non-study required laboratory tests, should be performed as 
clinically indicated or to comply with local regu lations. Laboratory toxicities (e.g. suspected drug 
induced liver enzyme evaluations) will be mo nitored during the follow-up phase via on-si te/local 
labs until all study drug-related toxicities resolve, return to baseline, or are deemed irreversible.
Evaluate participant immediately to rule out cardiac or pulmonary toxicity if participant shows 
cardiac- or pulmonary-related signs (hypoxia, abnor mal heart rate, or changes from baseline) or 
symptoms (eg, dyspnea, cough, chest pain, fatigue, palpi [INVESTIGATOR_814]).
Some of the assessments referred to in this section may not be captured as data in the eCRF. They 
are intended to be used as safety monitoring by [CONTACT_1963]. Additional testing or 
assessments may be performed as clinically necessary or where required by [CONTACT_20468].
9.[ADDRESS_602693] 1.1 for solid tumors (see appendix 7 ). For CNS tumors, response will be assessed
using RANO 2010 criteria53supplemented by [CONTACT_470389], as well as additional considerations as applicable e.g. adverse events or steroid
requirement. (See  Appendix 8 ).
9.1.1 Imaging Assessment for the Study 
Images will be submitted to an imaging core lab and may undergo blinded independent central 
review (BICR) at any time during the study. Prior to scanning the first participant sites should be 
qualified as well as understand the image acquisition guidelines and submission process as ou tlined 
in the CA209848 Imaging Manual provided by [CONTACT_186752]. For CNS participants, sites 
need to follow qualification procedures within the imaging manual to demonstrate the ability to 
perform required MRI sequences for this study.
Screening and on study tumor assessment will take place in accordance with the Section 2
Schedule of Activities, according to appropriate response criteria (Appendix 7 and Appendix 8). 
Any additional imaging that ma y demonstrate tumor response or progression (including scans 
performed at unscheduled timepoints and/or at an outside institution) should be co llected for 
RECIST 1.1 tumor assessment and submitted to the BICR.Scans should be performed until BICR confirmation of p rogression or treatment discontinuation 
(including treatment beyond progression), whichever occurs later. 
Protocol Amendment No.: 04
Date: 04-May-2021 94
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
9.1.2 Methods of Measurement
[IP_ADDRESS] Solid tumors Contrast-enhanced CT of the chest, abdomen, pelvis, and all other known and/or suspected sites 
of disease should be performed for tumor asse ssments. Images should be acquired with slice 
thickness of 5 mm or less with no intervening gap (contiguous). Ever y attempt should be made to 
image each participant using an identical acquisition protocol on the same scanner for all imaging 
timepoints. Tumor measurements should be made by [CONTACT_470390]. Change in tu mor measurements and tumor response to guide 
ongoing study treatment decisions will be asse ssed by [CONTACT_104145] 1.[ADDRESS_602694]-enhanced MRI of the, a bdomen, pelvis, and other known/suspected sites of 
disease should be obtained.
Should a participan t have contraindication for both MRI and CT intravenous contrasts, a non-
contrast CT of the chest and a non-contrast MRI of the abdomen, pelvis, and other 
known/suspected sites of disease should be obtained. 
Should a participant have contraindication for MRI (e.g., incompatible pacemaker) in addition to 
contraindication to CT intravenous contrast, a non -contrast CT of the chest, abdomen, pelvis, and 
other known/suspected sites of disease is acceptable.Use of CT component of a PET-CT scanner : Combined modality scanning such as with PET-CT 
is increasingly used in clinical care, and is a modality/technology that is in rapid evolution; 
therefore, the recommendations outlined here may ch ange rather quickly with time. At present, 
low dose or attenuation correction CT portions of a combined PET- CT are of limited use in 
anatomically-based efficacy assessments and it is therefore suggested th at they should not be 
substituted for dedicated diagnostic contrast-enhanced CT scans for anatomically-based 
RECIST 1.[ADDRESS_602695] (with IV and oral contrast) then the 
CT portion of the PET-CT can be used fo r RECIST 1.[ADDRESS_602696] 1.1 response in target lesions. 
In selected circumstances where such modalities are the sole mod ality used to assess cer tain 
non-target organs, those non-target organs may be evaluated less frequently. For example, bone 
scans may need to be repeated only when complete response is identified in target disease or when progression in bone is suspected.
Bone scans may be collected per local standards, as clinically indicated.MRI of brain should be acquired as outlined in  Section 2 (Schedule of Activities). CT of the Brain 
(without and with contrast) can be performed if MRI is contraindicated.
Protocol Amendment No.: 04
Date: 04-May-2021 95
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
[IP_ADDRESS] Primary CNS Neoplasms
Brain MRI without and with gadolinium contrast should be performed as outlined in Section 2
(Schedule of Activities). Participants who are unable (due to existent med ical c ondition, ie,
pacemaker or ICD device) or unwilling to have a contrast enhanced MRI of the brain at baseline
are excluded from the study. Participants who become unable to undergo MRI imaging after thestart of participation in the study may continue in the study for assessment of overall survival
as long as there is no safety issue which would require monitoring by [CONTACT_9268].
9.1.[ADDRESS_602697] 4 weeks (28 days) af ter initial res ponse. A Best Overall Res ponse of 
SD requires a minimum of [ADDRESS_602698] imaging 
assessment.
For participants with CNS malignancy, RANO 2010 criteria will be used. 
Table 9.1.3-1: RANO Criteria for Time-point Response Assessment Incorporating 
MRI and Clinical Factors
Response Criteria
CRRequires all of the following: complete disappearance of all enhancing measurable and nonmeasurable
disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions; participants must be of f 
corticosteroids (or on physiologic replacement doses only); and stable or improved clinically. Note:
Participants with nonmeasurable disease only cannot have a complete response; the best response 
possible is stable disease.
PRRequires all of the following: ‚â•50% decrease compared with baseline in the sum of products of
perpendicular diameters (SPD) of all measurable enhancing lesions; no progression of nonmeasurable
disease; no new lesions; stable or improved nonenhancing (T2/FLAIR) lesions on same or lower dose 
of corticosteroids compared with baseline scan; the corticosteroid dose at the time of the scan 
evaluation should be no greater than the dose at time of baseline scan; and stable or improved
clinically. Note: Participants with nonmeasurable disease only cannot have a partial response; the best 
response possible is stable disease.
SDRequires all of the following: does not qualify for complete response, partial response, or progression;
stable nonenhancing (T2/FLAIR) lesions on same or lower dose of corticosteroids compared with baseline scan. In the event that the corticosteroid dose was increased for new symptoms and signs 
without confirmation of disease progression on neuroimaging, and subsequent follow-up imaging 
shows that this increase in corticosteroids was re quired because of disease progre ssion, the last scan 
considered to show stable disease will be the scan obtained when the corticosteroid dose was equivalent 
to the baseline dose.
Protocol Amendment No.: 04
Date: 04-May-2021 96
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Table 9.1.3-1: RANO Criteria for Time-point Response Assessment Incorporating 
MRI and Clinical Factors
Response Criteria
PDDefined by [CONTACT_39132]: ‚â• 25% increase in sum of the products of perpendicular diameters of 
enhancing lesions compared with the smallest tumor measurement obtained either at baseline (if no 
decrease) or best response, on stable or increasing doses of corticosteroids (Stable doses of 
corticosteroids include participants not on cor ticosteroids); significant increase in T2/FLAIR 
nonenhancing lesions on stable or increasing doses of corticosteroids compared with baseline scan or 
best response after initiation of therapy not cau sed by [CONTACT_186754] (eg, radiation therapy, 
demyelination, ischemic injury, infection, seizures, postoperative changes, or other treatment effects); 
any new lesion; clear clinical deterioration not attributable to other causes apart from the tumor (eg, 
seizures, medication adverse effects, complications of th erapy, cerebrovascular events, infection, and so 
on) or changes in corticosteroid dose; failure to return for evaluation as a result of death or deteriorating 
condition; or clear progression of non measurable disease.
Table 9.1.3-2: Assessment of  Best Overall Response
Best Overall ResponseCriteria54
CR CR observed in assessments ‚â• 4 weeks apart per RANO
PR PR observed in assessments ‚â• 4 weeks apart per RANO
SD
Note: To qualify for SD there must be a
minimum on-treatment period of 6
weeks.)SD observed and does not qualify for CR or PR or
Suspected PD followed with histologic results not confirming PD, and 
no CR, PR or SD observed
Not Evaluable (NE) Insufficient data to determine disease progression or response
PD No CR, PR, or SD prior to PD
[IP_ADDRESS] BICR Confirmation of Radiographic Progression
Sites should submit all scans to the imaging core lab on a rolling basis, throughout the duration of 
the study. BICR of scans will occur on a rolling basis, blinded to treatment arm, clinical data, and investigator assessment of submitted scans. When radiographic progression per RECIST 1.[ADDRESS_602699] 1.1 or R ANO 
radiographic progression is not confirmed by [CONTACT_104147] (if clinically feasible) according to the protocol-specified schedule, or sooner if 
clinically indicated. Also, if participants disc ontinue treatment without radiographic progression, 
tumor assessments will continue according to the protocol specified schedule, as noted in  Section  
2(Schedule of Activities) until progression has been confir med by [CONTACT_19377]. All study treatment 
Protocol Amendment No.: 04
Date: 04-May-2021 97
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
decisions will be based on the investigator‚Äôs assessment of tumor images and not on the BICR 
assessment.
BICR confirmation of disease progression is mandatory for participants in Arm B (nivolumab 
monotherapy) prior to enrolling in Arm B roll over to receive treatment with nivolumab in 
combination with ipi[INVESTIGATOR_125]. The participant w ill be re-b aselined based on the investigat or‚Äôs 
assessment of the scans with which BICR progressi on was confirmed. Tumor assessments in 
participants in rollover cohort w ill be done by [CONTACT_470391] s hould comply with the requirements 
outlined in this protocol.
9.2 Adverse Events
The definitions of an AE or serious adverse event (SAE) can be found in Appendix 3.
AEs will be reported by [CONTACT_40198] (or, when appropriate, by a caregiver, surrogate, or the 
participant's legally au thorized repre sentative). 
The investigator and any designees are re sponsible for detecting, doc umenting, a nd reporting 
events that meet the definition of an AE or SAE and remain responsible for following up AEs that 
are serious, considered related to the study treatment or the study, or that caused the participant to 
discontinue before completing the study. 
Contacts for SAE reporting specified in Appendix 3.Immune-mediated adverse events are AEs consistent with an immune-mediated mechanism or 
immune-mediated component for which non-inflammatory etiologies (e.g. infection or tumor 
progression) have been ruled out. IMAEs can include events with an alternate etiology which were exacerbated by [CONTACT_104155] . Information supporting the assessment w ill be 
collected on the participant‚Äôs case report form.
9.2.1 Time Period and Frequency for Collecting AE and SAE Information
The collection of non-serious AE information (with  the exception of non-serious AEs related to 
SARS-CoV-2 infection) should begin at initiation of study treatment and for a minimum of 100 
days following discontinuation of study treatment and at the timepoints specified in the Schedule 
of Activities ( Section 2 ).
Sections 5.6.1 and 5.6.2 in the Investigator Brochure (IB) represent the Reference Safety 
Information to determine expectedness of serious adverse events for expedited reporting. 
Following the participant‚Äôs written consent to participate in the study, all SAEs, whether related 
or not related to study drug, must be collected, in cluding those thought to be associated with 
protocol-specified procedures.
All SAEs and all AEs (SAEs and non-serious AE s) associated with confirmed or suspected SARS-
CoV-[ADDRESS_602700] be collected from the time of  signing the consent, including those thought 
to be associated with protocol -specified procedures and until 100 days following discontinuation 
of dosing.
Protocol Amendment No.: 04
Date: 04-May-2021 98
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Note: for participants who signed a pre-screening consent with submission of an archived 
tumor sample for eligibility assessment, SAE collection will start at the time of signature [CONTACT_470410]. For participants wh o signed a pre-screening consent to agree to 
collection of a fresh biopsy, SAE collection will start at the time of signature [CONTACT_470411]-screening informed consent.
For participants ra ndomized and never tr eated with study drug, SAEs should be co llected for [ADDRESS_602701] report any SAE that occurs after these time periods and that is believed to 
be related to study drug or protocol-specified procedure, (eg, a follow-up skin biopsy).
‚Ä¢Medical occurrences that begin before the start of study treatment but after obtaining informed 
consent will be recorded on the appropriate section of the eCRF module.
‚Ä¢All SAEs will be rec orded and reported to Sponsor or designee within 24 hours, as indicated 
in Appendix 3. 
‚Ä¢The investigator will submit any updated SAE data to the sponsor or designee within 24 hoursof updated information being available.
Investigators are not obligated to actively seek AEs or SAEs in former study participants. 
However, if the investigator learns of any SAE, including a d eath, at any time after a participant 
has been discharged from the study, and he/she considers the event reasonably related to the study treatment or study participation, the invest igator must promptly notify the sponsor.
The method of evaluating, and assessing caus ality of AEs and SAEs and the procedures for 
completing and reporting/transmitting SAE reports are provided in Appendix 3.
9.2.2 Method of Detecting AEs and SAEs
Adverse events can be spontaneously reported or elicited duri ng open-ended questioning, 
examination, or evaluation of a participant. Care should be taken not to introduce bias when 
collecting AE and/or SAEs. Inquiry about specific AEs should be guided by [CONTACT_470392], when appropriate for the program or protocol.
All nonserious adverse events (not only those deemed to be treatment-related) should be collected 
continuously during the tr eatment period and for a minimum of [ADDRESS_602702] to whether it is considered
immune-mediated. For events which  are potentially immune-mediated, additional information will 
be collected on the participant‚Äôs case report form.
9.2.3 Follow-up of AEs and SAEs
‚Ä¢Nonserious AEs should be followed to resolution  or stabilization, or reported as SAEs if they 
become serious (see Appendix 3).
‚Ä¢Follow-up is also required for nonserious AEs that cause interruption or discontinuation of 
study treatment and for those present at the end of study treatmen t as appropriate.
Protocol Amendment No.: 04
Date: 04-May-2021 99
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
‚Ä¢All identified nonserious AEs must be recorde d and described on the nonserious AE page of 
the CRF (paper or electronic). Completion of s upplemental CRFs may be requested for AEs 
and/or laboratory abnormalities that are reported/identified during the course of the study.
After the initial AE/SAE report, the investigat or is required to proactively follow each participant 
at subsequent visits/contacts. All SAEs, non-serious AEs of special interest (as defined in Section 
9.2), and AEs (SAEs and non-serious AEs) associated with confirmed or suspected SARS-CoV-[ADDRESS_602703] 
to follow-up (as defined in Section 8.3), or until SARS-CoV-2 infection is ruled out.
Further information on follow-up procedures is given in Appendix 3.
9.2.4 Regulatory Reporting Requirements for SAEs
‚Ä¢Prompt notification by [CONTACT_104153] a 
product under clinical investigation are met.
‚Ä¢An investigator who receives an investigator safety report describing SAEs or other specific 
safety information (eg, summary or listing of SAEs) from the Sponsor w ill file it along with 
the Investigator Brochure and w ill notify the IRB/IEC, if appropri ate acc ording to  local 
requirements.
Sponsor or designee w ill be reporting adverse events to regu latory authorities and ethics 
committees according to local applicable laws including European Directive 2001/20/EC and FDA 
Code of Federal Regulations 21 CFR Parts 312 and 320. A S[LOCATION_003]R (Suspected, Unexpected Serious Adverse Reaction) is a subset of SAEs and will be reported to the appropriate regulatory 
authorities and investigators following local  and global guidelines and requirements.
All SAEs must be collected that occur during the screening period and within [ADDRESS_602704] 
dose of study treatment. For participants randomized/assigned to treatment and never treated with study drug, SAEs should be collected for [ADDRESS_602705] immediately notify the BMS 
Medical Monitor/designee of this event and complete and forward a Pregnancy Surveillance Form 
to BMS Designee within 24 hours of awareness of the event and in accordance with SAE reporting procedures described in Appendix 3.
If the investigator determines a possible favorable benefit/risk ratio that warrants continuation of 
study treatment, or re-initiation of study treatment, a discussion between the investigator and the BMS Medical Monitor/designee must occur. If, for whatever reason, the pregnancy has ended, 
confirmed by [CONTACT_197297], treatmen t may be resumed (at least 3 weeks and not 
Protocol Amendment No.: 04
Date: 04-May-2021 100
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
greater than 6 weeks after the pregnancy has ended), following approvals of participant /sponsor 
/IRB/EC, as applicable.
Follow-up information regarding the course of the pregnancy, including perinatal and neonatal 
outcome and, where applicable, offspring infor mation must be reported on the Pregnancy 
Surveillance Form.
9.2.[ADDRESS_602706] result abnormalities  should be captured on the nonserious AE CRF 
page or SAE Report Form electronic, as appropriate.  Paper forms are only intended as a back-up 
option when the electronic system is not functioning.
‚Ä¢Any laboratory test result that is clinically significant or meets the definition of an SAE 
‚Ä¢Any laboratory test result abnormality that required the participant to have study tr eatment 
discontinued or interrupted
‚Ä¢Any laboratory test result abnormality that required the pa rticipant to receive specific 
corrective therapy
It is expected that wherever possible, the clinical rather than laboratory term would be used by [CONTACT_35867] (eg, anemia versus low hemoglobin value).
9.2.7 Potential Drug Induced Liver Injury (DILI)
Wherever possible, timely confirmation of initial liver-rel ated laboratory abnormalities s hould 
occur prior to the reporting of a potential DILI event. All occurrences of potential DILIs, meeting 
the defined criteria, must be reported as SAEs (see  Section 9.2 and Appendix 3  for reporting 
details).
Potential drug induced liver injury is defined as: 
‚Ä¢AT (ALT or AST) elevation > 3 times upper limit of normal (ULN)
AND‚Ä¢Total bilirubin > [ADDRESS_602707], without init ial findings of cholestasis ( elevated serum alkaline 
phosphatase),
AND‚Ä¢No other immediately appa rent possible causes of AT elevation and hyperbilirubinemia, 
including, but not limited to, viral hepatitis, pre-existing chronic or acute liver disease, or the 
administration of other drug(s) known to be hepatotoxic.
9.2.8 Immune-mediated Adverse Events
Immune-mediated adverse events (IMAEs) are AEs consistent with an immune-mediated 
mechanism or immune-mediated component for which non-inflammatory etiologies (eg, infection 
or tumor progression) have been ruled out. IMAEs can  include events with an alternate etiology 
Protocol Amendment No.: 04
Date: 04-May-2021 101
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
which were exacerbated by [CONTACT_104155]. Information supporting the assessment 
will be collected on the participant‚Äôs case report form.
9.2.[ADDRESS_602708] that 
is considered both excessive and medically important. Overdoses that meet the regulatory 
definition of SAE will be reported as an SAE (see Appendix 3).
In the event of an overdose the investigator should:
‚Ä¢Contact [CONTACT_470393]
‚Ä¢Closely monitor the participant for AEs/SAEs and laboratory abnormalities 
‚Ä¢Document the quantity of the excess dose as well as the duration of the overdosing in the CRF.
Decisions regarding dose interruptions or modifications will be made by [CONTACT_470394].
9.[ADDRESS_602709] document their review of each laboratory safety re port.
Hematology
Hemoglobin
Hematocrit
Total leukocyte count, including differential
Platelet count
Serum Chemistry
Aspartate aminotransferase (AST)
Alanine aminotransferase (ALT)Albumin - screening onlySodium
Protocol Amendment No.: 04
Date: 04-May-2021 102
5.0 Approved 930106993 5.0v Approved 1.0 v
ClinicalProtocol CA209848
BMS-936558 nivolumab
Total bilirubin
Alkaline phosphatase (ALP)
Lactate dehydrogenase (LDH)
CreatinineBlood Urea Nitrogen (BUN) or serum urea GlucosePotassiumChloride
Calcium
PhosphorousTSH, free T3 and free T4 - screening 
TSH, with reflexive fT3 and fT4 if TSH is 
abnormal - on treatment 
Serology
Hepatitis B/C, (HBV sAG, HCV antibody or HCV RNA) - screening only
Serum for HIV testing where locally mandated
Other Analyses
Pregnancy test (WOCBP only: minimum sensitivity 25 IU/L or equivalent units of HCG). 
Follicle stimulating hormone (FSH) at screening - only required to confirm menopause in 
women < age 55)
9.4.[ADDRESS_602710] medical/clinical judgment. 
9.[ADDRESS_602711] prior to the delayed dose. However, if a predose sample is collected but the dose is s ubsequently delayed, an additional predose sample 
should not be collected. 
Draw blood samples from a site other than the infusion site (ie, contralateral arm) on days of 
infusion for all pre-dose and end of i nfusion-PK (EOI-PK) samples. Please ensure accurate 
documentation of the time a nd date of sample collection.
Samples will be evaluated for development of anti-drug antibody (ADA). Samples may also be 
analyzed for neutralizing antibodies, and PK samples may be used for ADA analysis in the event 
of insufficient volume, to complete immunogenicity assessment, or to follow up on suspected immunogenicity-related AEs.
Further details of sample collection, processing, and shipment will be provided in the laboratory 
procedures manual.
Protocol Amendment No.: 04
Date: 04-May-2021 103
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 9.5-1: Pharmacokinetic and Immunogenicity Sampling Schedule ‚Äì Arm A or Arm B Rollover ‚Äì Nivolumab in 
Combination with Ipi[INVESTIGATOR_470334]
2 weeks/cycleEventTime 
(Relative to Start 
of Infusion)
Hour: MinNivolumab 
PK
Blood SampleNivolumab 
Immunogenicity 
SampleIpi[INVESTIGATOR_470335]
C1 D1 
Ipi[INVESTIGATOR_470336] 1predosea00:00 X X X X
EOIbXX
C2D1 predosea00:00 X X X X
C5D1 predosea00:00 X X X X
C7 D1Ipi[INVESTIGATOR_470336] 3predose
a00:00 X X X X
EOIbXX
C11 D1 predosea00:00 X X X X
C17 D1 predosea00:00 X X X X
C25 D1 predosea00:00 X X X X
After C25 D1, every 8th cycle (16th 
week) until discontinuation or up to 2 yearspredosea00:[ADDRESS_602712] 2 Follow-up Visits 
(Approximately 30 days and up to ~ 
100 Days from the Discontinuation of Study treatment)NA X X X X
aPredose samples should be collected just before the start of nivolumab infusion (preferably within 30 minutes). If it is known that a dose is going to be delayed, 
then the predose sample should be collected just prior to the delayed dose. However, if a predose sample is collected but the d ose is subsequently delayed, an 
additional predose sample should not be collected.
bSince the end of infusion-PK (EOI-PK) sample is drawn with the intent of accurately estimating the maximum concentration (Cmax)  of the drug, draw 
the EOI-PK when all the study drug has been infused. If the site infuses drug without a flush, then collect the EOI-PK sample wit hin approximately 5 
Protocol Amendment No.: 04
Date: 04-May-2021 104
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
minutes a fter end of infusion. If a flush is administered to clear the IV lines of the drug and to ensure delivery of the entire drug dos e, then draw the 
EOI-PK sample within approximately 5 minutes after end of the flush. Do not draw EOI samples fr om the same IV access from which drug was 
administered.
cIf ipi[INVESTIGATOR_470337], resume ipi[INVESTIGATOR_470338] (immunogenicity) sample collection for the next scheduled sample collection, t hen discontinue
ipi[INVESTIGATOR_162] b sample collection.
Protocol Amendment No.: 04
Date: 04-May-2021 105
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 9.5-2: Pharmacokinetic and Immunogenicity Sampling Schedule Arm B -
Nivolumab Monotherapy
Study Day
4 weeks/cycleEventTime 
(Relative to Start of Infusion)
Hour: MinNivolumab 
PK
Blood SampleNivolumab 
Immunogenicity 
Sample
C1 D1 predosea00:00 X X
EOIb00:30 X
C2 D1 predosea00:00 X X
C5 D1 predosea00:00 X X
EOIb00:30 X
C9 D1 predosea00:00 X X
C13 D1 predosea00:00 X X
After C13 D1, every 4th 
cycle (16th week) until 
discontinuation or up to 2 yearspredosea00:[ADDRESS_602713] 2 Follow-up Visits 
(Approximately 30 days 
and up to ~ 100 Days 
from the Discontinuation 
of Study treatment)NA X X
aPredose samples should be collected just before the start of nivolumab infusion (preferably within 30 minutes). If 
it is known that a dose is going to be delayed, then the predose sample should be collected just prior to the delayed 
dose. However, if a predose sample is collected but the dose is subsequently delayed, an additional predose sample should not be collected.
bSince the end of infusion-PK (EOI- PK) sample is drawn with the intent of accurately estimating the maximum 
concentration (Cmax) of the drug, draw the EOI-PK when all the st udy drug has been infused. If the site infuses 
drug without a flush, then collect the EOI-PK sample with in approximately 5 minutes after end of infusion. If a 
flush is administered to clear the IV lines of the drug and to ensure delivery of the entire drug dose, then draw the EOI-PK sample within approximately 5 minutes after end of the flush. Do not draw EOI samples from the same IV access from which drug was administered.
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602714] clinical 
responses to nivolumab in combination with  ipi[INVESTIGATOR_125]. Peripheral blood and tumor specimens 
will be taken from all participants‚Äô prior to and on-tr eatment and as outlined in Table 9.8-1 and 
Table 9.8-2 : Biomarker Tissue and Blood Samples: Arm B Nivolumab Monotherapy .Data will 
be evaluated for associations with clinical response and survival (OS) data. All samples collected may also be used for future exploratory analyses (unless restricted by [CONTACT_5277]) to assess biomarkers associated with immunotherapy tr eatment. Complete instructions on the collection, 
processing, handling and shipment of all samp les described in th is section will be provided in a 
separate procedure manual.
Table 9.8-1: Biomarker Tissue and Blood Samples: Arm A and Arm B Rollover 
- Nivolumab in Combination with Ipi[INVESTIGATOR_470339]
1 Cycle = 2 weeksArchival Tumor or 
Fresh Biopsy TissueWhole Blood
DNAMyeloid-
Derived 
Suppressor 
Cells (MDSCs)Blood TMB Plasmaa
Pre-screeningbXcXdXd
C1D1 Xb X X
C7D1 X
Every 6 Cycles 
(starting at C13D1) until end of treatmentX
Disease progression X (optional)eX
aPlasma samples could be used for evaluation of bTMB or other biomarkers
bFor Arm B rollover, pre-screening samples and whole blood DNA are not applicable.
cFresh biopsies are preferred; however, archival samples are acceptable if obtained within 9 months of signing the 
initial consent form (pre-screening) a nd no additional intervening therapy (e xcluding palliative therapy) in between.
dBlood TMB and plasma samples collected during pre-screening should be collected on the same day.
eIf a biopsy has been performed and tissue is available, par ticipants are requested to submit fresh tumor tissue at 
disease progression for biomarker research. Tissue submission is optional and biopsy is not required by [CONTACT_990].
Protocol Amendment No.: 04
Date: 04-May-2021 107
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 9.8-2: Biomarker Tissue and Blood Samples: Arm B Nivolumab 
Monotherapy
Study Day
1 Cycle = 4 weeksArchival Tumor 
or Fresh Biopsy 
TissueWhole Blood 
DNAMyeloid-
Derived 
Suppressor 
Cells (MDSCs)Blood TMB Plasmaa
Pre-screening XbXcXc
C1D1 X X X
C4D1 X
Every 3 Cycles 
(starting at C7D1) 
until end of treatmentX
Disease progression X (optional)dX
aPlasma samples could be used for evaluation of bTMB or other biomarkers.
bFresh biopsies are preferred; however, archival samples are acceptable if obtained within 9 months of signing the 
initial consent form (pre-screening and no additional intervening therapy (excluding palliative therapy) in between.
cBlood TMB and plasma samples collected during pre-screening should be collected on the same day.
dIf a biopsy has been performed and tissue is available, par ticipants are requested to submit fresh tumor tissue at 
disease progression for biomarker research. Tissue submission is optional and biopsy is not required by [CONTACT_990].
For biomarker research testing, tumor tissue (formalin-fixed, paraffin embedded archival or recent 
acquisition) must be received during the pre-screening peri od. Fresh biopsies are preferred; 
however, archival samples (within 9 months of signing the initial study consent form [pre-screening or screening]) are acceptable. If the required number of slides are not available, the BMS 
Medical Monitor must be consulted, prior to enrollment, to discuss acceptability of the tissue 
available. Please note that fine needle aspi[INVESTIGATOR_1516] (FNA) and bone metastases samples are not acceptable for submission. Please see the CA209848 La boratory Manual for mo re details regarding 
tumor sample collection. 
If a fresh biopsy is warranted, the participant mu st have a lesion that can be biopsied at an 
acceptable clinical risk as judged by [CONTACT_470361].
9.8.1 Additional Research Collection
This protocol will include residual sample storage for additional research (AR).
For All US sites:
Additional research is required for all study participants, except where prohibited by [CONTACT_1202]/ethics 
committees
, or academic/institutional re quirements. Where one or more of these exceptions 
occurs, participation in the additional research should be encouraged but will not be a condition of 
overall study participation.
Protocol Amendment No.: 04
Date: 04-May-2021 108
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
‚Ä¢If the IRB/ethics committees and site agree to the mandatory additional research retention 
and/or collection, then the study participant must agree to the mandatory additional research 
as a requirement for inclusion in the study.
‚Ä¢If optional participation is permitted and approved, then the study participants may opt out of 
the additional research retention and/or collection.
For non-US Sites
Additional research is optional for all study participants, except where retention and/or collection 
is prohibited by [CONTACT_44896], ethics committees, or institutional requirements. 
This collection for additional research is intended to expand the translational R&D capability at 
Bristol-Myers Squibb, and w ill support as yet undefi ned research aims that w ill advance our 
understanding of disease and options for treatment. It may also be used to support health authority requests for analysis, and advancement of pharmacodiagnostic development to better target drugs 
to the right patients. This may also include genetic/genomic exploration aimed at exploring disease 
pathways, progression and response to treatment etc. 
Sample Collection and Storage
All requests for access to samples or data for a dditional research will be vetted through a diverse 
committee of the study sponsor‚Äôs senior leaders in Research and Development (or designee) to 
ensure the research supports appropriate and well-defined scientific research activities.
‚Ä¢Residual tumor biopsy, residual whole blood and plasma from biomarker collection and PK 
collections (see Table 9.8.1-1 ) will also be r etained for additional research purposes
Samples kept for future research will be stored at the BMS Biorepository in New Jersey, [LOCATION_003] or 
an independent, BMS-approved storage vendor.
The manager of these samples will ensure th ey are properly used throughout their usable life and 
will destroy the samples at the end of the sche duled storage period, no longer than fifteen (15) 
years after the end of the study or the maximum allowed by [CONTACT_1289].
Transfers of samples by [CONTACT_54004][INVESTIGATOR_841]‚Äôs 
agreement to establish similar storage procedures.
Samples will be stored in a coded fashion, and no researcher will have access to the key. The key 
is securely held by [CONTACT_470395] s ite, so there is no direct ability for a researcher 
to connect a sample to a specific individual.
Further details of sample collection and processing w ill be provided to the site in the procedure 
manual.
Protocol Amendment No.: 04
Date: 04-May-2021 109
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 9.8.1-1: Residual Samp le Retention for Additional Research Schedule
Sample Type Timepoints for which residual samples will be retained
Tumor biopsy Screening and at disease progression (if available)
Residual whole blood, plasma and serum All biomarker collections and all PK collection
9.8.2 Immunogenicity Assessments
Blood samples for immunogenicity analysis will be collected according to the schedule given in
Section 9.5 . Samples collected will be evaluated for development of Anti-Drug Antibody (ADA) 
by a validated electrochemiluminescent (ECL) immunoassay.
Samples may also be analyzed for neutralizing antibodies and PK samples may be used for ADA 
analysis in the event of insufficient volume, to complete immunogenicity assessment, or to follow up on suspected immunogenicity-related AEs.
Further details of sample collecti on, processing, and sh ipment will be provided in the laboratory 
procedures manual.
9.8.3 Blood-based Biomarkers
Blood samples will be co llected from all participants. Circulating free tumor DNA (also known as 
cfDNA or ctDNA) will be extracted from blood to assess tumor mutational burden. Genomic DNA 
from whole blood w ill also be collected and may be used as a comparator for par ticipants with 
tumors examined by [CONTACT_470396]. Whole blood 
will also be collected to asse ss myeloid derived suppressor cells ( MDSCs) which may be 
associated with response to checkpoint inhibitors. Other biomarkers such as but not limited to cytokines, metabolites, etc. may be assessed in plasma. Blood sample co llection will follow the 
same time points as mentioned in Table 9.8-1 andTable 9.8-2 : Biomarker Tissue and Blood 
Samples: Arm B Nivolumab Monotherapy .Please see CA209848 Laboratory Manual for 
additional information. 
9.8.4 Tissue-based Biomarkers
Tumor samples may be assessed for gene expression, protein expression, and/or for tumor
mutational burden analyses (TMB) using a variety of methodologies inclusive of, but not limited 
to RNAseq, immunohistochemistry, whole exome sequencing [WES], Next-Generation Sequencing [NGS], etc. Immunohistochemistry (IHC ) may be used to assess the number and 
composition of immune infiltrates in order to define the immune cell subsets present within 
formalin-fixed, paraffin embedded (FFPE) tumor tissue before and after exposure to therapy. 
These IHC analyses will include, but not necessarily be limited to, PD-L1, PD-L2, immune cell 
profiling to examine T cells, T regs, macrophages, MDSCs, and immune marker expression such 
as PD1, LAG3, IDO, etc. Please see CA209848 Laboratory Manual for additional information. 
Protocol Amendment No.: 04
Date: 04-May-2021 110
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
9.8.5 Other Assessments
With available archival tumor tissue and newly obtained biopsy tissue, plasma, and blood, genomic 
and genetic sequencing will be performed (using different sequencing methods, such as whole 
exome sequencing [WES], Next-Generation Sequencing [NGS], etc). Panels of specific genes will be performed to determine mutational burden and specific mutations that might affect response to nivolumab. Whole blood and plasma collection w ill follow the same timepoints as biomarker 
collection in Table 9.8-1 and Table 9.8-2 : Biomarker Tissue and Blood Samples: Arm B 
Nivolumab Monotherapy . Please see CA209848 Laboratory Manual for additional information. 
9.9 Medical Resource Utilization and Health Economics
Medical Resource Ut ilization and Health  Economics param eters will not be  evaluated in this study.
9.10 Patient-Reported Outcomes
Participants, ‚â•18 years of age at baseline, will be asked to complete the 30-item European
Organization for Research and Treatment of Can cer Quality of Life Questionnaire (EORTC QLQ-
C30) and 3-level version of the EuroQol Group‚Äôs EQ-5D (EQ-5D-3L) after randomization but 
prior to first dose, at on-study clinic visits planned to occur every 4 weeks (nivolumab arm) or 6 
weeks (nivolumab plus ipi[INVESTIGATOR_44772]) while on treatment, and at follow-up visits [ADDRESS_602715] commonly used quality of life instrument in oncol ogy 
trials. The instrument‚Äôs 30 items are divided among five functional scales (physical, role, 
cognitive, emotional, and social ), nine symptom scales (fatigue, pain, nausea/vomiting, dyspnea, 
insomnia, appetite loss, constipation, diarrhea, and financial difficulties), and a global 
health/quality of life s cale. With the exception of two items included in the global health/quality 
of life scale, for which responses range from 1 (Very poor) to 7 (Excellent), item responses range 
from 1 (Not at all) to 4 (Very muc h). Raw scores for the QLQ-C30 are transformed to a 0- 100 
metric such that higher values indicate better functioning or quality of life or a higher level of 
symptoms. The questionnaire uses a 1-week recall period.
The EQ-5D-3L56will be used to assess treatment effects on perceived health status and to generate 
utility data for health econo mic evalu ations. The EQ-5D-3L is a generic multi- attribute h ealth-
state classification system by [CONTACT_470397] 5 dimensions: mobility, self-care, usual 
activities, pain/discomfort, and anxiety/depression. Each dimension is evaluated using 3 levels: no 
problems, some problems, and seve re problems . Responses to these 5 d imensions are converted 
into 1 of 243 unique EQ-5D health state descri ptions, which range between no problems on all 5 
dimensions ([ZIP_CODE]) to severe/extreme problems on all 5 d imensions ([ZIP_CODE]). Using appropriate 
country-specific value weighting algorithms, a res pondent‚Äôs self-described health state can be 
converted into a utility representing the societal desirability of his/her own health. In addition, the EQ-5D includes a visual analogue scale (VAS) allowi ng a respondent to rate his/her health on a 
Protocol Amendment No.: 04
Date: 04-May-2021 111
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
scale ranging from 0‚Äì[ADDRESS_602716] 
health state imaginable. The questionnaire uses a recall period of ‚Äútoday.‚Äù
The questionnaires will be provided in the participant‚Äôs preferred la nguage, if available, and the 
EQ-5D-3L may be administered by [CONTACT_470398]- up. There exists a 
standardized guide that can be used to facilitate telephone administration of the EQ-5D-3L. If 
exceptional circumstances preclude the continued administration of measures using planned modalities, then alternate administration methods ma y be required after consultation with the 
Sponsor or the Sponsor‚Äôs representative. Table 2-2 through Table 2-5 provide i nformation 
regarding the timing of patient-reported outcomes assessments. 
10 STATISTICAL CONSIDERATIONS
10.1 Sample Size Determination 
Sample size calculation is based on BICR-assessed ORR and DOR.
The two primary objectives are to estimate ORR in tissue TMB (tTMB) high participants in the
salvage setting and blood TMB (bTMB) high participants in the salvage setting enrolled in the
nivolumab + ipi[INVESTIGATOR_44772]. A key secondary objective is DOR in the nivolumab + ipi[INVESTIGATOR_44772].
In CA209227 study, an ORR rate of 45.3% was obse rved for nivolumab in combination with 
ipi[INVESTIGATOR_470340] ‚â•10 mut/Mb population. In CA 209032, an ORR of 46% was 
observed for nivolumab + ipi[INVESTIGATOR_470341] 21% was 
observed for nivolumab.
57,58The target ORR chosen in the study is 40% for TMB-high 
participants treated with nivolumab + ipi[INVESTIGATOR_125].
A total of 76 TMB-evaluable subjects in the salvage setting treated with nivolumab + ipi[INVESTIGATOR_470237]. The sample size determination was not 
based on power consideration, but to provide precision on the estimation of ORR and DOR for
TMB-high participants treated with nivolumab + ipi[INVESTIGATOR_125]. The following table summarizes the exact 95% CIs for a sample size of 76 in the nivol umab + ipi[INVESTIGATOR_470238] 25% to50%.
Sample size Number of responses Response rate 95% Confidence interval
76 19 0.25 (0.16, 0.36)
76 22 0.29 (0.19, 0.40)
76 24 0.32 (0.21, 0.43)
76 26 0.34 (0.24, 0.46)
76 28 0.37 (0.26, 0.49)
76 30 0.39 (0.28, 0.51)
76 32 0.42 (0.31, 0.54)
76 34 0.45 (0.33, 0.57)
Protocol Amendment No.: 04
Date: 04-May-2021 112
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Sample size Number of responses Response rate 95% Confidence interval
76 36 0.47 (0.36, 0.59)
76 38 0.50 (0.38, 0.62)
In addition, with ORR of 40% for a sample size of 76 treated participants, the mean percentage of 
responders with DOR ‚â• 6 months is 70%, and the corresponding 95% lower bound for the 
responders with DOR ‚â• 6 months is 50%, based on [ZIP_CODE] simulations. The calculations assume 
the median DOR for nivolumab + ip ilimumab is 11.5 mont hs based on CA20903258and 
CA20901259studies. Note for an ORR rate of 10%, typ ical for standard of care in this refractory 
population, and a median DOR of 5.5 months, the proportion of responders with DOR ‚â•6 months 
is 47%.
Seventy-six (76) participants in the salvage setting are required for each of tTMB and bTMB for 
nivolumab in combination with ipi[INVESTIGATOR_44772]. Based on the currently observed approximate
40% concordance between tTMB-H and bTMB-H in this study, the total sample size for nivolumab in combination with ipi[INVESTIGATOR_470342] 122. Nivolumab monotherapy arm is a non-comparative arm to evaluate the contri bution of components. Approximately 183 to 342
participants will be ra ndomized into nivolumab in combination with ipi[INVESTIGATOR_125] (n=122) and 
nivolumab monotherapy (n=61) in a 2:1 randomization ratio. Moreover, if concordance rate between tTMB-H and bTMB-H is x%, sample size for nivolumab in combination with ipi[INVESTIGATOR_470342] 76[PHONE_9845]*x% and total sample size will be approximately 1.5*(76[PHONE_9845]*x%). For example, if  x=30% the total sample size will be 194 and if x is close to 0% the total 
sample size will be 228. Note the sample sizes(s) for the primary endpoint of ORR in each oftTMB-H and bTMB-H in nivolumab + ipi[INVESTIGATOR_470343] [ADDRESS_602717] 
interim analysis (see Section 10.3.6 ).
Should the tTMB-H population reach approximately [ADDRESS_602718] the overall pooled final eff icacy analysis, a cap of approximately 15% of participants per 
tumor type will be enforced.
The final analysis of the primary endpoint ORR based on BICR assessments for tTMB high 
population w ill be performed at least 12 months after all tTMB ‚â• 10 mut/Mb participants in the 
salvage setting have been randomized and study rando mization is comp leted. Final analysis of the 
primary endpoint ORR based on BICR assessments for bTMB high population will be performed 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602719] 12 months after approximately 76 participants with bTMB ‚â• 10 mut/Mb (or higher bTMB 
cutoff determined by [CONTACT_316299]; see Section 10.3.6 ) in the salvage setting are randomized in 
the nivolumab + ipi[INVESTIGATOR_470344].
Enrollment into the bTMB high population was closed in Dec-2019; enrollment into the tTMB
high population r emained ongoing. Given the approximate 40% concordance between tTMB high
and bTMB high, a fraction of the tTMB high partici pants subsequently randomized into the study
are also bTMB high. These participants will not be  included in the primary bTMB efficacy analysis 
population (see Table 10.2-1 ).
There are two planned interim analyses. The firs t interim analysis will be used to determine the 
cut-off value for bTMB. The sec ond interim analysis will be used to assess efficacy in the tTMB 
high population. These interim analyses are described in Section 10.3.6 . The positive efficacy 
decision is determined when one or both primary endpoints exceed(s) a clinically relevant response rate. A search of ORR with salvage therapy yielded a relative wide range of responses ranging from 
no response to more than 30% in various tumor types.
60,61,62,63,64,65,66,67,68,69,70,71,72,73,74,75,76,77,78
Caution should be taken in referencing these observed ORRs given the limitations on small sample 
size and/or local definition of salvage therapy in some studies. Desp ite lack of  a clearly defined 
clinical response rate across different tumor types, recent approvals by [CONTACT_470399] a refractory/rare tumor setting with ORRs ranging from 
12-14%, including small cell lung cancer, cervical cancer and neuroendocrine tumors.12,79,80
There is no formal comparison of ORR between treatment arms (and within tTMB and bTMB 
populations). However, a 95% confidence interval for the difference in ORR between the tr eatment 
arms will be computed for descriptive purposes for tTMB and bTMB populations separately. 
10.2 Populations for Analyses
The following defined populations w ill apply to pooled tumor types unless otherwise specified:
Population Description
Enrolled participants All participants who signed an informed consent form and were registered 
into the IVRS.
Randomized participants All participants who were randomized.
Treated participants All participants who received at least [ADDRESS_602720]-baseline 
immunogenicity assessment.
The primary endpoint of the trial is BICR-assessed ORR in the tTMB high population and the 
bTMB high population in a s alvage setting (Table 10.2-1).
Protocol Amendment No.: 04
Date: 04-May-2021 114
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 10.2-1: Timing of Analysis and Primary Populations for Primary Endpoint
Analysis Timing Primary Population to be Used for
Primary Endpoint
bTMB interim analysis Approximately the first 30 randomized 
participants in the nivolumab + 
ipi[INVESTIGATOR_470345] ‚â• 10 
mut/Mb at baseline have been 
randomized and followed for at least 6 
monthsAll bTMB high randomized participants
(followed for at least 6 months)
bTMB final analysisAt least 12 months after approximately 
76 bTMB high participants are treated in 
the nivolumab + ipi[INVESTIGATOR_470346]-[ADDRESS_602721] 50 randomized 
participants in the nivolumab + 
ipi[INVESTIGATOR_470347] ‚â• 10 
mut/Mb at baseline have been 
randomized and followed for at least [ADDRESS_602722] 12 months after all tTMB ‚â• 10 
mut/Mb participants have been 
randomizedAll tTMB high randomized participants
10.3 Statistical Analyses
Unless otherwise specified, all analyses will be performed for all rando mized participants in the 
salvage setting by [CONTACT_470400].
Demographic and baseline laboratory results will be summarized using descriptive statistics for all 
randomized participants. Bas eline characteristics, including demographics (age, gender, 
geographic location, race/ethnicity) a nd clinical characteristics (date of  diagnosis, disease stage, 
liver function status, performance status, co-morbidity/prognostic indicators, location of 
metastases) w ill be collected at the time of treatment initiation for each arm. General descriptive 
statistics, includi ng mean and standard deviation (SD) for continuous variables, count and 
percentage for categorical variables will be used extensively to examine these variables.
The statistical analysis plan will be developed and finalized before database lock and will describe 
the selection of participants to be included in the analyses, and procedures for accounting for 
missing, unused, and spurious data. A summary of planned s tatist ical analyses of the primary and 
secondary endpoints is in Sections 10.3.2 and 10.3.3 .
Protocol Amendment No.: 04
Date: 04-May-2021 115
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
10.3.1 Efficacy Analyses
Endpoint Definition Statistical Analysis Methods
Primary
ORR (based on BICR assessments) is defined as the 
number of participants with a best overall response of 
confirmed CR or PR divided by [CONTACT_470401]. Best overall response is 
defined as the best response designation, as determined 
by [CONTACT_19377], recorded between the date of randomization
and the date of objectively documented progression (per 
RECIST v1.1 or RANO criteria) or the date of 
subsequent therapy, whichever occurs first. For 
participants without documented progression or 
subsequent therapy, all available response designations 
will contribute to the BOR determination. For 
participants who continue treatment beyond 
progression, the BOR will be determined based on 
response assessments up to the time of initial RECIST 
1.1 progression.BICR-assessed objective response rate (ORR) using 
disease specific response criteria: Response Evaluation 
Criteria in Solid Tumors (RECIST 1.1), and Response 
Assessment for Neuro-Oncology (RANO) criteria for 
primary CNS neoplasms.
BICR-assessed ORR will be summarized by [CONTACT_20504]-sided 95%
exact CIs using Clopper-Pearson method.
Secondary
DOR (based on BICR assessments) is defined as the 
time from first confirmed response (CR or PR) to the 
date of the first documented tumor progression as 
determined using RECIST 1.[ADDRESS_602723] evaluable tumor 
assessment.BICR-assessed duration of response (DOR) will be 
estimated for all randomized participants who achieve 
confirmed PR or CR using the Kaplan-Meier (KM) 
product-limit method. Median values of DOR, along 
with two-sided 95% CI using Brookmeyer and 
Crowley method, will also be calculated. Probability 
of achieving DOR ‚â• 6 months will be calculated using 
KM method with 95% CI.
The investigator-assessed ORRInvestigator-assessed ORR will be summarized by 
[CONTACT_20372]-
sided 95% exact CIs using Clopper-Pearson method.
The investigator-assessed DORInvestigator- assessed duration of response (DOR) will 
be estimated for all randomized participants who 
achieve confirmed PR or CR using the Kaplan-Meier 
(KM) product-limit method. Median values of DOR, 
along with two-sided 95% CI using Brookmeyer and 
Crowley method, will also be calculated. Probability 
of achieving DOR ‚â• 6 months will be calculated using 
KM method with 95% CI.
TTR is defined as the time from randomization date to 
the date of the first confirmed response, as assessed by 
[CONTACT_53923].Time to response (TTR) will be summarized using 
descriptive summary statistics for the responders.
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602724] overall response (BOR) of confirmed complete 
response (CR) or partial response (PR) or stable disease 
(SD) divided by [CONTACT_470402].BICR and Investigator assessed CBR will be 
summarized by [CONTACT_102457]-sided 95% exact CIs using 
Clopper-Pearson method.
OS is defined as the time from the randomization date 
to the date of death.Time to event distribution will be estimated using 
Kaplan Meier techniques. Median OS along with 95% 
CI will be constructed based on a log-log transformed 
CI for the survivor function. Rates at some fixed 
timepoints (6, 12, 18 and 24 months) will be derived 
from the Kaplan Meier estimate and corresponding 
confidence interval will be derived based on 
Greenwood formula for variance derivation and on 
log-log transformation applied on the survivor 
function.
Participants without documentation of death will be 
censored on the last date the participant was known to 
be alive.
PFS is defined as the time from randomization date to 
the date of the first documented tumor progression, 
determined by [CONTACT_470403] (per RECIST 1.1 or 
RANO), or death due to any cause, whichever occurs 
first.BICR and investigator assessments will use Response 
Evaluation Criteria in Solid Tumors (RECIST 1.1), 
and Response Assessment for Neuro-Oncology 
(RANO) criteria for primary CNS neoplasms.
Participants without a reported progression will be 
considered to have progressed on the date of their 
death if no subsequent anti-cancer therapy initiated. 
Participants who did not progress or die will be 
censored on the date of the last tumor assessment. 
Participants who did not have any on study tumor 
assessments and did not die will be censored on the 
first dosing date. Participants who started any 
subsequent anti-cancer therapy and without a prior 
reported progression will be censored at the last tumor 
assessment prior to initiation of the subsequent 
therapy.
Time to event distribution will be estimated using 
Kaplan Meier techniques. Median PFS along with 
95% CI will be constructed based on a log-log 
transformed CI for the survivor function. Rates at 
some fixed time points (6, 12, 18 and 24 months) will 
be derived from the Kaplan Meier estimate and 
corresponding confidence interval will be derived 
based on Greenwood formula for variance derivation 
and on log-log transformation applied on the survivor 
function.
10.3.2 Safety Analyses
Endpoint Definition Statistical Analysis Methods
Primary Not applicable
Protocol Amendment No.: 04
Date: 04-May-2021 117
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Endpoint Definition Statistical Analysis Methods
Secondary
Safety and tolerabilityDescriptive statistics of safety will be presented using the National Cancer 
Institute (NCI) Common Terminology Criteria for Adverse Events (CTCAE) 
version 5.[ADDRESS_602725] grade per NCI CTCAE version 5.0 criteria by 
[CONTACT_470404].
On-study lab parameters including hematology, coagulation, chemistry, liver 
function and renal function will be summarized using worse grade per NCI 
CTCAE version 5.0 criteria.
Exploratory Will be described in the statistical analysis plan finalized before database lock
10.3.3 Pharmacokinetics Analysis
The nivolumab and ipi[INVESTIGATOR_470348]. 
These models may be used to evaluate the effects  of intrinsic and extrinsic covariates on the PK 
of nivolumab and to determine measures of individual exposure (such as steady state peak, trough 
and time averaged concentration). Model determined e xposures may be used for expos ure response 
analyses of selected efficacy and safety endpoints. If the analyses are conducted, the results of 
population PK and exposure re sponse analyses will be reported separately.
10.3.[ADDRESS_602726] 1 subsequent assessment while on tr eatment. 
Questionnaire completion rate, defined as th e proportion of ques tionnaires received out of the 
expected number, will be calculated and summarized at each assessment point. Analyses of PROs 
will be rep licated for subjects that are treated with nivolumab  combined with ipi[INVESTIGATOR_470349].
EQ-5D data will be described by [CONTACT_470405]:
‚Ä¢EQ-5D index scores and post-baseline changes in scores will be su mmarized at each 
assessment time point using descriptive statistics (ie, N, mean with SD and 95% CI, median, 
first and third quartiles, minimum, maximum).
‚Ä¢EQ-VAS scores and post-baseline changes in scores will be summar ized at each assessment 
time point using descriptive statistics (ie, N, mean with SD and 95% CI, median, first and third 
quartiles, minimum, maximum).
‚Ä¢The proportion (N) of participants  reporting no, moderate, or extr eme problems w ill be 
presented for each of the 5 EQ-5D dimensions at each assessment time point. Participants with 
missing data will be excluded from the analysis.
‚Ä¢A by- participant listing of the level of problems in each dimension, corresponding EQ-5D 
health state (ie, 5-digit vect or), EQ-5D index score, and EQ -VAS score will be provided.
EORTC QLQ-C30 data will be described by [CONTACT_470405]:
Protocol Amendment No.: 04
Date: 04-May-2021 118
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
‚Ä¢Scale and item scores will be summarized at each assessment time point using descriptive 
statistics (ie, N, mean with SD and 95% CI, median, first and third quartiles, minimum, 
maximum).
‚Ä¢Changes from baseline in scale a nd item scores will be su mmarized at each post-baseline 
assessment time point using descriptive statistics (ie, N, mean with SD and 95% CI, median, 
first and third quartiles, minimum, maximum).
10.3.5 Other Analyses
Immunogenicity: Serum samples collected will be analyzed  by a validated immunogenicity assay. 
Selected serum samples may be analyzed by [CONTACT_470406]-nivolumab. Potential results generated from any ort hogonal method are intended as 
informational for technology exploration purposes and will not be reported.
In addition, ad hoc serum samples designated for pharmacokinetic or biomarker assessments may 
also be used for immunogenicity analysis if required (e.g., insufficient volume for complete 
immunogenicity assessment or to follow up on suspected immunogenicity related AE).
Other exploratory analyses will be described in the statistical analysis plan. 
10.3.[ADDRESS_602727] the overall 
pooled efficacy analysis , a cap of approximately 15% participants per tumor type of the sample 
size for this interim analysis will be enforced. The analysis will be performed after approximately 
the first 30 randomized participants in nivolumab + ipi[INVESTIGATOR_470345] ‚â• 10 mut/Mb at 
baseline have been rando mized and followed for at least 6 months. 
BICR-assessed ORR will be estimated in the following groups 
‚Ä¢low group (10 ‚â§bTMB < cut-off )
‚Ä¢enriched group (bTMB ‚â•cut-off)
Decision rule: 
If the following 2 criteria are satisfied at the interim analysis,
1) estimated ORR in enriched group minus estimated ORR in low group ‚â•16.5% 
and 
2) estimated ORR in low group < 30%
then eligibility criteria will be  restricted to participants with either tTMB ‚â•10 mut/Mb or bTMB
‚â•new cut-off for the remainder of the trial until a total of approx imately 114 participants (76 in 
nivolumab + ipi[INVESTIGATOR_44771] 38 in nivolumab arm) with bTMB ‚â• new cut-off are enrolled
Protocol Amendment No.: 04
Date: 04-May-2021 119
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
and a total of approximately 114 participants with tTMB ‚â•10 mut/Mb are enrolled. The maximum 
number of participants for the study may be up to  [ADDRESS_602728] bTMB ‚â•new cut-off.  
Should the tTMB-H (tTMB ‚â•10 mut/Mb) population reach the targeted sample size 
(approximately 76 participants in nivolumab + ipi[INVESTIGATOR_470350] 38 in 
nivolumab arm), participants will continue to provide a tissue sample; however, eligibility will be 
based on a bTMB ‚â• new cut-off only.
Simulations have been conducted to evaluate the operating characteristics, including the decision 
rule, and details are provided in Appendix 10 . The Statistical Analysis Plan (SAP) will furt her 
describe the planned interim analyses.
Correlation between bTMB and tTMB will be assessed.
Efficacy for tTMB population
A formal interim analysis fo r BICR-assessed ORR will be c onducted on tTMB high participants
in the salvage setting after approximately the first 50 for nivolumab + ipi[INVESTIGATOR_44771] 25 for 
nivolumab monotherapy arm randomized participants in the salvage setting with tTMB ‚â• 10 
mut/Mb at baseline have been rando mized a nd followed for at least 12 months (approximately 75 
total tTMB high participants), and study-wide randomization has completed. In order to achieve 
the necessary number of study participants in the tTMB high population for the tTMB primary 
endpoint final analysis, enrollment into this population continued after the date on which criteria 
were met for the tTMB interim analysis. The pr imary analysis population for the interim analysis 
will be the interim tTM B high population (limited to all tTMB high participants rando mized at 
least 12 months prior to the LPLV for the analysis). 
BICR-assessed DOR will be analyzed for tTMB high participants who achieve confirmed PR or 
CR using the Kaplan-Meier (KM) product-limit method. Probability of achieving DOR ‚â•6 months 
will also be calculated.
Similar interim analysis may be conducted on bTMB high population.
All of the interim analyses and other unblinded efficacy/safety data will be reviewed by [CONTACT_470407] (See DMC charter for more detail).
The Statist ical Analysis Plan w ill further describe the planned interim analyses.
Protocol Amendment No.: 04
Date: 04-May-2021 120
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
11 REFERENCES
1Rizvi NA, Hellmann MD, Snyder A, et al. Cancer immunology. Mu tational landscape 
determine sensitivity to PD-1 blockade in  non-small cell lung cancer. Science. 2015; 348:124-
8.
2Kowanetz M, Zou W, Shames DS, et al. Tumor mutation burden (TMB) is associated with 
improved efficacy of atezolizumab in 1L and 2L+ NSCLC patients. Oral presentation at: The 
17th Annual World Conference on Lung Cancer; December 4-7, 2016; Vienna, Austria.
3Peters S, Creelan B, Hellmann MD, et al. Impact of tumor mutation burden on the efficacy of 
first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis 
of CheckMate 026. Oral presentation at the Annua l Meeting of th e American Association of 
Cancer Research; April 1-5, 2017; Washington, DC, [LOCATION_003].
4Peters S, Creelan B, Hellmann MD, et al. Impact of tumor mutation burden on the efficacy of 
first-line nivolumab in stage IV or recurrent non-small cell lung cancer: an exploratory analysis 
of CheckMate 026. Oral presentation at the Annual Meeting of the Amer ican Association of 
Cancer Research; April 1-5, 2017; Washington, DC, [LOCATION_003].
5Reck M, Rodri guez-Abreu D, Robinson AG, et al. Pembrolizumab versus chemotherapy for 
PD-L1-positive non-small-cell lung cancer. NEJM. 2016; 375:1823-33. 
6Yarchoan M, Hopkins A and Jaffee EM. NEJM, Dec 21, 2017
7Alexandrov LB, et al. Nature 2013;500:415-21
8Chuk MK, Mulug eta Y, Roth-Cline M, et al. E nrolling adolescents in disease/target-
appropriate adult oncology clinical trials of investigational agents. Clin Cancer Res. 2017; 23: 9-12.
9Beaver JA, Ison G, and Pazdur R. Reevaluating Eligibility Criteria - Balancing Patient 
Protection and Participation in Oncology Trials. N Engl J Med. 2017; 376:1504-1505.
10Buyse M, Thirion P, Carlson RW, et al. Relation between tum our res ponse to first-line 
chemotherapy and survival in advanced colo rectal cancer: a meta-analysis. The Lancet 
2000;356:373-378.
11Blank CU, Haanen JB, Ribas A, Schumacher TN. The "cancer immunogram": visualizing the 
state of cancer-immune system interactions may spur personalized therapy.2016 Science 
352:658-60.
12OPDIVO [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2016.
13Pardoll D. Does the immune system see tumors as foreign or self? Annu Rev Immunol. 
2003;21:807-39.
14Zitvogel L, Tesniere A, Kroemer G. Cancer despi[INVESTIGATOR_53899]: immunoselection and immunosubversion. Nat Rev Immunol. 2006;6:715-27.
Protocol Amendment No.: 04
Date: 04-May-2021 121
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
15Dunn GP, Bruce AT, Ikeda H, et al. Cancer immunoediting: from immunosurveillance to 
tumor escape. Nat Immunol. 2002;3:991-8.
16Greenwald RJ, Freeman GH, Sharpe AH. The B7 family revisited. Annu Rev Immunol. 
2004;23:515-48.
17Freeman FJ, Long AJ, Iwai Y, et al. Engagement of the PD-1 immunohibitory receptor by a 
novel B7 family member l eads to negative regu lation of lymphocyte activation. J Exp Med 
2000; 192(7): 1027-34.
18Sharpe AH, Wherry EJ, Ahmed R, et al. The function of programmed cell d eath 1 and its 
ligands in regulating autoimmunity and infection. Nature Immunol. 2007;8:237-45.
19Wolchok JD, Hoos A, O‚ÄôDay S, et al. Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria. Clin Cancer Res. 2009;15:7412-20.
20Postow MA, Harding J, Wolchok JD. Targeting immune checkpoints: Releasing the restraints on anti-tumor immunity for patients with melanoma. Cancer J 2012; 18:153-159.
21BMS Clinical Study Report CA209004, December 2014
22Nivolumab Clinical Study Report: CA209-016 December 2016 
23Hellmann, MD, Gettinger, SN, Goldman, JW, et al. J Clin Oncol 34, 2016 (suppl; abstr 3001) 
24BMS Clinical Study Report CA209067, December [ADDRESS_602729] K, Wexler LH, et al. Ipi[INVESTIGATOR_125]: First results of a phase I trial in pediatric patients with advanced solid tumors. J Clin Oncol. 2012;30(suppl). 
27Xu Z, Davis HM, Zhou H. Rational development and utilization of antibody-based therapeutic proteins in pediatrics. Pharmacol Ther 2013;137:225‚Äì47
28Zhang Y, Wei X, Bajaj G, Barr ett JS, Mei bohm B, Joshi A, et al. Challenges and considerations 
for development of therapeutic proteins in pediatric patients. J Clin Pharmacol 2015;[ADDRESS_602730] 
3:S103‚Äì15.
29Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid 
tumours: revised RECIST guideline (ver sion 1.1). Eur J Cancer 2009;45:228-247.
30Wen PY, Macdonald DR, Reardon DA, et al. Updated Response Assessment Criteria for High-
Grade Gliomas: Response Assessment in Neuro -Oncology Working Group J Clin Oncol 28;1 
3059-3067. 2010
31Goodman AM, Kato S, B azhenova L et al. Tumor Mu tational Burde n as an Independent 
Predictor of Response to Immunotherapy in Diverse Cancers. Mol Cancer Ther. 2017 
Nov;16(11):2598-2608. doi: 10.1158/[ADDRESS_602731]-17-0386. Epub 2017 Aug 23
32Creighton CJ, Morgan M, Gunaratne PH, et al. Comprehensive molecular characterization of clear cell renal cell carcinoma. Nature. 2013;499:43‚Äì49.
Protocol Amendment No.: 04
Date: 04-May-2021 122
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
33Sato Y, Yoshizato T, Shiraishi Y, et al.  Integrated molecular  analysis of clear- cell renal cell 
carcinoma. Nat Genet. 2013;45:860‚Äì867. 
34Maia, MC et al. JCO 2018.36.6_suppl.662, Feb 2018 
35Yarchoan M, et cal. N Engl J Med 2017; 377:2500-2501
36Schadendorf D et al Efficacy and quality of life outcomes in patients with advanced melanoma 
(MEL) who discontinued treatment with nivolumab (NIVO) plus ip ilimumab (IPI) due to 
toxicity in a phase III trial (CheckMate 067). 2016 A nnual Meeting of the European 
Association of Dermato-Oncology; August 31-September 3, 2016; Vienna, Austria.
37Schadendorf D, et al. Pooled Analysis of Long-Term Survival Data from Phase II and Phase III Trials of Ip ilimumab in Unresectable or Metastatic Melanoma. J Clin Oncol 2015; 33: 1889-
94.
38Brahmer J, et al. Five-year follow-up from the CA209- 003 st udy of nivolumab in previously 
treated advanced non-small cell lung cancer: clinical char acteristics of long-term survivors. 
Oral presentation presented at: American Associ ation for Cancer Research (AACR) Annual 
Meeting; April 1-5, 2017; Washington, DC, [LOCATION_003].
39Felip E et al., Three-year follow-up from Checkmate 017/057: Nivolumab versus docetaxel in 
patients with previously treated advanced non-small lung cancer (NSCLC). Poster discussion 
presentation at the European Society of Me dical Oncology Annual Meeting. 2017 Sep 8-12; 
Madrid, Spain. Poster 1301PD
40Spi[INVESTIGATOR_43942], et al. Randomized results of continuous vs 1-year fixed- duration in patients with 
advanced non-small cell lung cancer. Oral presentation at the European Society of Medi cal 
Oncology Annual Meeting. 2017 Sep 8-12; Madrid, Spain
[ZIP_CODE] mg Q4W Flat Dose Simulation Multiple Tumor Types, DCN 930111854.
42Interim Safety Report to Support 480 mg Q4W. Bristol-Myers Squibb Company; 2017.
Document Control No. 930112964)
43Yervoy (Ipi[INVESTIGATOR_125]) US Prescribing Information. Bristol-M yers Squibb, 2016. 
http://packageinserts.bms.com/pi/pi_yervoy .pdf. Acce ssed: 18-Mar-2016.
44Summary of Product Characteris tics (SmPC), Nivolumab. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR__Product_Information/hu
man/003985/WC500189765.pdf. Accessed: 18-Mar-2016.
45Summary of Product Characteristics (SmPC), Ipi[INVESTIGATOR_125]. 
http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-
Product_Information/human/002213/WC500109299.pdf. Accessed: 18-Mar-2016.
46Opdivo (nivolumab) US Prescribing Information. Bristol-Myers Squibb, 2016. 
http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed 18-Mar-2016.
47Nivolumab Investigator Brochure, Version no 15. Bristol-Myers Squibb; 2016. Document 
Control Number 930038243.
Protocol Amendment No.: 04
Date: 04-May-2021 123
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
48Opdivo (nivolumab) US Prescribing Information. Bristol-Myers Squibb, 2021. 
http://packageinserts.bms.com/pi/pi_opdivo.pdf. Accessed 15-Mar-2021.
49Yervoy (ipi[INVESTIGATOR_125]) US Prescribing Information. Bristol-Myers Squibb, 2020. 
http://packageinserts.bms.com/pi/pi_yervoy .pdf. Acce ssed: 15-Mar-2021.
50Schwartz et al. J Peds. 1985;106:522. 
51Ipi[INVESTIGATOR_125] (BMS-734016) Investigator Brochure.
52Wolchok JD, Hoos A, O‚ÄôDay S, et al. Guidelines for the evaluation of immune therapy activity 
in solid tumors: immune related response criteria. Clin Cancer Res. 2009;15:7412-20.
53Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for 
highgrade gliomas: Response assessment in neuro-oncology working group; J Clin Oncol 
2010; 28(11):1963-72.
54Wen PY, Macdonald DR, Reardon DA, et al. Updated response assessment criteria for 
highgrade gliomas: Response assessment in neuro-oncology working group; J Clin Oncol 
2010; 28(11):1963-72
55Aaronson, N. K. et al. The European Organizatio n for Research and Treatment of Cancer QLQ-
C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology. JNCI 
J. Natl. Cancer Inst. 85, 365‚Äì376 (1993).
56EuroQol Group. EuroQol--a new facility for the measurement of health-related quality of life. 
Health Policy 16, 199‚Äì208 (1990).
57M.D. Hellmann, et al, Nivolumab plus Ipi[INVESTIGATOR_470351] a High Tumor 
Mutational Burden, The New England Journal of Medicine
58Naiyer R, et al, Impact of Tumor Mutation Burden on the Efficacy of Nivolumab or Nivolumab 
+ Ipi[INVESTIGATOR_452693]: An Exploratory Analysis of CheckMate 032, WCLC 
2017 
59BMS Clinical Study Report CA209012, January 2017
60Li X-K, Wang W-L. The role novel targeted agents in the treatment of previously treated 
patients with advanced urothelial carcinoma (UC): a meta-analysis. Eur Rev Med Pharmacol 
Sci, 2018, 22,16, 5165-5171.
61Kim J, Kim L, Sang-Cheol, etal. Attenuated FOLF IRINOX in the salvage tr eatment of 
gemcitabine-refractory advanced pancreatic cancer: a phase II study. Cancer Commun (Lond),
2018,38,1, p32.
62Fenner, Martin, Oing, et al. Everolimus in patients with multiply relapsed or cisplatin 
refractory germ cell tumors: results of a phase II, single-arm, open-label mult icenter trial 
(RADIT) of the German Testicular Cancer Study. J Cancer Res Clin. Oncol, 2018.
63Francis, Karabou, Abdoulaye, et al. Cetuximab and circadian chronomodulated chemotherapy 
as salvage treatment for metastatic colorectal cancer (m CRC): safety, efficacy and improved 
secondary s urgical res ectability. Cancer Chemother Pharmacol, 2011, 67,2, 339-48.
Protocol Amendment No.: 04
Date: 04-May-2021 124
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
64Gwak, Ho-Shin, Yee G, et al. Temozolomide salvage chemotherapy for recurrent anaplastic 
oligodendroglioma and oligo-astrocytoma. J Korean Neurosurg Soc, 2013, 54,6, 489-95.
65Fox E, Fox Mosse, Yael, et al. Time to disease progression in children with relapsed or 
refractory neuroblastoma treated with ABT-751: a report from the Children's Oncology Group 
(ANBL0621). Pediatr Blood Cancer, 2014, 61, 6, 990-6.
66Bayoglu, Abrahim, Yildiz, et al. Uracil/tegafur as a possible salvage therapy in chemo-
refractory colorectal cancer patien ts: a single institutional retr ospective study, Contemp Oncol  
(Poznan, Poland), 2015, 19, 5, 385-90. 
67Guo W, Wu Z, Huang M, et al. A retrospective study of raltitrexed combined with S-[ADDRESS_602732] 
chemotherapy. doi: 10.1200/JCO.2017.35.15_suppl.e15066 Journal of Clinical Oncology 35, 
no. 15_suppl - published online before print.
68Arnold D, Prager GW, Quintela A, et al. Beyond second-line therapy in patients with 
metastatic colorectal cancer: a systematic review. Ann Oncol. 2018 Apr; 29(4): 835‚Äì856. 
Published online 2018 Feb 14. doi: [10.1093/annonc/mdy038].
69Kondoh C, Kadowaki S, Komori A, et al. Salvage chemotherapy with the combination of 
oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant 
to fluoropyrimidines, platinum, taxanes, and irinotecan. Gastric Cancer. 2018 Nov;21(6):1050-
1057. doi: 10.1007/s10120-018-0825-y. Epub 2018 Apr 16.
70ESMO Oncology News. Nivolumab as Salvage Therapy in Pretreated Patients with Advanced 
Gastric or Gastro-oesophageal Junction Can cer. Results from a randomised, phase III study 
presented at 2017 Gastrointestinal Cancers Symposium. (26 Jan 2017).
71BMS Protocol CA209040, October 2016, Document Control Number 930060281.
72BMS Protocol CA209627, May 2018, Document Control Number 930100104.
73Boussios S,Seraj E, Zarkavelis G, et al. Management of patients with recurrent/advanced 
cervical cancer beyond first line platinum regimen s: Where do we stand? A literature review. 
Critical Review in On cology/Hematol ogy, 108, Dec 2016, 164-174. 
https://doi.org/10.1016/j.critrevonc.2016.11.006.
74Montemurro F, Redana S, Nole F, et al. Vinorelbine-based salvage therapy in HER2-positive 
metastatic breast cancer pa tients progressing during trastuzumab-containing regimens: a 
retrospective study. BMC Cancer. 2008 Jul 24;8:209. do i: 10.1186/1471- 2407-8-209.
75BMS Protocol CA209275, September 2016, Document Control Number 930085080.
76Raggi D, Miceli R, Sonpavde G, et al. Second-line single-agent versus doublet chemotherapy as salvage therapy for metastatic urothelial cancer: a systematic review and meta-analysis. Ann 
Oncol. 2016 Jan;27(1):49-61. doi: 10.1093/annonc/mdv509. Epub [ADDRESS_602733] 20.
77BMS protocol CA209141, November 2016, Document Control Number 930075071.
Protocol Amendment No.: 04
Date: 04-May-2021 125
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
78Konda B, Kirschner LS. Novel Targeted Therapi[INVESTIGATOR_470352]. Curr Opin 
Endocrinol Diabetes Obes. 2016 Jun; 23(3): 233‚Äì 241. doi:  
[10.1097/MED.0000000000000247].
79Keytruda [package insert]. Whitehouse Station, NJ: [COMPANY_006] & Co., Inc.; 2014-2018.
80Lutathera [package insert]. NJ: Advan ced Accelerator Applications [LOCATION_003], Inc., 2018.
81Simon N. et al, Adaptive enrichment designs for clinical trials, Bios tatistics (2013), 14, 4, 
p613-625. 
82Simon N. et al, Using Bayesian modeling in frequentist adaptive enrichment designs,   Biostatistics ( 2018), 19, 1, p27-41.
Protocol Amendment No.: 04
Date: 04-May-2021 126
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
12 APPENDICES
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602734] overall response
BP blood pressure
BSA body surface area
bTMB blood TMB
bTMB-H blood TMB high
BUN blood urea nitrogen
C cycle
Ca calcium
Cavg average concentration
Cavgss average steady-state exposure
CBC complete blood count
CBR clinical benefit rate
CFR Code of Federal Regulations 
cHL classical Hodgkin‚Äôs lymphoma
CI confidence interval
C1- chloride
CL clearance
CLIA Clinical Laboratory Improvement Amendments
CLcr creatinine clearance
Cmax maximum concentration
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602735] computerized tomography
CTCAE Common Terminology Criteria for Adverse Events
CTLA-4 cytotoxic T-lymphocyte-associated protein 4
CV coefficient of variation
Dd ay
DC/D discontinuation/death
dL deciliter
DLT Dose Limiting Toxicity
DMC data monitoring committee
dMMR deficient mismatch repair deficiency
DNA deoxynucleic acid
DOR duration of response
DRESS drug reaction with eosinophilia and systemic symptoms
EC endometrial cancer
ECG electrocardiogram
ECL electrochemiluminescent
ECOG Eastern Cooperative Oncology Group
EDC electronic data capture
eg exempli gratia (for example)
eGFR estimated glomerular filtration rate
EOI end of infusion
EOI-PK end of infusion pharmacokinetics
EORTC European Organization for Research and Treatment of Cancer 
EORTC-QLQ-
C30European Organization for Research and Treatment of Cancer quality of life questionnaire 30
EQ-5D EuroQol questionnaire comprising 5 dimensions
Protocol Amendment No.: 04
Date: 04-May-2021 129
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Term Definition
EQ-5D-3L the 3-level version of the EuroQol questionnaire comprising 5 
dimensions
ER exposure response
EU European Union
F1CDx FoundationOne¬Æ Companion Diagnostic
FDG fluorodeoxyglucose
FFPET formalin-fixed, paraffin-embedded tumor tissue
FLAIR fluid-attenuated inversion recovery
FMI Foundation Medicine Incorporated
FNA fine needle aspi[INVESTIGATOR_470353]-up
gg ram
GBS Guillain-Barre syndrome
GC gastric cancer
GCP Good Clinical Practice
GFR glomerular filtration rate
GGT gamma-glutamyl transferase
h hour
H&N head and neck
HBsAg hepatitis B surface antigen
HBV hepatitis B virus
HCG human chorionic gonadotropin
HCV hepatitis C virus
HCO 3- bicarbonate
HIV human immunodeficiency virus
HR hazard ratio
IA interim analysis
IB Investigator Brochure
ICH International Conference on Harmonisation 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602736] (that is)
IEC Independent Ethics Committee
IHC immunohistochemistry
IMP investigational medicinal products
IND Investigational New Drug Exemption
IO immuno-oncology
IP investigational product
IRB Institutional Review Board
IRC Independent Review Committee
IRT Interactive Response Technology
IU International Unit
IV intravenous
IVRS interactive voice response systems
K+ potassium
kg kilogram
L liter
LAG-[ADDRESS_602737] visit
MDSC myeloid-derived suppressor cell
mg milligram
Mg++ magnesium
MG myasthenia gravis
MHC major histocompatibility complex
MI myocardial Infarction
min minute
mL milliliter
MMR mismatch repair
mo month
Protocol Amendment No.: 04
Date: 04-May-2021 131
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Term Definition
mPFS median progression-free survival
MRI magnetic resonance imaging
MSI microsatellite instability
MSI-H microsatellite instability high
MTD maximum tolerated dose
mut/Mb mutations per megabase
N number of subjects or observations
Na sodium
N/A not applicable
NCI National Cancer Institute
NGS Next-Generation Sequencing
NIMP non-investigational medicinal products 
NSAID nonsteroidal anti-inflammatory drug
NSCLC non-small cell l ung cancer
ORR objective response rate
OS overall survival
PCR polymerase chain reaction
PD progressive disease
PD-1 programmed cell death protein 1
PD-L1 programmed death ligand 1
PET positron emission tomography
PFS progression free survival
PK pharmacokinetics
PPK population pharmacokinetics
PR Partial response
PRO Patient-reported outcome
Q2W every 2 weeks
Q4W every 4 weeks
Q6W every 6 weeks
QOL quality of life
Protocol Amendment No.: 04
Date: 04-May-2021 132
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Term Definition
R&D research and development
RANO Response Assessment for Neuro-Oncology
RECIST Response Evaluation Criteria in Solid Tumors
RBC red blood cell
RCC renal cell carcinoma
RT-PCR reverse transcription polymerase chain reaction
SAE serious adverse event
SARS-CoV-[ADDRESS_602738] Operating Procedures
SPD Sum of the products of perpendicular diameters
t temperature
T time
t1/2 half-life
T2 transverse relaxation time
T3 triiodothyronine
T4 thyroxine
T.bili total bilirubin
TEN toxic epi[INVESTIGATOR_470354]-H high tumor mutational burden
Treg regulatory T cell
tTMB tissue TMB
TTR time to response
TSH thyroid stimulating hormone
UC urothelial carcinoma
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602739] upper limit of normal
USPI [INVESTIGATOR_470355].: 04
Date: 04-May-2021 134
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 2 STUDY GOVERNANCE CONSIDERATIONS
The term ‚ÄòParticipant‚Äô is used in the protocol to refer to a person who has consented to participate 
in the clinical research study.  The term ‚ÄòSubject‚Äô used in the eCRF is intended to refer to a person 
(Participant) who has consented to participate in the clinical research study.
REGULATORY AND ETHICAL CONSIDERATIONS
GOOD CLINICAL PRACTICE
This study will be conducted in accordance with:
‚Ä¢Consensus ethical principles derived from international guidelines including the Declaration 
of Helsinki and Council for International Organizations of Medical Sciences (CIOMS) 
International Ethical Guidelines Good Clinical Practice (GCP),
‚Ä¢as defined by [CONTACT_102462] (ICH)
‚Ä¢in accordance with the ethical principles underlying European Union Directive 2001/20/EC
‚Ä¢[LOCATION_002] Code of Federal Regulations, Title 21, Part 50 (21CFR50) 
‚Ä¢applicable local requirements.
The study will be conducted in compliance with the protocol. The protocol and any amendments 
and the participant informed consent will r eceive approval/favorable opi[INVESTIGATOR_102401]/Independent Ethics Committee (IRB/IEC) , and regulatory authorities according to 
applicable local regulations prior to initiation of the study.
All potential serious breaches must be reported to Sponsor or designee immediately. A serious
breach is a breach of the conditions and principles of Good Clinical Practice (GCP) (occurring in 
any country) in connection with that trial or the protocol to the trial which is likely to affect to a significant degree, the safety or physical or mental integrity of [ADDRESS_602740] or fraud (e.g., loss of medical licensure, debarment). INSTITUTIONAL REVIEW BOARD/INDEPENDENT ETHICS COMMITTEE
Before study initiation, the investigator must ha ve written and dated approval/favorable opi[INVESTIGATOR_20291]/IEC for the protocol, consent form , participant recruitmen t materials (e.g., 
advertisements), and any other written informatio n to be provided to subjects. The investigator or 
BMS should also provide the IRB/IEC with a copy of the Investigator Brochure or product labeling 
information to be provided to subjects and any updates. 
The investigator, Sponsor or designee should provide the IRB/IEC with reports, updates and other 
information (e.g., expe dited safety reports, amendments, and administrative letters) according to 
regulatory requirements or institution procedures.
Protocol Amendment No.: 04
Date: 04-May-2021 135
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
COMPLIANCE WITH THE PROTOCOL AND PROTOCOL REVISIONS
The investigator should not implement any deviation or change to the protocol without prior 
review and documented approval/favorable opi[INVESTIGATOR_102403]/IEC (and if 
applicable, also by [CONTACT_14306]) except where necessary to eliminate an immediate 
hazard(s) to study subjects. 
If a deviation or change to a protocol is implemented to eliminate an immediate hazard(s) prior to 
obtaining relevant  approval/favorable opi[INVESTIGATOR_1649](s) th e deviation or change will be submitted, as 
soon as possible to:
‚Ä¢IRB/IEC 
‚Ä¢Regulatory Authority(ies), if applicable by [CONTACT_427] (per national requirements)
Documentation of approval/favorable opi[INVESTIGATOR_102404](s)/IEC(s) and if applicable, also by [CONTACT_102463].
If an amendment substantially alters the study design or increases the potential risk to the 
participant: (1) the consent form must be revised and submitted to the IRB(s)/IEC(s) for review 
and approval/favorable opi[INVESTIGATOR_1649]; (2) the revised form must be used to obtain consent from subjects 
currently enrolled in the study if they are affected by [CONTACT_29991]; and (3) the new form must 
be used to obtain consent from new subjects prior to enrollment.
If the revision is done via an administrative letter, investigators must inform their IRB(s)/IEC(s).
FINANCIAL DISCLOSURE
Investigators and su b-Investigators will provide the Sponsor with sufficient, accurate financial 
information in accordance with local regulations to allow the Sponsor to submit comp lete and 
accurate financial certification or disclos ure statements to the appropriate h ealth aut horities. 
Investigators are responsible for providing information on financial interests during the course of 
the study and for [ADDRESS_602741] ensure that subjects are clearly and fully informed about the purpose, potential 
risks, and other critical issues regarding clinical studies in which they volunteer to participate. 
In situations where consent cannot be given to subjects, their legally acceptable representatives (as 
per country guidelines) are clearly and fully informed about the purpose, potential risks, and other critical issues regarding clinical studies in which the participant volunteers to participate. 
Sponsor or designee will provide the investigator with an appropr iate (i.e., Global or Local) sample
informed consent form which will include all elements required by [CONTACT_12212], GCP and app licable
regulatory requirements. The sample informed cons ent form will adhere to the ethical principles 
that have their origin in the Declaration of Helsinki.Investigators must:
Protocol Amendment No.: 04
Date: 04-May-2021 136
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
‚Ä¢Provide a copy of the consent form and written information about the study in the language in 
which the participant is most proficient prior to clinical study participation. The language must be non-technical and easily understood. 
‚Ä¢Allow time necessary for participant or participant's legally acceptable representative to 
inquire about the details of the study.
‚Ä¢Obtain an informed consent signed and personally dated by [CONTACT_98901]'s legally acceptable representative and by [CONTACT_102464]. 
‚Ä¢Obtain the IRB/IEC‚Äôs written approval/favorable opi[INVESTIGATOR_132831], prior to the beginning of the study, and after any revisions are completed for new information.
If informed consent is initially given by a par ticipant‚Äôs legally acceptable representative or legal 
guardian, and the participant subsequently becomes capable of making and communicating his or 
her informed consent during the study, consent must additionally be obtained from the participant.
Revise the informed consent whenever impor tant new information becomes available that is 
relevant to the participant's consent. The investigator, or a person designated by [CONTACT_093], 
should fully inform the participant or the part icipant's legally acceptable representative or legal 
guardian, of all pertinent aspects of the study  and of any new information relevant to the 
participant's willingness to continue participation in the st udy. This commun ication should be 
documented. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules applicable to regulatory re quirements, the subjects' signed ICF and, in the 
US, the subjects‚Äô signed HIPAA Authorization.The consent form must also include a statement that BMS and regulatory authorities have direct 
access to par ticipant records. 
The rights, safety, and well-being of the study s ubjects are the most important considerations and 
should prevail over interests of science and society.
SOURCE DOCUMENTS
The Investigator is responsible for ensuring that the source data are accurate, legible, 
contemporaneous, original and attributable, whether  the data are hand-written on paper or entered 
electronically. If source data  are created (first entered), modified, maintained, archived, retrieved, 
or transmitted electronically via computer ized systems (and/or any other kind of electronic 
devices) as part of regulated clinical trial activities, such systems must be compliant with all 
applicable laws and regulations governing use of electronic records and/ or electronic signatures. 
Such systems may include, but are not limited to, electronic medical/health records (EMRs/EHRs), 
adverse event tracking/reporting, protocol re quired assessments, and/or drug accountability 
records).
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602742] copy 
having all of the same attributes and i nformation as the original. 
STUDY TREATMENT RECORDS
Records for study treatments (whether  supplied by [CONTACT_20444], its vendors, or the site) must substantiate 
study treatment integrity and traceability from receipt, preparation, administration, and through 
destruction or return. Records must be made available for review at the request of BMS/designee 
or a Health Authority.
If Then
Supplied by [CONTACT_20444] (or its vendors): Records or logs must comply with applicable 
regulations and guidelines and should include:
‚Ä¢amount received and placed in storage 
area
‚Ä¢amount currently in storage area
‚Ä¢label identification number or b atch 
number
‚Ä¢amount dispensed to and returned by [CONTACT_37117], including unique participantidentifiers
‚Ä¢amount transferred to another area/site for 
dispensing or storage
‚Ä¢nonstudy disposition (e.g., lost, wasted) 
‚Ä¢amount destroyed at study site, if applicable
‚Ä¢amount returned to BMS
‚Ä¢retain samples for 
bioavailability/bioequivalence, if applicable 
‚Ä¢dates and initials of person responsible for Investigational Product dispensing/accountability, as per the Delegation of Authority Form.
Sourced by [CONTACT_3725], and not supplied by [CONTACT_82769] (examples include IP sourced from the sites stock or commercial supply, or a 
specialty pharmacy)The investigator or designee accepts 
responsibility for documenting traceability and study treatment integrity in accordance with 
requirements applicable under law and the 
SOPs/standards of the sourcing pharmacy.
BMS or designee will provide forms to facilitate inventory control if the i nvestigational site does not have an 
established system that meets these requirements.
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602743] safety. CRFs may be reque sted for AEs and/or laboratory abnormalities 
that are reported or identified during the course of the study.
For sites using the Sponsor or designee elect ronic data capture tool, electronic CRFs w ill be 
prepared for all data collection fields except for fields specific to SAEs and pregnancy, which will 
be reported on the electronic SAE form and Pregnancy Surveillance form, respectively.  If 
electronic SAE form is not av ailable, a paper SAE form can be used. Spaces may be left blank 
only in those circumstances permitted by [CONTACT_3449]-s pecific CRF completion  guidelines  provide d by 
[CONTACT_35886]. 
The confidentiality of records that could identify subjects must be protected, respecting the privacy 
and confidentiality rules in accordance with  the applicable regulatory requirement(s).
The investigator will maintain a signature [CONTACT_470412]/or corrections on CRFs. The completed CRF, SAE/pregnancy CRFs, must be  promptly reviewed, signed, and dated by [CONTACT_54025] a subinve stigator and who is delegated this task on the 
Delegation of Authority Form. Subinvestigators in Japan may not be delegated the CRF approval 
task. For electronic CRFs, review and approval/s ignature is completed electronically through the 
BMS electronic data capture tool. The investigator must r etain a copy of the CRFs including 
records of the changes and corrections.
Each individual electronically signing electronic CRFs must meet S ponsor or designee training 
requirements and must only access the BMS elect ronic data capture tool using the unique user 
account provided by [CONTACT_35886]. User accounts are not to be shared or reassigned to other 
individuals
MONITORING
Monitoring d etails describing strategy, including definition of study critical d ata items and 
processes (eg, risk-based initiatives in operations and quality such as risk management and 
mitigation strategies and analytical risk-b ased monitoring), methods, responsibilities, and 
requirements, including handling of noncomplian ce issues and monitoring techniques (central, 
remote, or on-site monitoring) are provided in the monitoring plan.
Representatives of BMS must be allowed to visit all study site locations periodically to assess the 
data quality and study integrity. On site they will  review study records and directly compare them 
with source documents, discuss the conduct of the study with the investigator, and verify that the 
facilities remain acceptable .Certain CRF pages and/or electronic files may serve as the source documents:
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602744] copi[INVESTIGATOR_35813].
RECORDS RETENTION
The investigator (or head of the study site in Japan) must retain all study records and source 
documents for the maximum period required by [CONTACT_8666], or institution procedures, or for the period specified  by [CONTACT_54029], whichever is longer. The 
investigator (or head of the study site in Japan) must contact [CONTACT_35890].
BMS or designee will notify the investigator (or head of the study site in Japan) when the study 
records are no longer needed.
If the investigator withdraws from the study (e .g., relocation, retirement), the records sh all be 
transferred to a mutually agreed upon designee (e.g., another investigator, study site, IRB). Notice 
of such transfer will be given in writing to BMS or designee. 
RETURN OF STUDY TREATMENT
For this study, study treatments (those supplied by [CONTACT_20444], a vendor or sourced by [CONTACT_093]) 
such as partially used study treatment contain ers, vials and syringes may be destroyed on site.
If.. Then
Study treatments supplied by [CONTACT_20444] (including its vendorsAny unused study treatments supplied by [CONTACT_470408], 
or to meet local regulations (e.g., cytotoxics or biologics).
If study treatments will be returned, the return 
will be arranged by [CONTACT_82772].
Study treatments sourced by [CONTACT_3725], not supplied 
by [CONTACT_20444] (or its vendors) (examples include 
study treatments sourced from the sites stock 
or commercial suppl y, or a specialty 
pharmacy)It is the investigator‚Äôs or designee‚Äôs 
responsibility to dispose of all containers 
according to the institutional guidelines and 
proce dures.
Protocol Amendment No.: 04
Date: 04-May-2021 140
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
It is the investigator‚Äôs or designee‚Äôs responsibility to arrange for disposal, provided that procedures 
for proper disposal have been established accord ing to applicable feder al, state, local, and 
institutional guidelines and procedures, and provided that appropriate records of disposal are kept. 
The following minimal standards must be met:
‚Ä¢On-site disposal practices must not expose humans to risks from the drug.
‚Ä¢On-site disposal practices and procedures are in agr eement with applicable laws and 
regulations, including any special requirements for controlled or hazardous substances.
‚Ä¢Written procedures for on-site disposal are available and followed. The procedures must be 
filed with the site‚Äôs SOPs and a copy provide d to BMS upon request.
‚Ä¢Records are maintained that allow for traceab ility of each container, including the d ate 
disposed of, quantity disposed, and identificati on of the person disposing the containers. The 
method of disposal, i.e., incinerator, licensed sanitary landfill, or licensed waste disposal 
vendor must be documented.
‚Ä¢Accountability and disposal records are comp lete, up-to-date, and available for the Monitor to 
review throughout the clinical trial period.
It is the investigator‚Äôs or designee‚Äôs responsibility to arrange for disposal of all empty containers.
If conditions for destruction cannot be met the responsible Study Monitor will make arrangements 
for return of study treatments provided by [CONTACT_20444] (or its vendors). Destruction of non- study 
treatments s ourced by [CONTACT_779], not supplied by [CONTACT_20444], is solely the responsibility of the investigator 
or designee.
For this study, study treatments (those supplied by [CONTACT_54024]) such as full or partially 
used study treatm ent containers, vials, syringes cannot be destroyed on-site.
CLINICAL STUDY REPORT AND PUBLICATIONS
A Signatory Investigator must be selected to sign the clinical study report. 
For this protocol, the Signatory Investigator will be selected as appropriate based on the following 
criteria:
‚Ä¢Participant recruitment (e.g., among the top quartile of enrollers)
‚Ä¢Involvement in trial design
‚Ä¢Regional representation (e.g ., among top quartile of enro llers from a specified region or 
country)
‚Ä¢Other criteria (as determined by [CONTACT_3476])
The data collected during this study are confident ial and proprietary to Sponsor or designee. Any 
publications or abstracts arising from this study must adhere to the publication requirements set 
forth in the clinical trial agreement (CTAg) governing [Study site or Investigator] participation in 
the study. These requirements include, but are not  limited to, submitting proposed publications to 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602745] practicable time prior to submission or presentation and 
otherwise within the time period set forth in the CTAg.
Protocol Amendment No.: 04
Date: 04-May-2021 142
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 3 ADVERSE EVENTS AND SERIOUS ADVERSE EVENTS: 
DEFINITIONS AND PROCEDURES FOR RECORDING, 
EVALUATING, FOLLOW UP AND REPORTING
ADVERSE EVENTS
Adverse Event Definition:
An Adverse Event (AE) is defined as any new untoward medical occurrence or worsening of a 
preexisting medical condition in a clinical investigation par ticipant administered study treatment
and that does not necessarily have a causal relationship with this treatment. 
An AE can therefore be any unfavorable and unintended sign (such as an abnormal laboratory 
finding), symptom, or disease temporally associated with the use of study treatment, whether or 
not considered related to the study treatment.
Events Meeting the AE Definition
‚Ä¢Any abnormal laboratory test results (hemato logy, clinical ch emistry, or uri nalysis) or 
results from other safety assessments (eg, ECG, radiological scans, vital signs 
measurements), including those that worsen from baseline, considered clinically significant 
in the medical a nd scientific judgment of the investigator. Note that abnormal lab tests or 
other safety assessments should only be reported as AEs if the final diagnosis is not available. Once the final diagnosis is known, the reported term should be updated to be the 
diagnosis.
‚Ä¢Exacerbation of a chronic or intermittent pre-exis ting condition including either an increase 
in frequency and/or intensity of the condition.
‚Ä¢New conditions detected or diagnosed after study intervention administration even though it 
may have been present before the start of the study.
‚Ä¢Signs, symptoms, or the clinical sequelae of a suspected drug-drug interaction.
‚Ä¢Signs, symptoms, or the clinical sequelae of a suspected overdose of either study intervention 
or a concomitant medication. Overdose, as a verbatim term (as reported by [CONTACT_093]), should not be reported as an AE/SAE unless it is an intentional overdose taken with possible 
suicidal/self-harming intent. Such overdoses should be reported regardless of sequelae and 
should specify "intentional overdose" as the verbatim term
Events NOT Meeting the AE Definition
‚Ä¢Medical or surgical procedure  (eg, endoscopy, appendectomy): the condition that leads to 
the procedure is the AE.
‚Ä¢Situations in which an untoward medical occ urrence did not occur (so cial and/or 
convenience admission to a hospi[INVESTIGATOR_307]).
Protocol Amendment No.: 04
Date: 04-May-2021 143
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
DEFINITION OF SAE
If an event is not an AE per definition above, th en it cannot be an SAE even if serious conditions 
are met.
SERIOUS ADVERSE EVENTS
Serious Adverse Event (SAE) is defined as any untoward medical occurrence that, at any 
dose:
Results in death
Is life-threatening (defined as an event in which  the participant was at risk of death at the time 
of the event; it does not refer to an event which hypothetically might have caused death if it were more severe)
Requires inpatient hospi[INVESTIGATOR_312] (see NOTE below)
NOTE:
The following hospi[INVESTIGATOR_102412]: 
‚Ä¢a visit to the emergency room or other hospi[INVESTIGATOR_20347] < 24 hours, that does not result 
in admission (unless considered an important medical or life-threatening event)
‚Ä¢elective surgery, planned prior to signing consent
‚Ä¢admissions as per protocol for a planned medical/surgical procedure
‚Ä¢routine health assessment requiring admission fo r baseline/trending of health status (e.g., 
routine colonoscopy)
‚Ä¢medical/surgical admission other than to reme dy ill health and planned prior to entry into 
the study. Appropriate documentation is required in these cases
‚Ä¢admission encountered for another life circumstance that carries no bearing on health status 
and requires no medical/surgical intervention (e.g., lack of housing, economic inadequacy, 
caregiver respi[INVESTIGATOR_040], family circumstances, administrative reason)
‚Ä¢admission for administration of anticancer therapy in the absence of any other SAEs (applies to oncology protocols)
Results in persistent or significant disability/incapacity
Is a congenital anomaly/birth defect
Protocol Amendment No.: 04
Date: 04-May-2021 144
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Is an important medical event (defined as a med ical event(s) that may not be immediately life-
threatening or result in death or hospi[INVESTIGATOR_313], based upon appropriate medical and 
scientific judgment, may jeopardize the particip ant or may require intervention [e.g., medical, 
surgical] to prevent one of the other serious outcomes listed in the definition above.) Examples 
of such events include, but are not limited to, intensive tr eatment in an emergency room or at 
home for allergic bronchospasm; blood dyscrasias or co nvulsions that do not result in 
hospi[INVESTIGATOR_059].) Potential drug induced liver injury (DILI) is also considered an important 
medical event. (See  Section 9.2.7 for the definition of potential DILI.) 
Pregnancy and potential drug induced liver injury (DILI) must follow the same transmission timing 
and processes to BMS as used for SAEs (see  section 9.2.5  for reporting pregnancies).
EVALUATING AES AND SAES
Assessment of Causality
‚Ä¢The investigator is obligated to assess the relationship between study intervention and each 
occurrence of each AE/SAE.
‚Ä¢A ‚Äúreasonable possibility‚Äù of a relationship conveys that there are facts, evidence, and/or arguments to suggest a causal relationship, rath er than a relationship cannot be ruled out.
‚Ä¢The investigator will use clinical judgment to determine the relationship.
‚Ä¢Alternative causes, such as underlying disease(s), concomitant therapy, and other risk 
factors, as well as the temporal relationship of the event to study intervention administration 
will be considered and investigated.
‚Ä¢The investigator will also consult the Investigator‚Äôs Brochure  (IB) and/or Product 
Information, for marketed  products, in his/her assessment.
‚Ä¢For each AE/SAE, the investigator must document in the medical notes that he/she has reviewed the AE/SAE and has provided an assessment of causality.
‚Ä¢There may be situations in which an SAE has occurred and the investigator has minimal 
information to in clude in the initial report to Sponsor. However, it is very important that the 
investigator always make an assessment of causality for every event before the initial 
transmission of the SAE data to Sponsor.
‚Ä¢The investigator may change his/her opi[INVESTIGATOR_470356]-up information 
and send a SAE follow-up report with the updated causality assessment.
‚Ä¢The causality assessment is one of the criter ia used when determining regulatory reporting 
requirements.
Follow-up of AEs and SAEs
If only limited information is initially available, follow-up re ports are required. (Note: Follow-
up SAE reports must include the same investigator term(s) initially reported.) 
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602746] be updated and submitted within 24 hours 
to BMS (or designee) using the same procedure used for transmitting the initial SAE report.
All SAEs must be followed to resolution or stabilization.
REPORTING OF SAES TO SPONSOR OR DESIGNEE
‚Ä¢SAEs, whether related or not related to study treatment, and pregnancies must be reported 
to BMS (or designee) immediately within 24 hours of awareness of the event.
‚Ä¢SAEs must be recorded on the SAE Report Form.
‚àíThe required method for SAE data reporting is through the eCRF.
‚àíThe paper SAE Report Form is only intended as a back-up option when the electronic 
data capture (EDC) system is unavailable/not functioning for transmission of the eCRF to BMS (or designee).
‚ô¶In this case, the paper form is trans mitted via email or confi rmed facsimile (fax) 
transmission
‚ô¶When paper forms are used, the original paper forms are to remain on site
‚Ä¢Pregnancies must be recorded on a paper Pregnancy Surveillance Form and transmitted via email or 
confirmed facsimile (fax) transmission 
SAE Email Address: Refer to Contact [CONTACT_20491].
SAE Facsimile Number: Refer to Contact [CONTACT_20491].
SAE Telephone Contact (required for SAE and pregnancy reporti ng): Refer to Contact 
[CONTACT_470409].: 04
Date: 04-May-2021 146
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 4 WOMEN OF CHILDBEARING POTENTIAL DEFINITIONS AND 
METHODS OF CONTRACEPTION
DEFINITIONS
Woman of Childbearing Potential (WOCBP)
A woman is considered fertile following menarche and until becoming post-menopausal unless 
permanently sterile. Permanent sterilization methods include hysterectomy, bilateral 
salpi[INVESTIGATOR_1656], and bilateral oophorectomy.
Women in the following categories are not considered WOCBP
‚Ä¢Premenarchal
‚Ä¢Premenopausal female with 1 of the following:
‚àíDocumented hysterectomy
‚àíDocumented bilateral salpi[INVESTIGATOR_1656]
‚àíDocumented bilateral oophorectomy
Note: Documentation can come from the site personn el‚Äôs review of the participant‚Äôs medical 
records, medical examination, or medical history interview.
‚Ä¢Postmenopausal female‚àíA postmenopausal state is defined as [ADDRESS_602747] a serum follicle stimulating hormone, (FSH) level > 40 
mIU/mL to confirm menopause.
CONTRACEPTION GUIDANCE FOR FEMALE PARTICIPANTS OF CHILD BEARING 
POTENTIAL
One of the highly effective methods of contracep tion listed below is required during study duration 
and until the end of relevant systemic exposure, defined as 5 months after the end of study 
treatment. *
Highly Effective Contraceptive Methods That Are User Dependent 
Failure rate of <1% per year when used consistently and correctly.
a
‚Ä¢Combined (estrogen- and progestogen-containi ng) hormonal contraception associated with 
inhibition of ovulationb 
‚àíoral 
‚àíintravaginal 
‚àítransdermal 
‚Ä¢Progestogen -only hormonal contraception associated with inhibition of ovulationb 
‚àíoral 
‚àíinjectable 
Protocol Amendment No.: 04
Date: 04-May-2021 147
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Highly Effective Methods That Are User Independent
‚Ä¢Implantable progestogen-only hormonal contraception associated with inhibition of 
ovulationb
‚Ä¢Intrauterine hormone-releasing system (IUS)c
‚Ä¢Intrauterine device (IUD)c
‚Ä¢Bilateral tubal occlusion
‚Ä¢Vasectomized partner 
A vasectomized partner is a highly effective contraception method provided that the partner 
is the sole male sexual partner of the WOCBP and the absence of sperm has been confirmed. 
If not, an additional highly effective method of contraception should be used. 
‚Ä¢Sexual abstinence
Sexual abstinence is considered a highly effective method only if defined as refraining from heterosexual intercourse during the entire period of risk associated with the study drug. The reliability of sexual abstinence needs to be evaluated in relation to the duration of the study 
and the preferred and usual lifestyle of the participant.
‚Ä¢It is not necessary to use any other method of contraception when complete abstinence is 
elected. 
‚Ä¢WOCBP participants who choose complete abstin ence must continue to have pregnancy 
tests, as specified in  Section 2. 
‚Ä¢Acceptable alternate methods of highly effective contraception must be discussed in the event that the WOCBP participants chooses to forego complete abstinence 
NOTES: 
aTypi[INVESTIGATOR_35818]. Use should be consistent 
with local regulations regarding the use of contraceptiv e methods for participants participating in clinical studies. 
bHormonal contraception may be sus ceptible to interaction with the st udy drug, which may reduce the efficacy 
of the contraceptive method.  Hormonal contraception is permissible only when there is sufficient evidence that 
the IMP and other study med ications will not alter hormonal exposures such that contraception would be 
ineffective or result in increased exposures that could be potentially hazardous.  In this case, alternative methods of contraception should be utilized. 
cIntrauterine devices and intrauteri ne hormone releasing systems are acceptable methods of contraception in the 
absence of definitive drug interaction studies when horm one exposures from intrauter ine devices do not alter 
contraception effectiveness
Unacceptable Methods of Contraception*
‚Ä¢Male or female c ondom with or without spermicide.  Male and female c ondoms cannot be 
used simultaneously
‚Ä¢Diaphragm with spermicide
‚Ä¢Cervical cap with spermicide
‚Ä¢Vaginal Sponge with spermicide
‚Ä¢Progestogen-only oral hormonal contraception, where inhibition of ovulation is not the 
primary mechanism of action
Protocol Amendment No.: 04
Date: 04-May-2021 148
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
‚Ä¢Periodic abstinence (calendar, symp tothermal, post- ovulation methods)
‚Ä¢Withdrawal (coitus interruptus).
‚Ä¢Spermicide only
‚Ä¢Lactation amenorrhea method (LAM)
* Local laws and regulations may require use of alternative and/or additional contraception 
methods.
NOT APPLICABLE PER PROTOCOL AMENDMENT 04 : CONTRACEPTION 
GUIDANCE FOR MALE PARTICIPANTS WITH PARTNER(S) OF CHILD BEARING 
POTENTIAL.
Male participants with female partners of childb earing potential are eligible to participate if they 
agree to the following during the treatment and until the end of relevant systemic exposure.
‚Ä¢Inform any and all partner(s) of their participation in a clinical drug study and the need to 
comply with contraception instructions as directed by [CONTACT_093].
‚Ä¢Male participants are required to use a condom for study duration and until end of relevant 
systemic exposure defined as 7 months after the end of study treatment.
‚Ä¢Female partners of males participating in the study to consider use of effective methods of contraception until the end of relevant systemic exposure, defined as 7 months after the end of 
treatment in the male participant.
‚Ä¢Male participants with a pregnant or breastfeeding partner must agree to remain abstinent from penile vaginal intercourse or use a male condo m during each epi[INVESTIGATOR_82710] 7 months a fter the end of study treatment.
‚Ä¢Refrain from donating sperm for the duration of the study treatment and until 7 months after 
the end of study treatment.
COLLECTION OF PREGNANCY INFORMATION
Guidance for collection of Pregna ncy Information and outcome of pregnancy on the Pregnancy 
Surveillance Form is provided in  Section 9.2.5 and the Appendix for Adverse Events and Serious 
Adverse Events Definitions and procedur es for Evaluating, Fo llow-up and Reporting
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602748], especially prior to an invasive diagnostic or 
procedure, is recommended.The frequency and severity of the related advers e events covered by [CONTACT_20520]-oncology agent or regimen being used.
Protocol Amendment No.: 04
Date: 04-May-2021 150
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 151
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 152
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 153
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 154
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 155
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 156
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 157
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Â≠µÂ≠ªÂ≠∞ÂÆñÂÆ®ÂÆ≥Â≠∞Â≠µÂ≠≥Â≠µÂ≠≥
Protocol Amendment No.: 04
Date: 04-May-2021 158
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 6 ECOG PERFORMANCE STATUS
Table 1: ECOG Performance Status
ECOG PERFORMANCE STATUS
0‚ÄîFully active, able to carry on all pre-d isease performance without restriction
1‚ÄîRestricted in physically strenuous activity but ambulatory and able to carry out work of a light or sedentary 
nature, e.g., light house work, office work
2‚ÄîAmbulatory and capable of all selfcare but unable to carry out any work activities; up and about more than 
50% of waking hours
3‚ÄîCapable of only limited selfcare; confined to bed or chair more than 50% of waking hours
4‚ÄîCompletely disabled; cannot carry on any selfcare; totally confined to bed or chair
5‚ÄîDead
References: Oken MM, Creech RH, Tormey DC, et al. Toxicity and Res ponse Criteria of the Eastern Cooperative
Oncology Group. Am J Clin Oncol 1982;5:649-655.
Protocol Amendment No.: 04
Date: 04-May-2021 159
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 7 RESPONSE EVALUATION CRITERIA IN SOLID TUMORS 
GUIDELINES (VERSION 1.1) WITH BMS MODIFICATIONS
1 EVALUATION OF LESIONS
Solid tumors will be evalu ated using Response Evaluation Criteria In Solid Tumors version 1.1 
(RECIST 1.1) guideline with BMS modifications.1
At baseline, tumor lesions/lymph nodes will be categorized as measurab le or non-measurable as 
follows:
1.1 Measurable
Tumor lesions: Must be accurately measured in at least one dimension (longest diameter in the 
plane of measurement is to be recorded) with a minimum size of:
[ADDRESS_602749]/MRI scan (scan slice thickness no greater than 5 mm), or ‡µí2x slice thickness if 
greater than 5mm.Malignant lymph nodes: To be considered pathologically enlarged and measurable, a lymph node 
must be ‚â•[ADDRESS_602750]/MRI scan (scan slice thickness recommended 
to be no greater than 5 mm).Lymph nodes merit special mention since they are normal anatomical structures which may be 
visible by [CONTACT_33490]. Pathological nodes which are defined as 
measurable and may be identified as target lesi ons must meet the criterion of a short axis of 
‚â•[ADDRESS_602751]/MRI scan. Only the short axis of these nodes will contribute to the baseline sum. 
The short axis of the node is the diameter normally used by [CONTACT_102470] j udge if a node is 
involved by [CONTACT_70188]. Nodal size is normally re ported as two dimensions in the plane in which 
the image is obtained (for CT scan this is almos t always the axial plane; for MRI the plane of 
acquisition may be axial, sagittal or coronal). The smaller of these measures is the short axis. For 
example, an abdominal node which is reported as being 20 mm x 30 mm has a short axis of 20 mm 
and qualifies as a malignant, measurable node. In this example, 20 mm should be recorded as the 
node measurement. All other pathol ogical nodes (those with short axis ‚â• 10 mm but < 15 mm) 
should be considered non-target lesions. Nodes that have a short axis < 10 mm are considered 
non-pathological and should not be recorded or followed.
Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.
1.2 Non-Measurable
All other lesions are considered non-measur able, including small les ions (longest diameter 
< 10mm or pathological lymph nodes with ‚â•10 to < 15 mm short axis) as w ell as truly 
non-measurable lesions. Lesions considered truly non-measurable include: leptomeningeal 
disease, inflammatory breast disease, lymphangitic involvement of skin or lung, abdominal 
masses/abdominal organomegaly identified by [CONTACT_87415].
Note: Lesions on X-Ray are not to be selected as Target or Non-Target Lesions.
Protocol Amendment No.: 04
Date: 04-May-2021 160
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
1.3 Special considerations regarding lesion measurability
1.3.1 Bone lesions
‚Ä¢Bone scan, PET scan and plain films are notconsidered adequate imaging techniques to 
measure bone lesions. However, these techniques can be used to confirm the presence or 
disappearance of bone lesions. 
‚Ä¢Lytic bone lesions or mixed lytic-blastic lesions, with identifiable soft tissue components , that 
can be evaluated by [CONTACT_102471].
‚Ä¢Blastic bone lesions are non-measurable.
1.4 Baseline Documentation Of ‚ÄòTarget‚Äô And ‚ÄòNon-Target‚Äô Lesions
When more than one measurable lesion is present  at baseline all lesions up to a maximum of five 
lesions total (and a maximum of two lesions per organ) representative of all involved organs s hould 
be identified as target lesions and will be recorded and measured at baseline (this means in 
instances where patients have only one or two organ sites involved a maximum of two and four 
lesions respectively will be recorded).
Note: A maximum of two lesions can be selected per organ system. For example, a maximum of 
two lung lesions can be selected (selected from one lung or one lesion from each). A maximum of 
two lymph nodes can be selected at baseline, as the lymphatic system is considered one organ.
Target lesions should be selected on the basis of their size (lesions with the longest diameter), be 
representative of all involved organs, but in addition should be those that lend themselves to 
reproducible repeated measurements. It may be the case that, on occasion, the largest lesion does 
not lend itself to reproducible measurement in which circumstance the next largest lesion which 
can be measured reproducibly should be selected.
A sum of the diameters (longest for non-nodal lesions, short axis for nodal lesions) for all target 
lesions will be calculated and reported as the ba seline sum diameters. If lymph nodes are to be 
included in the sum, then as noted above, only the short axis is added into the sum. The baseline 
sum diameters will be used as reference to furt her characterize any objective tumor regression in 
the measurable dimension of the disease.All other lesions (or sites of disease) including pathological lymph nodes should be id entified as 
non-target lesions and should also be recorded at baseline. Measurements are not required and 
these lesions should be followed as ‚Äòpresent‚Äô, ‚Äòabsent‚Äô, or in rare cases ‚Äòunequivocal progression‚Äô 
(more details to follow). In addition, it is possib le to record multiple non-target lesions involving 
the same organ as a single item on the case rec ord form (eg, ‚Äòmultiple en larged pelvic lymph nodes‚Äô 
or ‚Äòmultiple liver metastases‚Äô).
Protocol Amendment No.: 04
Date: 04-May-2021 161
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
2 RESPONSE CRITERIA
2.1 Evaluation of Target Lesions
‚Ä¢Complete Response (CR): Disappearance of all target lesions. Any pathological lymph nodes 
(whether target or non-target) must have reduction in short axis to < 10 mm.
‚Ä¢Partial Response (PR): At least a 30% decrease in the sum of diameters of target lesions, 
taking as reference the baseline sum diameters.
‚Ä¢Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, 
taking as reference th e smallest sum on study (t his includes the baseline sum if that is the 
smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate 
an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also 
considered progression).
‚Ä¢Stable Disease (SD): Neither sufficient shrinkage to qualify for PR nor suff icient increase to 
qualify for PD, taking as reference the smallest sum diameters while on study.
‚Ä¢Not Evaluable (NE): If one or more target lesions cannot be measured or adequately assessed 
as either fully resolved or too small to m easure (due to missing or poor quality i mages), and 
the sum of diameters of the remaining measured target lesions (if any) has not increased sufficiently to meet Progressive Disease as defined above. 
2.1.1 Special Notes on the Assessment of Target Lesions
[IP_ADDRESS] Lymph nodes
Lymph nodes identified as target lesions s hould always have the actual short axis measurement 
recorded (measured in the same anatomical plane as the baseline examination), even if the nodes 
regress to below 10 mm on study. This means that when lymph nodes are included as target lesions, 
the ‚Äòsum‚Äô of lesions may not be zero even if complete response criteria are met, since a normal lymph node is defined as having a short axis of < [ADDRESS_602752]  achieve a short axis < 10 mm. For PR, SD and 
PD, the actual short axis measurement of the nodes is to be included in the sum of target lesions.
[IP_ADDRESS] Target lesions that become ‚Äòtoo small to measure‚Äô
While on study, all lesions (nodal and non-nodal) r ecorded at baseline s hould have their actual 
measurements recorded at each subsequent evalu ation, even when very small (eg, 2 mm). 
However, sometimes lesions or lymph nodes which are recorded as target lesions at baseline 
become so faint on CT scan that the radiologist may not feel com fortable assigning an exact 
measure and may report them as being ‚Äòtoo small to  measure‚Äô. When this occurs it is important 
that a value be recorded on the case report form. If it is the opi[INVESTIGATOR_13051], the measurement should be recorded as 0 mm. If the lesion is believed to 
be present and is faintly seen but too small to measure, a default value of 5 mm should be assigned
as the reference diameter. (Note: It is less likely that this rule will be used for lymph nodes since 
they usually have a definable size when normal and are frequently surrounded by [CONTACT_12156]; however, if a lymph node is believed to be present and is faintly seen but too 
Protocol Amendment No.: 04
Date: 04-May-2021 162
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
small to measure, a default value of 5 mm should be assigned in this circumstance as well). This 
default value is derived from the [ADDRESS_602753] slice thickness (but should not be changed with varying 
CT slice thickness). The measurement of these lesions is potenti ally non-re producible, therefore 
providing this default value will prevent false responses or progressions based upon measurement 
error. To reiterate, however, if the radiologist is able to provide an actual measure, that should be recorded, even if it is below 5 mm.
[IP_ADDRESS] Lesions that split or coalesce on treatment
When non-nodal lesions ‚Äòfragment‚Äô, the longest diameters of the fragmented  portions should be 
added together to calculate the target lesion sum.  Similarly, as lesions coalesce, a plane between 
them may be maintained that would aid in obtaining maximal diameter measurements of each 
individual lesion. If the lesions have truly coalesced such that they are no longer separable, the 
vector of the longest diameter in this instance should be the maximal longest diameter for the 
‚Äòcoalesced lesion‚Äô.
2.2 Evaluation of Non-Target Lesions
This section provides the definitions of the criteria used to determine the tumor response for the 
group of non-target lesions. While some non-target lesions may actually be measurable, they need 
not be measured and instead should be assessed only qualitatively at the time points specified in 
the protocol.
‚Ä¢Complete Response (CR): Disappearance of all non-target lesions. All lymph nodes must be 
non-pathological in size (< 10mm short axis). 
‚Ä¢Non-CR/Non-PD: Persistence of one or more non-target lesion(s)
‚Ä¢Progressive Disease (PD): Unequivocal progression of existing non-target lesions.
2.2.1 Special Notes on Assessment of Progression of Non-Target Disease
The concept of progression of non-target disease re quires additional explanation as follows:
[IP_ADDRESS] When the patient also has measurable diseaseIn this setti ng, to achieve ‚Äòunequivocal progression‚Äô on the basis of the non-target disease, there 
must be an overall level of substantial worsening in non-target disease such that, even in presence 
of SD or PR in target disease, the overall tumor burden has increased sufficiently to merit 
discontinuation of therapy A modest ‚Äòincrease‚Äô in the size of one or more non-target lesions is 
usually not sufficient to qualify for unequivocal progression status. Pleural effusions, pericardial 
effusions and ascites will not be followed as targe t or non-target lesions and will not contribute to 
response or progression. The designation of overall progression solely on the basis of change in 
non-target disease in the face of SD or PR of target disease will therefore be extremely rare.
[IP_ADDRESS] When the patient has only non -measurable disease
This circumstance arises in some trials when it is not a criterion of study entry to have measurable 
disease. The same general concepts apply here as noted above, however, in this instance there is 
no measurable disease assessment to factor into the interpretation of an increase in non-measurable 
Protocol Amendment No.: 04
Date: 04-May-2021 163
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
disease burden. Because worsening in non-ta rget disease cannot be easily quantified (by [CONTACT_108]: 
if all lesions are truly non-measur able) a useful test that can be applied when assessing patients for 
unequivocal progression is to consider if the increase in overall disease burden based on the change 
in non-measurable disease is comparable in magnitude to the increase that would be required to 
declare PD for measurable disease: ie, an increase in tumor burden representing an additional 73% increase in ‚Äòvolume‚Äô (which is equivalent to  a 20% increase di ameter in a meas urable lesion). 
Examples include, an increase in lymphangitic disease from localized to widespread, or may be 
described as ‚Äòsufficient to require a change in therapy‚Äô. If ‚Äòunequivocal progression‚Äô is seen, the 
patient should be considered to have had overall PD at that point. While it would be ideal to have 
objective criteria to apply to non-measurable disease, the very nature of that disease makes it impossible to do so; therefore the increase must be substantial.
2.2.2 New Lesions
The appearance of new malignant lesions denotes disease progression; therefore, some comments 
on detection of new lesions are important. There are no specific criteria for the identification of 
new radiographic lesions; however, the finding of a new lesion should be unequivocal: ie, not 
attributable to differences in scanning technique, change in imaging mod ality or findings t hought 
to represent something other than tumor (for example, some ‚Äònew‚Äô bone lesions may be simply 
healing or flare of pre-existing lesions). This is particularly important when the patient‚Äôs baseline 
lesions show partial or complete response. For example, necrosis of a liver lesion may be reported
on a CT scan report as a ‚Äònew‚Äô cystic lesion, which it is not.
NOTE: Fluid collections (pleural effusions, pericardial effusions, and ascites) will not be 
considered new lesions and will not contribute to response or progression. In the event a new fluid 
collection is seen on a post-baseline imaging exam, a commen t may be made, but the appearance 
of a new fluid collection alone should not result in an assessment of Progressive Disease (PD). A 
lesion identified on a follow-up study in an anatomical location that was not scanned at baseline 
is considered a new lesion and will indicate disease progression. An example of this is the patient who has visceral disease at baseline a nd while on st udy has a CT or MRI brain ordered which 
reveals metastases. The patient‚Äôs brain metastases ar e considered to be evidence of PD even if 
he/she did not have brain imaging at baseline. A lesion identified on Chest X-Ray that was not 
present in prior CT can be considered a new lesion and will result in Progressive Disease (PD).
If a new lesion is equivocal, for example because of its small size, continued follow-up evaluation 
will clarify if it represents truly new disease. If repeat scans confirm there is definitely a new 
lesion, then progression should be declared using the date of the init ial scan. While FDG-PET 
response assessments need additional study , it is sometimes reasonable to inc orporate the use of 
FDG-PET scanning to complement CT scanning in  assessment of progression (particularly 
possible ‚Äònew‚Äô disease). New lesions on the basi s of FDG-PET imaging can be identified according 
to the following algorithm:
1) Negative FDG-PET at baseline, with a positive FDG-PET at follow-up is a sign of PD based 
on a new lesion.
Protocol Amendment No.: 04
Date: 04-May-2021 164
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
2) No FDG-PET at baseline and a positive FDG-PET at follow-up: If the positive FDG-PET at 
follow-up corresponds to a new site of disease confirmed by [CONTACT_4654], this is PD. If the positive 
FDG-PET at follow-up is not confirmed as a new site of disease on CT, additional follow-up 
CT scans are needed to determine if there is truly progression occurring at that site (if so, the 
date of PD w ill be the d ate of the init ial abnormal FDG-PET sca n). If the positive FDG-PET 
at follow-up corresponds to a pre-existing site  of disease on CT that is not progressing on the 
basis of the anatomic images, this is not PD.
2.[ADDRESS_602754] response recorded, taking into account any requirement for 
confirmation and censoring rules regarding subseque nt therapy. The patient‚Äôs best overall res ponse 
assignment will depend on the findings of both target and non-target disease and will also take into 
consideration the appearance of new lesions. Furthermore, depending on the nature of the study and the protocol requirements, it may also require confirmatory measurement.
2.3.[ADDRESS_602755] non-measurable (therefore non-target) disease 
only, Table 2.3.2-2 is to be used. 
Table 2.3.2-1: Time Point Response: Patients With Target (¬± Non-Target) Disease
Target Lesions Non-Target Lesions New Lesions Overall Response
CR CR No CR
CR Non-CR/non-PD No PR
CR Not evaluated No PR
PRNon-PD or not all 
evaluatedNo PR
SDNon-PD or not all 
evaluatedNo SD
Not all evaluated Non-PD No NE
PD Any Yes or No PD
Any PD Yes or No PD
Any Any Yes PD
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease and NE = inevaluable
Protocol Amendment No.: 04
Date: 04-May-2021 165
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2.3.2-2: Time Point Response: Patients With Non-Target Disease Only
Non-Target Lesions New Lesions Overall Response
CR No CR
Non-CR/non-PD No Non-CR/non-PDa
Not all evaluated No NE
Unequivocal PD Yes or No PD
Any Yes PD
CR = complete response, PD = progressive disease and NE = inevaluable
aNon-CR/non-PD is preferred over SD for non-target disease since SD is increasingly used as en dpoint for 
assessment of efficacy in some trials so to assign this category when no lesions can be measured is not advised.
2.3.[ADDRESS_602756] response determin ation of complete or par tial res ponse requires confirmation: Complete or 
partial responses may be claimed only if the criteria for each are met at a subsequent time point of 
‚â•4 weeks (28 days) later. In this circumstance, the best overall response can be interpreted as in 
Table 2.3.3-[ADDRESS_602757] scheduled follow-up imaging visit is Week 6 (¬± 7 days) for a particular 
protocol, a Best Response of SD can only be made after the subject is on-study for a minimum of 
6 weeks (42 days) minus 7 days, for an absolute minimum time on-study of 35 days from the 
reference start date (reference date is considered Day 1 on study).  If the subject is not on-study for at least this am ount of t ime, any tumor assessment indicating stable disease before this time 
period will have a Best Response of NE unless PD is identified.
Special note on response assessment: When nodal disease is included in the sum of target lesions 
and the nodes decrease to ‚Äònormal‚Äô s ize (< 10 mm), they may st ill have a measurement reported 
on scans. This measurement should be recorded even though the nodes are normal in order not to 
overstate progression should it be based on increase in size of the nodes. As noted earlier, this 
means that patients with CR may not have a total sum of ‚Äòzero‚Äô on the case report form (CRF).
Table 2.3.3-1: Best Overall Response (Confirmation of CR and PR Required)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR CR CR
CR PR SD, PD OR PRa
CR SDSD provided minimum criteria for SD duration met, otherwise, 
PD
CR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
Protocol Amendment No.: 04
Date: 04-May-2021 166
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2.3.3-1: Best Overall Response (Confirmation of CR and PR Required)
Overall Response 
First Time PointOverall Response 
Subsequent Time PointBest Overall Response
CR NESD provided minimum criteria for SD duration met, otherwise, 
NE
PR CR PR
PR PR PR
PR SD SD
PR PDSD provided minimum criteria for SD duration met, otherwise, 
PD
PR NESD provided minimum criteria for SD duration met, otherwise, NE
NE NE NE
CR = complete response, PR = partial response, SD = stable disease, PD = progressive disease, and NE = inevaluable
aIf a CR is truly met at first time point, then any disease seen  at a subsequent time point, even disease meeting PR 
criteria relative to baseline, makes the disease PD at that point (since disease must have reappeared after CR). Best response would depend on whether minimum duration for SD was met. However, sometimes ‚ÄòCR‚Äô may be claimed when subsequent scans suggest small lesions were likely still present and in fact the patient had PR, not CR at the first time point. Under these circumstances, the original CR should be changed to PR and the best response is PR.
2.3.4 Confirmation Scans
Verification of Response: To be assigned a status of CR or PR, changes in tumor measurements 
must be confirmed by [CONTACT_102472] [ADDRESS_602758] met. Subsequent documentation of a CR may provide confirmation of a previously identified CR even with an intervening NE or PR (eg, CR NE CR or CR PR CR). Subsequent documentation of a PR may provide confirmation of a
previously identified PR even with an in tervening NE or SD (eg, PR NE PR or PR SD PR). 
However, only one (1) intervening time point will be allowed between PR/CRs for confirmation.
Verification of Progression : Progressi on of disease should be verified in cases where progression 
is equivocal. If repeat scans confirm PD, then progression should be declared using the date of the 
initial scan. If repeat scans do not confirm PD, then the subject is considered to not have 
progressive disease.
REFERENCES
1Eisenhauer EA, Therasse P, Bogaerts J, et al. New response evaluation criteria in solid tumors:
revised RECIST guideline (version 1.1). Eur J Cancer 2009; 45: 228-47.
Protocol Amendment No.: 04
Date: 04-May-2021 167
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 8 RADIOGRAPHIC ASSESSMENT FOR NEURO-ONCOLOGY 
(RANO) CRITERIA FOR HIGH-GRADE GLIOMAS
Table 1: Summary of Proposed Radiographic Assessment for Neuro-
Oncology
Criterion Complete Response Partial Response Stable Disease Progressive Disease
T1 gadolinium 
enhancing diseaseNone ‚â•50% ‚Üì < 50% ‚Üì but < 25% ‚Üë ‚â•25% ‚Üë*
T2/FLAIR Stable or ‚Üì Stable or ‚Üì Stable or ‚Üì‚Üë*
New lesion None None None Present*
Corticosteroids None Stable or ‚Üì Stable or ‚Üì NA‚Ä†
Clinical status Stable or ‚Üë Stable or ‚Üë Stable or ‚Üë‚Üì*
Requirement for 
responseAll All All Any*
Abbreviations: RANO, Response Assessment in Neuro-Oncology; CR, complete response; PR, partial response; SD, 
stable disease; PD, progressive disease; FLAIR, fluid-attenuated inversion recovery; NA, not applicable.
* Progression occurs when this criterion is present.
‚Ä†Increase in corticosteroids alone will not be taken into acc ount in determining progression in the absence of persistent 
clinical deterioration.
NOTE. All measurable and nonmeasurable lesions must be assessed using the same techniques as at baseline.
Reference: Wen PY, Macdonald DR, Reardon DA, et al. Upd ated Response Assessment Criteria for High-Grade 
Gliomas: Response Assessment in Neuro-Oncol ogy Working Group J Clin Oncol 2010;28-1:3059-3067. 
Protocol Amendment No.: 04
Date: 04-May-2021 168
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 9 KARNOFSKY AND LANSKY CRITERIA
STATUS STATUS
KARNOFSKY LANSKYKARNOFSKY or 
LANSKY
Normal, no complaints Fully active, normal 100
Able to carry on normal activities; minor signs or 
symptoms of diseaseMinor restrictions in 
physically strenuous 
activity90
Normal activity with effort; some signs or symptoms of 
diseaseActive, but tires more 
quickly80
Cares for self. Unable to carry on normal activity or to do 
active workSubstantial restriction of, 
and less time spent, in play 
activity70
Requires occasional assistance, but able to care for most of 
his needsOut of bed, but minimal 
active play; keeps busy 
with quiet activities60
Requires considerable assistance and frequent medical care Gets dressed, but inactive 
much of day; no active 
play, able to participate in 
quiet play50
Disabled. Requires special care and assistance Mostly in bed; participates 
in some quiet activities40
Severely disabled. Hospi[INVESTIGATOR_186724]; needs assistance 
even for quiet play30
Very sick. Hospi[INVESTIGATOR_20545]. Active supportive 
treatment necessaryOften sleepi[INVESTIGATOR_007]; play 
limited to passive 
activities20
Moribund No play; does not get out 
of bed10
Protocol Amendment No.: 04
Date: 04-May-[ADDRESS_602759] been conducted under the following assumed scenarios:
‚Ä¢Proportions for enriched group and low group: 0.75 vs. 0.25, 0.7 vs. 0.3, 0.6 vs. 0.4, 0.5 vs. 0.5 
‚Ä¢True ORRs for enriched group and low group: 40% vs. 25%, 35% vs. 10%, 20% vs. 10%, 10% 
vs. 10%
10,000 replications of trials were simulated with a total of 76 bTMB evaluable participants and 
30 bTMB ‚â• 10 mut/MB participants at the time of interim analysis. As shown in Table 1, the 
simulated power for the adaptive procedures (power  adapt) and non-adaptive procedures (power 
non-adapt) are calculated for each assumed scenario.
Table 2: The power for adaptive vs. non-adaptive procedures
GroupProportion of entire 
populationTrue ORR Power non-adapt Power adapt
Enriched group 0.75 40%
0.723 0.999
Low group 0.25 25%
Enriched group 0.75 35%
0.726 0.987
Low group 0.25 10%
Enriched group 0.75 20%
0.411 0.471
Low group 0.25 10%
Enriched group 0.75 10%
0.019 0.020
Low group 0.25 10%
Enriched group 0.7 40%
0.660 0.999
Low group 0.3 25%
Enriched group 0.7 35%
0.636 0.979
Low group 0.3 10%
Enriched group 0.7 20%
0.346 0.442
Low group 0.3 10%
Enriched group 0.7 10%
0.016 0.017
Low group 0.3 10%
Enriched group 0.6 40%
0.602 0.999
Low group 0.4 25%
Enriched group 0.6 35%
0.467 0.948
Low group 0.4 10%
Enriched group 0.6 20%
0.226 0.383
Low group 0.4 10%
Protocol Amendment No.: 04
Date: 04-May-2021 170
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Table 2: The power for adaptive vs. non-adaptive procedures
GroupProportion of entire 
populationTrue ORR Power non-adapt Power adapt
Enriched group 0.6 10%
0.012 0.015
Low group 0.4 10%
Enriched group 0.5 40%
0.570 0.999
Low group 0.5 25%
Enriched group 0.5 35%
0.342 0.896
Low group 0.5 10%
Enriched group 0.5 20%
0.149 0.347
Low group 0.5 10%
Enriched group 0.5 10%
0.013 0.017
Low group 0.5 10%
Note: Enriched group include pa rticipants with bTMB>=cut- off and Low group include participants with 
10<=bTMB<cut-off
The simulation result shows that adaptive enrichment procedure appears to increase the power in 
most scenarios. In addition, type I error is well controlled (<0.025).  
Protocol Amendment No.: 04
Date: 04-May-2021 171
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 11 COUNTRY SPECIFIC AMENDMENTS
Argentina, [LOCATION_009], [LOCATION_013], Italy, Spain, and Any Other Countries Where Exclusion of 
HIV Positive Participants Is Locally Mandated
Country-specific language
Section 2 Flow Chart/Time and Events Schedule, Table
2-1: Screening Assessments - Laboratory TestsAdd ‚ÄúHIV‚Äù to the list of laboratory tests
Section 6.2 Exclusion
Criteria, Exclusion criterion 1.a‚ÄúKnown history of testing positive for human
immunodeficiency virus (HIV) or known acquired
immunodeficiency syndrome (AIDS)‚Äùto be replaced with
‚ÄúPositive test for HIV‚Äù.
Protocol Amendment No.: 04
Date: 04-May-2021 172
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
APPENDIX 12 REVISED PROTOCOL SUMMARY OF CHANGE HISTORY
Overall Rationale for Revised Protocol 03:
This protocol revision serves to update the protocol per program requirements, company and 
document standards, as well as make change s per the Administrativ e Letter 02 and 03. The 
following content has also been updated:
‚Ä¢Updated the range and number of participants and clarified statistical analyses and sample size.
‚Ä¢Provided clarification on requirements for pre-screening and eligibility.
‚Ä¢Added language regarding adolescent participants not being included for sites in Belgium and 
the Netherlands per the Country Specific Amendment 03.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number & 
TitleDescription of Change Brief Rationale
Title PageUpdated Study Director and Medical Monitor 
informationUpdated study personnel
Section 2
Schedule of Activities 
Table 2-1Added the following language-
tTMB and bTMB results should be ‚â• 10 mut/Mb 
(tTMB ‚â• [ADDRESS_602760] interim analysis)Provided clarification on pre-
screening requirements and 
interim analyses
Section [ADDRESS_602761] of Belgium and 
the Netherlands sites
Protocol Amendment No.: 04
Date: 04-May-2021 173
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number & 
TitleDescription of Change Brief Rationale
Section 7.1.2 Arm B ‚Äì
Nivolumab Monotherapy
Section 2
Schedule of Activities 
Table 2-2
Table 2-3
Table 2-4Added the following language in the Outcomes 
research row-
If the dose is delayed, then PRO completion 
should also be delayed.Bring protocol in line with drug 
program standards
Section 3.2.5 Nivolumab 
Clinical PharmacologyAdded updated clinical pharmacology section to 
backgroundBring protocol in line with 
document standards
Section 4 Objectives and 
Endpoints Table 4-1Clarified endpoints for exploratory objectivesProvide further detail on study 
scope
Section 5.1 Overall Design 
Figure 5.1-1Updated figure to include language regarding 
tTMB ‚â• [ADDRESS_602762] of Belgium and 
the Netherlands sites
Section 6.1 Inclusion 
Criteria Figure 6.1-1Updated figure to include language regarding 
biomarker testing, prescreening and ‚â• [ADDRESS_602763] of management 
algorithmsBring protocol in line with drug 
program standards
Section [IP_ADDRESS] Solid 
tumorsAdded language regarding CT component of a 
PET-CT ScannerBring protocol in line with 
document standards
Protocol Amendment No.: 04
Date: 04-May-2021 174
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 03
Section Number & 
TitleDescription of Change Brief Rationale
Section [IP_ADDRESS] BICR 
Confirmation of 
Radiographic ProgressionAdded language regarding BICR confirmation 
of disease progression.Bring protocol in line with drug 
program standards
Section 9.[ADDRESS_602764] not been 
summarized
Protocol Amendment No.: 04
Date: 04-May-2021 175
5.0 Approved 930106993 5.0v Approved 1.0 v
Clinical Protocol CA209848
BMS-936558 nivolumab
Overall Rationale for Revised Protocol 02:
This amendment incorporates feedback received from FDA on pursuing a tumor-agnostic 
indication with TMB for the study design of CA209-848.  The key changes include:
1) Revision of the statistical method to be base d on precision of the estimation of ORR. The 
efficacy decision is revised to be based on the lower limit of a 95% confidence interval to 
exceed a clinically relevant response rate. Previous ly, the primary endpoint is to be compared 
with a historical control with a type I error rate set to 0.05. 
2) Clarification on targeted population as in a salvage setting. The inclusion criteria is revised to 
stress participants being ‚Äúrefractory to standard local therapi[INVESTIGATOR_014], or for which no standard 
treatment is available‚Äù. Previously, it was ‚Äúreceived at least one prior line of therapy including standard of care, if available‚Äù.
SUMMARY OF KEY CHANGES OF REVISED PROTOCOL 02
Section Number & 
TitleDescription of Change Brief Rationale
Document HistoryIncluded Revised Protocol 02; incorporated 
Administrative Letter 01.Updated summary of 
changes.
Section 2, Schedule of 
Activities, Table 2-1, 
Screening Procedural 
Outline (CA209848)Revised Notes for Pre-screening for TMB-
H.Provided more clarity on the 
pre-screening and screening 
procedures.
Section 2, Schedule of 
Activities, Table 2-1, 
Screening Procedural 
Outline (CA209848)Revised Notes for Tumor tissue collection.Added section reference 
regarding details for tumor 
tissue collection.
Overall Rationale for Revised Protocol 01:
This protocol is listed a ‚ÄúRevised protocol 1‚Äù to remain Title 21 CFR Part 11 compliant (FDA 
regulations on electronic records and electronic signatures). The init ial protocol CA209848 was 
never activated as initially written. The study was fully revised and, therefore, there are no 
summary of changes to compare to the initial protocol.
Protocol Amendment No.: 04
Date: 04-May-2021 176
5.0 Approved 930106993 5.0v Approved 1.0 v